Dartmouth College

Dartmouth Digital Commons
Dartmouth College Ph.D Dissertations

Theses and Dissertations

2022

Phase-changing Nanodroplets as Nanotheranostic Platform for
Combination Cancer Therapy
Catalina-Paula Spatarelu
Dartmouth College, catalina-paula.spatarelu.th@dartmouth.edu

Follow this and additional works at: https://digitalcommons.dartmouth.edu/dissertations
Part of the Bioimaging and Biomedical Optics Commons, Biomaterials Commons, and the
Nanoscience and Nanotechnology Commons

Recommended Citation
Spatarelu, Catalina-Paula, "Phase-changing Nanodroplets as Nanotheranostic Platform for Combination
Cancer Therapy" (2022). Dartmouth College Ph.D Dissertations. 96.
https://digitalcommons.dartmouth.edu/dissertations/96

This Thesis (Ph.D.) is brought to you for free and open access by the Theses and Dissertations at Dartmouth Digital
Commons. It has been accepted for inclusion in Dartmouth College Ph.D Dissertations by an authorized
administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.

PHASE-CHANGING NANODROPLETS AS NANOTHERANOSTIC PLATFORM
FOR COMBINATION CANCER THERAPY
A Thesis
Submitted to the Faculty
in partial fulfillment of the requirements for the
degree of
Doctor of Philosophy
in
Engineering Sciences
by CATALINA-PAULA SPATARELU
Thayer School of Engineering
Guarini School of Graduate and Advanced Studies
Dartmouth College
Hanover, New Hampshire
JUNE 2022
Examining Committee:
Chairman_______________________
Geoffrey Luke, PhD
Member________________________
P. Jack Hoopes, PhD
Member________________________
Kimberley Samkoe, PhD
Member________________________
___________________
F. Jon Kull, Ph.D.
Dean of the Guarini School of Graduate and Advanced Studies

Emily Day, PhD

THIS PAGE IS INTENTIONALLY LEFT BLANK

Abstract
Cancer is a cluster of diseases, and 1.8 million Americans are newly diagnosed each year.
Treatment issues such as drug instability, the occurrence of severe side effects, as well as
resistance make the need for solutions to improve conventional methods, like
chemotherapy, apparent. Nano-sized drug-delivery platforms, particles loaded with
therapeutic molecules that escape the immune system clearance and accumulate at the
tumor site, were proposed as one of these solutions. Despite the expansion of the field,
several aspects still need to be addressed: inconsistent delivery of the drugs, inability of
measuring the effective dose being delivered to the tumor, lack of predictability of a
response.
Hence, the field

of nanotheranostics was born, that combines d rug-delivery

nanoparticulate systems with imaging capabilities. By enabling a noninvasive
visualization of delivered therapeutic molecules, nanotheranostics offer the opportunity
of rapid optimization of drug delivery systems during in vivo testing. This insight into the
kinetics and the fate of nanoparticle-encapsulated therapeutics can aid validate basic
properties without needing to wait a long time for a pathological outcome. In the clinic,
this feature would allow for a fast response in modifying a treatment course.
This work describes a versatile nanotheranostic platform capable of triggered release of
therapeutic molecules and strong ultrasound imaging contrast simultaneously. The
activatable release is designed to minimize off-target effects, while the ultrasound
contrast can enable visualization of the delivered dose to a region of interest.
The particles described herein consist of a shell-core structure, with a perfluorocarbon
ii

core that can be externally vaporized by acoustical or optical stimuli. The activation
generates highly echogenic microbubbles, together with the release of the loaded
compounds. Notably, the release of the payload is correlated to the ultrasound magnitude
after activation, enabling the basis for ultrasound dose-monitoring. The design, synthesis
and characterization of perfluorocarbon nanodroplets aimed at several applications are
described. These include co-delivery of hydrophobic and hydrophilic chemotherapeutics,
delivery of a-PD-L1 immunecheckpoint inhibitors together with chemotherapeutics, as
well as multimodal imaging capabilities.
Overall, this work contributes towards expanding the utility of perfluorocarbon
nanodroplets towards combinatorial therapies, and proposes necessary improvements for
increased translatability of the technology.
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Chapter 1 : Introduction, Background and
Motivation
1.1 Nanoparticles for Image-guided Cancer Therapy
Cancer is a cluster of complex diseases originating from DNA mutations that impact cell growth,
proliferation, and cell cycle processes. Due to high variability and heterogeneity among different
cancer types, clinicians are faced with a variety of challenges in diagnosis and effective
treatment 1 . These factors contribute to making the cancer family of conditions a major public
health concern, with the USA alone expecting over 1.8 million newly diagnosed cases in 2020.
The lifetime probability of being diagnosed with cancer is at ~40%, meaning 1 in 3 women or 1
in 2 men are expected to develop and get diagnosed with a form of invasive cancer. The cost of
cancer care has risen, to an imposing 151 billion dollars in 2018, and expected to rise, even
without factoring in the economic burden by loss of productivity 2 .
Current treatment methods are similarly widely different depending on many factors, and
include: surgery, chemotherapy, radiotherapy, hormone therapy, molecular therapy,
hyperthermia, immunotherapy, stem cell therapy and combinations of two or more of them.
Given the public health and the financial implications of cancer, there is an impetus in improving
existing strategies and developing new ones that could achieve better treatment efficacies, while
being as cost-effective as possible.
Many agents currently used in clinic for chemotherapy face several challenges that decrease their
effectiveness against cancer3 . Some drugs have poor pharmacokinetics and generate
inappropriate biodistribution when administered systematically. Other molecules are highly
hydrophobic, and tend to present with a large volume of distribution, accumulating in various
different healthy tissue without any preference for the tumor tissue in the body. This causes off site toxicity, and side-effects that can range from mild (e.g. fatigue, appetite changes, etc.) to
severe (e.g., nerve damage, nephrotoxicity, heart failure etc.).
In an attempt to address these concerns and minimize the off-site effects while maintaining or
increasing therapeutic effectiveness, submicron sized carrier materials have been proposed.
Clinically relevant examples include liposomes, polymers, micelles and antibodies 4 . The first
three types of nanomedicine formulations usually aim at encapsulating or conjugating a
therapeutic agent and increasing its accumulation at the tumor site by means of the enhanced
permeability and retention (EPR) effect. This is often times dubbed “passive targeting”. On the
other hand, antibody-based carriers are designed to actively target tumor tissue by target cell
1

recognition and uptake5 . Both these methods have been used in several types of cancer, as well
as other diseases (table 1.1).

Table 1-1 Approved nanomedicine, material of carrier, disease, targeting type (passive active).
Adapted from 6
Nanomedicine
commercial name

Composition

Disease

Targeting
type

PegIntron

PEGylated proteins

Hepatitis

-

PegAsys

PEGylated proteins

Hepatitis

-

PegVisomant

PEGylated proteins

Acromegaly

-

AmBisome

Liposome

Fungal infection

-

DepoCyt

Liposome

Lymphomatous meningitis

-

Myocet

Liposomal
Doxorubicin

Kaposi sarcoma, multiple
myeloma, metastatic breast
cancer, ovarian carcinoma

Passive

Doxil

PEGylated liposome
with Doxorubicin

Kaposi sarcoma, multiple
myeloma, metastatic breast
cancer, ovarian carcinoma

Passive

Onco-TCS

Liposomal vincristine

Non-Hodgkin’s lymphoma

Passive

Oncaspar

PEGylated L-aspartase

Acute lymphoblastic leukemia

Passive

Abraxane

Albumin PTX

Breast cancer, non-small cell lung
cancer

Passive

Xyotax

Polymeric PTX

Breast cancer, non-small cell lung
cancer

Passive

Zevalin

Ytrium-90 labeled
ibritumomabtiuxetan

Non-Hodgkin’s lymphoma,
cutaneous T-cell lymphoma

Antibodybased

Ontak

Denileukin diftitox

Non-Hodgkin’s lymphoma,
cutaneous T-cell lymphoma

Antibodybased
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Apart from their therapeutic applications, nanomedicines are increasingly being proposed for
diagnosis purposes7 . Carriers loaded with contrast agents, like MR imaging probes or
radionuclides, are increasing used to detect diseases or visualize aspects of the drug delivery
process. “Classic” nanomedicines that are co-functionalized to provide imaging contrast in vivo
are normally referred to as “nanotheranostics” or “nanotheragnostics”4 . The development of
such agents is an important focus in the field of image-guided therapy. The main features and
advantages that image-guided therapy provides are described below, with examples from cancer
applications.
1. Visualizing Biodistribution in real time. Enabling a noninvasive visualization of the
biodistribution, nanotheranostics offer the opportunity of rapid optimization of the drug
delivery systems during in vivo testing3 . This insight into the kinetics and the fate of
nanoparticles can validate basic properties of the systems without needing to wait a long time
for a pathological outcome. In the clinic, this feature would allow for a fast -response in
modifying a treatment course.
2. Noninvasively Assessing Target Site Accumulation. Monitoring targeted drug delivery to
the pathological region of interest is a particularly attractive feature of image-guided therapy.
This feature is useful for both a clinical and a preclinical setting. In a preclinical application,
multiple carriers can be compared within the same animal, minimizing the variability
generated by inter-tumor differences8 . From a clinical point-of-view, being able to visualize
and quantify drug targeting to tumor sites is potentially one of the most important benefits of
image-guided drug delivery. By assessing whether nano formulations are able to get to the
tumor site, and the dose that is successful in doing so, it is possible to stratify potential
responders from non-responders8 .

3. Monitoring Drug Distribution at the Target Site. Going a step further, being able to
monitor and furthermore quantify drug distribution at the target site (i.e the tumor), provides
timely information about the functional and molecular feedback. These are necessary to
meaningfully predict the efficacy of targeted therapeutic interventions. For certain systems,
this input can mean intervening to encourage a more uniform distribution to ensure that
treatment is effective within the volume of the tumor (e.g., include ultrasound -guided
systems, magnetically-guided carriers etc).
4. Visualizing Drug Release. Another interesting aspect of image-guided drug delivery is the
possibility of using these systems to visualize in vivo drug release 1 . As the drugs, conjugated
or entrapped in the carriers, are inactive in that formulation, it is important to ensure that the
agents are being released. While quantifying the release in vitro is not very difficult, the in
vivo environment brings its own challenges. For preclinical testing, the classical method is
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harvesting the target organ or tissue, homogenize it and separate the components to be
analyzed by analytical methods (UV-VIS, MS, etc)9 . However, it is often tough to keep the
carriers from being destabilized in the process, making distinguishing between released and
still encapsulated drug difficult 10 . To address this, imaging agents and drugs can be coincorporated into the same delivery system to take advantage of the imaging. The choice of
imaging modality needs to account for the difference between encapsulated and released drug
by, for example, connecting the drug release process with the emergence of contrast (e.g., for
phase-shifting nanodroplets, the drug release is correlated with the appearance of
microbubbles that act as ultrasound contrast agents). Alternative methods based on optical
imaging and quenching-dequenching effects are also being investigated for this purpose 4,8 .
When agents can provide both image-based confirmation of the drug being delivered, as well
as the possibility to quantify it, they can be used for rational dosimetry10 . Image-based
rational dosimetry is an important tool that helps assess the efficacy of a treatment and
inform fast decisions.
5. Facilitating Triggered Drug Release. Resulting from the previously mentioned applications
of nanotheranostics is their ability to facilitate externally triggered drug release. Being able to
visualize the accumulation and target site distribution of a stimuli-sensitive formulation and
allows for applying the stimulus (temperature, ultrasound, light, magnetic field, etc.) with
high special and temporal specificity. For this to be possible, the nano-formulation needs to
allow two imaging modalities: one to enable the visualization of the carriers as they circulate
through the body and accumulate at the tumor site, and a secondary one to be able to
visualize and confirm the drug being released.
6. Predicting Drug Responses. Particularly important for the clinical setting is the application
of theranostic nanomedicine to predict therapeutic responses. As mentioned before, the
imaging of the biodistribution and target accumulation can allow for a discrimination
between patients with low or high tumor accumulation. Based on this input, predictions can
be made as to which patients are more likely to respond to the continuation of the
nanomedicine regime and enable optimizing treatment protocols in a more personalized
manner. However, the clinical situation is rarely “black and white” and involves layers of
complexity that might not be easily resolved, and heterogeneity between patients as well as
within patients (Fig 1.1). One such example is the fact that many cancer patients do not have
a singular tumor, but rather, several metastases, each with property variance. For such cases,
image-guided drug delivery can still provide important information to complement classical
imaging diagnosis techniques, and aid in developing a more complex treatment plan
addressing each tumor based on how it presents 8 .
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Figure 1-1 Schematic of the different layers of heterogeneity encountered in cancer patients:
from interpatient differences, to intrapatient heterogeneity, both between primary tumors and
metastasis sites, as well as within each of the tumors, due to different cell populations being
present. Image inspired from 8
Therefore, image-guided therapy systems represent a promising tool starting in preclinical
applications and extending to the clinic. Preclinically, they can be used to facilitate efficacy
analysis, rapid optimization of the properties of drug delivery systems by receiving real-time
feedback on biodistribution and accumulation behaviors. At both pre and clinical stages,
functional information about the fate of an administered drug in vivo could inform decisions for
treatment regimens that minimize off-target effects while maintaining the therapeutic index.
Finally, nanotheranostics can also aid in stratifying patients from a group, tumor within the same
patient or areas of interest within a tumor, for fast intervention. Image-guided techniques
extended beyond drug delivery to include biotherapeutics or gene delivery, could also mean
more personalized treatment plans for patients.

1.2 Image-guided drug delivery barriers
While image-guided drug delivery offers great opportunities towards personalized medicine, it
also faces several challenges in order to be translated into the clinic. This section will focus on
the technical and design aspects of these issues, while a more comprehensive review can be
found in reference #10.
Some of the main challenges image-guided drug delivery strategies face are common to
nanoparticle-based drug delivery systems in general.
Firstly, an issue to address is the optimization of the drug concentration that gets delivered to the
target cells11 . In order to reach their target, these nanoparticles need to traverse several barriers,
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and the rapidity of drug washout in blood from the tumor can diminish its expected therapeutic
effect. Passive targeted systems, that rely on accumulation at the tumor site through the
enhanced permeation and retention (EPR) effect suffer from high variability and are not equally
suitable for different types of tumors3,7 . However, efforts to provide exogeneous energy to
mechanically weaken or destroy some of these biological barriers can give increased results in
nanoparticle extravasation3,12,13.
Secondly, even before they reach their target, systemically administered nanotheranostics need to
circulate through blood and avoid being cleared out prematurely by the RES system. This is a
system composed of phagocytic cells in the lungs, spleen, liver and marrow. In order to achieve
therapeutically relevant concentrations at the tumor site nanoparticles need to avoid early
detection and clearance by RES 14 . Apart from removing the active agents prematurely, an
activated RES also impacts the patients’ comfort, manifesting with “flu-like” symptoms when
cytokines get released.
On the other hand, RES clearance can be beneficial in reducing off-target effects, meaning less
systemic toxicity for the patient. From an imaging standpoint, clearing out the blood background
signal would generate better contrast for the targeted tumors/organs 8 . This tradeoff would ideally
be resolved by finding more efficient extravascular targeting, taking advantage of the cell
transport mechanisms. This would mean requiring lower dosing levels, a decreased whole-body
particle burden and improved safety profiles.
A related design-challenge is the need to avoid complement activation and adaptive immune
responses when administering particulate-based technologies. In situations where they cannot be
avoided completely, a comprehensive risk-benefit analysis must be performed to assess clinical
viability10 . An example of such a situation that is met in the clinic is related to the use of
microbubbles for diagnosis with ultrasound 15 . These agents have been shown to trigger transient
complement activation processes resulting in mild side effects such as back pain. While these
effects can cause discomfort in patients, the overall benefit of the improved diagnosis compared
to the low health risk make this method viable.
A large body of research is dedicated to characterizing the physicochemical properties of
nanoparticles that can alter each of the interactions between nanoparticles and elements they
encounter in their in vivo route to address the aforementioned challenges. One such aspect is
surface charge, and the electrostatic interactions that the charge can impact. For example, past
studies have shown that a high surface charge density could result in faster blood clearance due
to increased interactions between nanoparticles and RES16–18 . Across several compositions of
nanoparticles, high charges, either positive or negative, caused the particles to be phagocytosed
more by liver macrophages, while more neutral or only slightly charged particles has a different
biodistribution19 .
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The type and amount of protein corona, the proteins that attach to the surface of nanoparticles,
that each type of nanoparticle forms while circulating influences their interaction with the
immune system cells17,20 , and translate into the differences in the clearance rates and pathways.
During the particle circulation in blood, surface charge has both qualitative as well as
quantitative effects on the nanoparticle- plasma protein interaction. Surface charge affects the
type of plasma proteins that get adsorbed to nanoparticles, with cationic nanoparticles being
shown to preponderantly adsorb plasma proteins with a pI< 5.5 (like albumin), and anionic ones
binding proteins with pIs> 5.5 (like IgGs)21 . Quantitatively, the density of the charge impacts the
amount of the proteins being bound to the surface.
Additionally, the size of nanoparticles plays a crucial role in their behavior across all the
different barriers encountered on their path to the tumor site, determining how many of the
injected nanodroplets reach the tumor site22,23 . The size of nanoparticles has been shown to
impact their uptake in macrophages and clearance, with particles of sizes between 5-100 nm
considered to have the longest circulation times22 . However, the implication of the size goes
beyond a directly linear relation between macrophage uptake and radius. Smaller particles have
higher surface area, which allows for more proteins to bind onto them, which in turn might
accelerate detection and uptake by macrophages24 . This tradeoff hints at the higher complexity of
design for nanoparticles, which explains why across several studies looking at different
compositions, cancer models and targeting strategies, the delivery efficiency of nanoparticles to
tumors’ sites remained under 1%25 .
Other challenges related to image-guided techniques relate to standardizing the methods and the
way biomedical imaging results are reported from relativistic terms to more quantitative ones.
The robustness of any image-guided method should be verified across institutions and calibrated
uniformly to generate reproducible results10 .

1.3 Imaging Modality Choice
The choice of imaging modality depends on the particular application that the nanotheranostic
carriers are designed to fit. Factors such as the type of tissue, the desired length of the imaging
window, as well as the depth of the tissue being imaged and the required resolution 26,27 .
Nanotheranostic platforms have been described in literature leveraging imaging modalities such
as MRI, computer tomography (CT), positron emission tomography (PET), optical techniques
such as fluorescence or NIR fluorescence, ultrasound, photoacoustic imaging, or combinations of
two or more modalities within the same construct 26–28 .
Table 1-2 Image modalities and their characteristics. Adapted from 19 and 20
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Modality

Type

Singlesource multislice CT

Depth

>10 cm

Spatial
Resolution

500 μm

Contrast
Resolution

Low to
moderate

Information

Advantages

Drawbacks

Anatomical

High
resolution,
very high
depth limit

Radiation,
poor soft
tissue
delineation,
low
sensitivity to
probes

Anatomical,
physiological

Good
temporal
resolution,
good soft
tissue
contrast

Limited
temporal and
spatial
registration
resulting in
difficult
reconstructio
n

Anatomical,
physiological

High spatial
resolution, no
ionizing
radiation,
excellent soft
tissue
contrast

Poor
sensitivity to
probes, low
temporal
resolution,
expensive

Excellent
sensitivity,
non ionizing
radiation

Low
temporal
resolution,
expensive,
potential
mild
physiologica
l sideeffects, not
yet widely
available

X-ray CT

Dual-source
computed
tomography

3 T whole
body

> 10
cm

> 10
cm

200-400
μm

250-500
μm

High

High

MRI

7 T whole
body

> 10
cm

100 μm

High to
very high

Anatomical,
physiological

PETε

Whole body

> 10
cm

2-10 mm

Very high*

Physiological,
molecular

High
sensitivity to
probes

Need for
hard to
manufacture
probes,
radiation,
expensive

SPECT

Single-

> 10

2-5 mm

High

Anatomical,

Great contrast

Poor spatial
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photon
emission
computed
tomography ε

2-12 MHz

cm

Up to
30 cm

physiological

50-500
μm Δ

Low to
moderate
Easy, fast, no
ionizing
radiation,
cost-effective

Depth limit,
poor
contrast, not
suitable for
aircontaining
organs,
bones, the
brain

Physiological,
molecular

Multichannel
imaging, no
ionizing
radiation,
sensitive to
probe dose

Need for
probes, not
widely
available in
clinics, low
depth
penetration,
low
resolution

Physiological,
molecular

Multichannel
imaging, no
ionizing
radiation,

Small field
of view, iv
or topical
probes are
needed

Anatomical,
physiological

Ultrasound
40 MHz

Diffuse NIR
fluorescence

1 cm

1 cm ¥

40 μm Δ

1-5 mm

Moderate

Varies

φ

Optical

Highresolution
fluorescent
molecular
endoscopy

<1 cm ×

5 µm

High

*

varies with the radiotracer specificity

¥

up to 3 cm for NIR-II window (1000-1700 nm)

φ

large variation based on depth of imaging

ε

usually used together with CT or MRI

Δ axial
×

resolution,
needs to be
used
together with
a different
technique

resolution; lateral resolution is depth-dependent and typically 1.5x poorer than axial.

varies with the fluorophore used.

As an image-guided drug delivery modality, ultrasound has a series of advantages that make it
preferable over other physical modalities. It is cost effective and generally accessible, w hile
simultaneously being a safe, non-ionizing imaging technique, compared to CT/PET. Ultrasound
imaging is based on acoustic impedance and provides high resolution images, at depths of 10 cm
or higher, with the possibility of live imaging. Additionally, using ultrasound as a drug-delivery
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triggering mechanism is also possible, allowing for tumor sonication with good control and the
ability to target deep seated tumors. Sonication of this type can also be performed noninvasively,
or minimally invasively through laparoscopic or percutaneous means31 .
Ultrasound has been shown to have biological effects on tissue that might be beneficial in the
context of drug-delivery. Bubbles (endogenous or exogenous) in the environment cavitate when
ultrasound is applied, 2 main regimes being described: stable cavitation or inertial cavitation.
These terms are used to describe the type of oscillations that microbubbles undergo when
subjected to an ultrasound field: either sustained small amplitude oscillations (stable cavitation),
or rapid and violent oscillations resulting in the microbubble’s collapse (inertial cavitation) 32 .
Both types of cavitation events can contribute to ultrasound -mediated drug delivery (Fig 1.2). In
the case of stable cavitation, microbubbles push on the walls of blood vessels, widening the
interendothelial gaps, to allow for more flow into the interstitial tumor 33 . Systemically injected
microbubbles have been shows to induce alternating invaginations and distensions of the blood
vessel walls34 , damaging the endothelial lining temporarily. If the cavitation happens within the
tissue, studies have shown that the sonoporation affects individual cell membranes, allowing for
the diffusion of drugs, biotherapeutics or genes to penetrate in the intracellular space and reach
the nucleus35,36 . Inertial cavitation, on the other hand, is characterized by more powerful
mechanical forces, in the form of microjets or shockwaves that result from the collapse of
bubbles32 . These phenomena can also aid in propelling drug-delivery systems or drugs across the
vessels into the interstitial tumor space, and across cell membranes. While for endogenous
microbubbles, the energies required to cause such effects would exceed the safety limits, by
generating exogeneous microbubbles these thresholds are greatly reduced.
In vitro studies showed the effects acoustic droplet vaporization on cells in the close proximity of
perfluorocarbon nanodroplets. As in the case of endothelial lining, the membranes of cells got
permeabilized by ultrasound, some reversibly and some irreversibly 35 . In the case of ADV, two
mechanisms are thought to be responsible for cell sonoporation: 1) the rapid phase transition
from liquid to gas and bubble evolution and 2) the resulting bubbles behavior under ultrasound
(cavitation and displacement)35 . While factors such as distance between bubbles and cells,
droplet concentration and intensity of ultrasound used for ADV were investigated in vitro, it is
not completely clear how these factors would play in an in vivo environment when it comes to
reversible or irreversible sonoporation.
Apart from cavitation-related effects in tissue, ultrasound has also been shown to produce
localized heating at various frequencies37 . These effects might be leveraged for increasing
permeability of blood capillaries, or cell membrane fluidization in some cases, but good control
has to be possible to minimize off-target effects. Other effects of ultrasound that might be of
interest in the field of drug-delivery relate to acoustic streaming and ultrasound radiation
forces38 . The force sound propagating through a medium produces upon the medium, that results
in fluid translation, is called acoustic streaming. Similarly, the force displacing particles
suspended in the medium is called the radiation force. Employing these effects, one could find a
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regimen to help localize and concentrate droplets at the vessel walls, potentially assisting in the
delivery of agents on target. Using high-intensity focused ultrasound (HIFU), droplets flowing in
the direction opposite to the ultrasound radiation were moved and concentrated from the bulk of
a blood vessel to the wall, to enable adhesion and penetration across the vessel wall 39 . The
radiation force and the resultant particle velocity and displacement are proportional to the
frequency and intensity of ultrasound, and are also dependent on particle size and impedance.
This might be a needed precursor for targeted droplets to be able to approach the proximity
required for ligand-receptor interactions.

Figure 1-2 Representation of physical events cavitation nuclei undergo as a result of cavitation,
and their potential biological effects. As the scheme suggests, the interaction between the two
can be leveraged to enable and enhance drug release and uptake.
Diagnostic ultrasound imaging with contrast agents make use of the acoustic impedance
mismatch between the tissue and the fluids containing microbubbles, making them the golden
standard for diagnostic using ultrasound 15 . This status has made microbubbles attractive to drug
and gene delivery applications as well, particularly for image-guided strategies.
Strategies for ultrasound enabled drug delivery include co-injection of drugs or siRNA with
microbubbles, encapsulation of small molecular weight compounds in microbubbles, or
encapsulation in a dedicated drug nanocarrier and co-delivery with microbubbles40 .
Despite their attractiveness derived from being FDA-approved contrast agents, in the context of
image-guided drug delivery microbubbles have certain disadvantages that limit their use41 . Due
to their size they are confined in the vasculature, and not able to extravasate into the tumor
tissue. Moreover, their short circulation times as well as the mismatch between microbubbles
circulation time and potential separate nanoparticle drug carriers might cause issues in achieving
enhanced drug delivery. Additionally, in order to impart sufficient momentum to drug carriers to
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push against several barriers higher energies are needed to cause inertial cavitation that might
damage the healthy tissue/destroy the vessels permanently 42 . This might cause drug-loaded NPs
to not be able to accumulate afterwards, and for the imaging and drug release events to be
disjoint.

1.4 Phase-shift perfluorocarbon nanodroplets
Emulsions are one of the oldest drug carriers that have been used in the clinic, and
nanoemulsions of several types have been proposed as passive drug-delivery systems43 . Among
them, perfluorocarbon (PFC) nanoparticles are a multifunctional theranostic technology that has
been proposed in preclinical models of cancer, atherosclerosis or for tissue ablation. These
particles consist of a PFC core stabilized by a surfactant, polymer or lipid layer, and dispersed in
an aqueous media. Different types of PFC have been used for the development of these NPs,
benefiting from being biocompatible even at large doses, with no toxicity or carcinogenicity, and
a half-life of 3 days in vivo44 . As their name suggests, perfluorocarbon nanodroplets are
nanosized, hence they can address two of the main issues with the microbubbles system: they are
able to extravasate into the tumor tissue through the endothelial gaps, and have considerably
larger circulation times due to their small size.
When exposed to the proper stimulus -acoustic energy, optical energy or magnetic energy- the
core transitions from a liquid to a gas state. The vaporization results in microbubbles 43 . This
implies that drug-loaded, nanoscale droplets can serve as micro-bubble precursors that are able to
accumulate in tumor tissue due to their nanoscale sizes and then convert into microbubbles in
situ under the use of the proper external stimulus45 . The mechanisms for vaporization by
different means are discussed later in this chapter (Section 1.5.2-1.5.4). Nanodroplets lack the
mismatch in acoustic impedance that microbubbles have, so they are not highly echogenic. This
means that nanodroplets are not visible under ultrasound prior to vaporization, although some
applications employing PFC nanodroplets without activating them have been researched and
some notable examples are included in the section 1.6, “PFC nanodroplets beyond cancer drugdelivery”.

1.4.1 Design criteria for PFC nanodroplets
In terms of design criteria, an ideal iv injectable ultrasound-guided drug delivery system should
satisfy the following: i) stability in the vasculature for a prolonged time period; ii) capability of
extravasation into the tumor tissue; iii) sensitivity to vaporization at clinically relevant int ensities
with minimal tissue damage14 . Nanodroplets for ultrasound-guided drug delivery need to be
designed keeping in mind the hurdles mentioned in the previous section about image-guided
therapy.
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One challenge specific for phase-shifting nanoemulsions is overcoming the increase in
vaporization energy for nanoscale constructs. The choice of PFC influences the activation
threshold 2-fold: once through its own boiling point, and second by changing the size of the
nanodroplet. Low boiling point PFCs, which have a shorter carbon chain, are more volatile, and
PFC nanodroplets made from them need less energy to vaporize. However, if the boiling point is
too low, the droplets are hard to synthesize and can spontaneously vaporize before reaching the
desired target. The elevation in boiling point due to the Laplace pressure effect at nanoscale that
is observed for PFC nanodroplets allows them to be stable when exposed to physiological
temperatures46 . However, this increase is directly proportional to an increase in the amount of
energy required to vaporized said nanodroplets.
A second challenge is to ensure the activation is uniform46 . As previously discussed, the
activation threshold of a droplet is dependent on its size, which means polydisperse distributions
result in nonuniform activation profiles. Several techniques to produce and separate nanodroplets
based on size have to be analyzed with respect to the polydispersity of the final result. Common
employed synthesis method include: double emulsions formed by high-energy sonication,
condensation of microbubbles to nanodroplets or microfluidic methods. Beyond polydispersity,
the choice of method influences the reproducibility of results from batch to batch, calling for
techniques to purify and store nanodroplets is such manner that their properties are maintained
for a sufficient amount of time47 .
Moreover, appropriate activation thresholds for polydisperse emulsions need to be determined in
conditions as close to in vivo as possible. Methods to improve on the detection of submicron
particle activation thresholds are needed to create an activation profile of polydistributed
emulsions.
The choice of which activation method to use – some requiring the incorporation of other agents
in the formulation- is discussed more in the section about vaporization mechanisms.

1.5 Mechanisms of extravasation and distribution of carriers/drugs in the
tumor tissue
Several processes control the fate of the carriers, each dominating potentially at different steps of
the way48 . Initially particle extravasation is the dominant factor, later followed by diffusion of
nanoparticles and tumor tissue uptake. Extravasation can happen under different regimes:
membrane (internalization rate >> diffusion rate), stationary (rate of internalization high, initial
concentration low), kinetic (diffusion rate is high)34,49 . Nanodroplets act more like “nano
implants” with low rates of dissemination in tissue 44 . This can lead to nonhomogeneous
distributions of droplets within the tissue, but this aspect can be resolved or improved by the
application of ultrasound. An “ideal” carrier should involve not only an optimized drug retention
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during circulation, but also optimization of the carriers’ diffusion parameters to ensure uniform
distribution in the tumor and minimize flow to the normal tissue 14 . This makes nanodroplets a
superior candidate to drug-loaded micelles, particularly given the fact that their distribution can
be tuned by applying ultrasound 44 .

1.5.1 Passive accumulation by enhanced permeability and retention (EPR) effect of
nanosized constructs and EPR limitations
Tumor tissue has been proven to have poor vascularization, and a poorly organizer architecture,
together with reduced or deficient lymphatic drainage. These have been shown to generate the
enhanced permeability and retention effect that enables the permeation and accumulation of
nanoparticles of appropriate sizes13 . The interendothelial gaps have been shown to be in the
range of 380-780 nm for various tumors, with some going up to 2 µm pore size. To contrast that,
normal tissue endothelial linings have tight junctions with much lower cutoff sizes, with 7.5 nm
being a characteristic one43 .
However, the same characteristics (i.e., the leaky nature of the vasculature coupled with the lack
of a proper lymphatic drainage) often result in high interstitial fluid pressures, that hinder
transport of drug carriers across blood vessels11,14 . Moreover, tumors show spatial heterogeneity
in the interendothelial gaps that causes heterogeneity in the distribution of nanoparticles and
potential enabling of drug resistance in areas with low or lacking vasculature that get exposed to
sub-therapeutic amounts of drugs13,50 .
As mentioned before, ultrasound used together with certain agents (i.e., microbubbles, phasechanging nanodroplets) has been shown to increase the permeability of vessels by vascular
disruption12,13,50 . It is theorized that the radiation force that concentrates droplets at the vessel
wall, together with the cavitation of the resulting microbubbles mechanically impact the
junctions in the endothelial lining34 . Changes in the type or size of agent, its concentration, as
well as the activation parameters like duration, pulsed vs. continuous stimulus, frequency and so
on- were shown to modulate this effect 12,51 . Thus, a wide range of phenomena can be observed,
from increased tumor perfusion to temporary vessel shutdown.
Drug-loaded PFC nanodroplets might be used alone to enhance the EPR effect, or in
combination with microbubbles, or empty nanodroplets with a different activation threshold to
allow for multi-phase vaporization52 . To obtain two types of nanodroplets that activate at
different thresholds there are several options. First, two different cores could be used, with
different boiling points which will give a difference in activation threshold. Secondly, a bimodal
size distribution of the same droplets can be used (one loaded to deliver the drugs, and another
empty to disrupt the vasculature). It is a documented fact that activation threshold is inversely
proportional to droplet size – the smaller the construct, the higher the peak negative pressure to
activate it has to be43 . Lastly, in the case of using optically-activatable nanodroplets, two
different dyes can be used to separate the two activation events 53 .
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1.5.2 Acoustic Droplet Vaporization (ADV)
The phenomenon of acoustic droplet vaporization describes the phase transition of the core from
a liquid to a gas triggered by an acoustic wave. The ultrasound waves start propagating nonlinearly, generating subharmonics. These high-frequency waves focus within the droplet, causing
a peak negative pressure that lowers the perfluorocarbon’s boiling point 54 . ADV is usually
initiated using strong focusing of the generated beam, high frequency of the emitted sound waves
and a relatively long distance between the transducer and droplet. In fact, this constitutes one of
the main advantages of ADV as a triggering mechanism- the depth of penetration on the order of
centimeters.
After vaporization starts, the bubbles behavior is dominated by inertia and heat transfer events.
Both processes happen simultaneously, with inertia dominating at the early stage and the
diffusion effect dominant at later growth stages 55 . Bubbles can grow due to droplet-bubble or
bubble-bubble coalescence or due to diffusion of dissolved air and/or perfluorocarbon from
smaller to larger bubbles (Oswald ripening)41,56 .
Interestingly, microbubbles formed after ADV in vivo were shown to be able to be translated
using ultrasound stimulation of the tumor after vaporization, at lower intensity than the
vaporization threshold. The microbubbles were seemingly stable and could be moved towards
poorly perfused regions of the tumor, allowing for a more uniform reach within the tissue 57 .
Beyond enabling drug or gene delivery to tumors, ADV has also been used in vascular occlusion
to cut the blood supply to tumors, or for high-intensity focused ultrasound tumor ablation.

1.5.3 Optical Droplet Vaporization (ODV)
On the other hand, optical droplet vaporization relies on the absorption of optical energy - in the
form of short-pulsed laser light - by the certain absorbers, and its conversion into thermal energy.
This results in a localized temporary temperature increase and broadband pressure waves. Above
a particular laser fluence, threshold that is characteristic to each system, the perflurocarbon core
receives enough energy for the phase-transition to occur. Several light absorbing species have
been investigated for this purpose, including gold nanorods or nanoparticles, other inorganic
nanoparticles (PbS, iron-based nanoparticles etc.), and organic dyes (e.g., indocyanine green,
methylene blue, Nile red etc.). Near infrared light is preferred for the absorption domain due to
its good penetration depth in vivo, as well as low background in human tissue 58 .
Beyond the advantage of allowing for a supplementary imaging modality, photoacoustic
imaging, ODV is also a prime candidate to use in situations where ultrasound beams cannot
effectively penetrate, such as gaseous enclosures in the human body like the lungs. Additionally,
this strategy could be used to form multiplexed droplets, with various functionalities or staged

15

deployments. For example, using different optical absorbers can be used to separate the
wavelengths used for photoacoustic imaging and for vaporization/drug release triggering. The
photoacoustic functionality of the same droplets could be used to image their location before the
therapy, and coupled with ultrasound imaging after ODV to confirm the payload delivery 59 .
Moreover, ODV and ADV can be combined to contribute to lowering the necessary thresholds in
terms of laser fluence or ultrasound intensity necessary for triggering the vaporization. This
strategy may be particularly useful in vivo, as it decreases the chances of unwanted side effects
like tissue heating, especially important when dealing with biotherapeutics60 .

1.5.4 Magnetic Droplet Vaporization
Magnetic hyperthermia has also been explored as a potential vaporization triggering mechanism.
Its working principle is that under alternating current magnetic fields, certain magnetic particles
can transform electromagnetic energy into heat. The advantage of using AC current is that it has
good tissue penetration depth and it could cover the whole organs, removing the need of
knowing the exact location of the tumor prior to starting the treatment. Provided a good targeting
of the droplets is achieved, the magnetic droplets would deposit energy at the tumor site with
minimal effects to other organs61,62 . Magnetic particles were generally dispersed in the liquid
core and work determining their fate after the phase-transition is still lacking. Another point to
note is that all the magnetic droplet vaporization has been applied to imaging alone, rather than
drug delivery, so this mechanism would not be the preferred one for drugs that might be thermoor magneto-sensitive63 .
Perfluorocarbon nanodroplets with magnetic particles have also been used to give an external
guiding modality by employing a magnetic field to concentrate the droplets at the site of the
tumor, while using ADV for the triggering itself 64 . Similar constructs were used for the
ultrasound-mediated delivery of paclitaxel65 .

1.6 PFC nanodroplets beyond small molecule-delivery
Beyond being extremely useful as ultrasound-guided drug or gene delivery systems as discussed
so far, perfluorocarbon nanodroplets have been proposed for various other applications in the
medical field. This section briefly mentions the most notable examples of PFC nanodroplets
applications, some of which have applications in the field of cancer theranostics and some of
which expand beyond that.
1.6.1 Immunotherapy
Immunotherapy has been shown to be one of the most promising strategies for cancer patients.
The main principle behind the type of strategies that fall under the immunotherapy umbrella is
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using a patient’s own immune system to attack and destroy cancer cells. An effective immune
response consists of three steps: 1) dendritic cells capture tumor antigens and process them to
acquire “mature signals” to activate an immune response; 2) dendritic cells transfer this
information to immature T cells and activate them; 3) T cells infiltrate the cancer tissue,
specifically recognizing and killing cancer cells66 . However, these processes are many times
hindered by mutations in the cancer cells, making the eradication of the tumor by the immune
system difficult 67 . Immunotherapy tries to activate or boost the immune system in a precise
manner to aid in fighting cancer cells. Immunotherapy can be classified in active or passive, and
both these strategies have been shown to be reinforced by ultrasound responsive agents
(microbubbles/nanodroplets)68 .
One strategy implies using nanocarriers to deliver tumor antigens to immune cells in vivo to
boost a tumor-specific immune response66 . Another proposed method is adoptive cell therapy, in
which immune cells such as T-cells or natural killer cells are modified ex-vivo and injected back
into the patient, while nanodroplets/microbubbles are used to enhance their permeation at the
tumor site. The same role of enhanced permeation is being leveraged in the administration
monoclonal antibodies to inhibit regulatory immune checkpoints that block T cell action 55 .
Although several clinical studies have shown efficacy of such checkpoint inhibitors (e.g CTLA4, PD-1)69 , one of the major hurdles of this therapy is the unavailability of intra-tumoral Tcells68 . Localized delivery of immune checkpoint inhibitors have been shown to lead to an
enhanced therapeutic effect and minimize side effects70 , however the potential of phasechanging nanodroplets in this area has not been explored.

1.6.2 Blood-brain barrier (BBB) opening
An interesting application that PFC droplets have been proposed for is the opening of barriers of
the central nervous system- the blood-brain barrier and the blood-spinal cord barrier. Although
this might fall under cancer therapy when opening the BBB is used to target brain tumors, its
applications extend beyond that, with clinical trials looking at several neurological diseases, such
as Alzheimer’s disease55 .
The opening is realized due to the interaction of a focused ultrasound field and oscillating
microbubbles that stretch endothelial tight junctions and increase uptake through
mechanotransduction pathways71,72 . An advantage of using phase-changing nanodroplets over
microbubbles is their longer circulation time, as well as the possibility to very narrowly target a
specific area to be opened. This is thanks to the droplet’s activation being dependent of the
locally applied stimulus (laser light, ultrasound pressure). Once the initial permeabilization of the
barrier is achieved, the non-activated droplets could permeate within the cerebral tissue and be
activated at a later time point, enabling enhanced delivery at sites that are deeper in the brain.
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1.6.3 Oxygen delivery
The oxygen dissolving and shuttling capacity of PFCs creates an oxygen sink, which, in pure
form, provides a substantial reservoir of oxygen for biological applications. This property of
PFCs has been exploited to create oxygen-delivering nanodroplets for various applications.
Originally, PFC emulsions were designed as blood substitutes, with several studies demonstrated
that the oxygenated emulsions have similar outcomes to whole blood transfusion in traumatic
injuries73 . More recently, these properties of PFC nanodroplets have been investigated in the
context of cancer treatment to address one of main hallmarks of solid cancer tumors: hypoxia.
Experimental evidence indicates that hypoxic regions in the tumor microenvironment play an
important role in promoting growth, as well as in producing treatment resistance to
chemotherapy or radiotherapy74 . Dissolving oxygen into the core of PFC droplets, and
administering the droplets, followed by their activation was shown to be beneficial in
reoxygenating hypoxic regions in vivo75 . A different strategy aiming to address the resistance to
treatment involves loading a photosensitizer into the nanodroplets to generate an enhanced
response to photo-dynamic therapy76,77 .
PFC nanodroplets have also found their place as oxygen-delivering vehicles in the treatment of
preeclampsia. Preeclampsia is diagnosed as pregnancy related high blood pressure, and it is
believed to be initiated by placental ischemia. This event increases the expression of hypoxia
inducible factors and the production of antiangiogenic factors that result in maternal endothelial
dysfunction leading to hypertension78,79 .
A third category of hypoxia-related afflictions is represented by rheumatoid arthritis. Similar to
locally invasive tumors, abnormal proliferation of synoviocytes leads to local hypoxia that plays
an important role in the pathogenesis of rheumatoid arthritis. The cells perpetuate inflammation
by secreting cytokines and proteases and advance cartilage destruction, while hypoxia leads to
increased angiogenesis that feeds back into the enhancement of inflammation 80 . PFC
nanodroplets can be used in this context taking advantage of the EPR effect that is characteristic
to inflamed tissue such as the one in rheumatoid arthritis. Drug-loaded or oxygen-loaded
nanodroplets for anti-angiogenic treatment or photodynamic therapy, respectively, were
developed and employed in this application 81,82 .
1.6.4 Molecular Ultrasound Imaging
Molecular ultrasound imaging refers to using targeting strategies on ultrasound contrast agents to
image specific biomarkers. Molecular ultrasound imaging offers a good amount of tissue
contrast, superior to more harmful modalities such as PET, and can give access to important
functional information. The targeting capabilities are obtained by the same methods as active
targeted drug delivery systems: attachment of target-specific molecules to the surface either
covalently or non-covalently83 . In the case of using functionalized microbubbles as molecular
ultrasound contrast agents, their size once again impedes their use beyond vasculature 84 .
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Therefore, molecular targeting with PFC droplets by functionalization of the shell with various
targeting moieties was proposed.
In the case of thrombosis, fibrin-targeted nanodroplets were used to generate an acoustical
enhancement of acute vascular thrombi85 . While droplets in circulation do not give a high
ultrasound signal, their accumulation in high enough concentration when bound to a surface
enhances the echogenicity of the target. While this approach could take advantage of higher
boiling points PFC thus using more stable droplets, other applications where the target is not as
abundant would not generate the same contrast without the activation of droplets and their
transformation into microbubbles86 .
Similarly, PFC nanodroplets have been proposed for anti-VEGF therapy and proposed to enable
a contact facilitated drug delivery, in the case of some types of cancer and atherosclerosis
models. In the case of cancer treatment, multiple ligands were proposed to improve the targeting
capability of droplets87,88 , alas most of them were not used primarily for molecular imaging.

1.6.5 Other imaging modalities
The possibility of a secondary imaging modality that does not depend on the activation might
help estimate the distribution of nanodroplets within the body and its kinetics. In turn, this
information could guide the temporal regime of activation, as well as potentially enable
predictions related to potential side effects.
PFC nanodroplets have been proposed in the context of MRI imaging, by incorporating
gadoliunium compounds in the shells or the core of the particles. Additionally, the presence of
perfluorocarbons in the core, that present with 19F isotopes, coupled with the very low
background for 19F in vivo, makes these structures uniquely appropriate for 19F MRI
quantitative imaging89 , quality that has been explored in the context of thrombosis and
angiogenesis90,91 . Other functionalities that were explored include the encapsulation of
radiolabeled components used in conjuncture with microPET or SPECT90 .
Another imaging modality that has been explored and brought interest with relation to PFC
nanodroplets is photoacoustic imaging. Droplets that encapsulate a dye that allows ODV can also
be imaged via photoacoustic imaging or tomography, as touched upon in the section dedicated to
ODV. Photoacoustic (PA) imaging or optoacoustic imaging is a modality based on the use of
laser-generated ultrasound 92 . The contrast in PA imaging depends on the optical absorption of
chromophores, rather than the mechanical and elastic properties of tissues like ultrasound. Thus,
PA imaging can offer greater specificity towards certain clinically relevant molecules such as
hemoglobin, lipids, water and other light-absorbing species, while maintaining higher depth of
penetration than purely optical modalities93,94 . These properties have made PA imaging an
interesting option for a variety of clinical and preclinical applications, in the study of cancer,
cardiovascular disease, or other conditions that are associated with microvasculature
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abnormalities92,95,96 . Chromophores that could be imaged by PA include endogenous agents
(such as melanin, hemoglobin etc.), or exogenous agents (like colored dyes, certain metal
nanoparticles or quantum dots).
As with US imaging, nanoparticle structures have been designed to enhance the PA image
contrast, absorbing more light than tissue chromophores to enable the identification of the
targeted tissue. Recently in the photoacoustic research world, a lot of attention has been directed
toward leveraging vaporization as a way to generate high PA signals and improve signal to noise
ratios60,78,97–99 . Combining PFC nanodroplets with PA contrast agents, by encapsulating various
dyes or plasmonic particles, has created a new class of photoacoustic nanodroplets 97 . These
leverage the optical absorption of laser pulses two-fold: for ODV of the liquid core that generates
US contrast and for producing a high amplitude PA signal due to bubble formation.

1.6.6 Anti-bacterial treatment
Acoustically activated PFC nanodroplets were leveraged for their enhancement of antibiotics’
activity on biofilms made up from antibiotic resistant bacteria like methicillin-resistant
Staphylococcus aureus (MRSA). The activation of droplets, done sequentially with low-intensity
pulsed US coupled with vancomycin increased the bactericidal efficacy100 . In a different study,
optically activated nanodroplets, loaded with rifampicin, were used to deliver a synergistic
photo-, chemo- and probiotic therapeutic anti P. acnes, the bacteria that causes acne 101 . Although
neither of these applications take advantage of the imaging capabilities of PFC nanodroplets
platforms, they are worth noting as they exemplify the versatility of these constructs.

1.7 Conclusions
Given the properties discussed here, we believe phase-changing nanodroplets are a promising
platform for the development of several image-guided cancer combination therapies. With the
proper design, and changes in the formulation of nanodroplets, we can produce nanoparticles
capable of delivering small molecular compounds or large molecules, while at the same time
serving as precursors of ultrasound contrast agents.
In this thesis, we design, synthesize and characterize a perfluoropentane nanodroplet platf orm to
be used for a variety of applications: combination chemotherapy as a potential neoadjuvant
treatment (Chapter 2), combination chemotherapy and immunotherapy (Chapter 3), and
fluorescence-ultrasound multimodal imaging by switchable probes (Chapter 4). Further,
optimization methods for nanodroplets formulation and storage are explored (Chapter 5). The
following chapters highlight the need that our platform addresses, as well as the design rationale
and the methods employed to characterize it. The results to date are presented in the context of
other works, and current limitations and points to address in future developments are addressed
(Chapter 6).
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Chapter 2 : Nanodroplets for Ultrasound-guided Codelivery of Hydrophobic and Hydrophilic
Chemotherapeutics
This chapter describes design criteria for drug-loaded perfluorocarbon nanodroplets, the
components and decision making for choosing them. Further, the functionality of the droplets is
discussed, together with some other potential functionalities and limitations of the constructs.
The synthesis process and characterization methods are described in detail, together with results
from representative batches of nanodroplets. Characterizations such as size, stability, loading
efficiency, on-demand drug release, as well as biological activity are included.

2.1 Nanodroplets Components
The choice of perfluorocarbon nanodroplets for image-guided drug delivery is based on their
benefits as expressed in Chapter 1.4, when compared to gaseous microbubbles. Microbubbles are
the gold standard in the clinic for ultrasound contrast agents due to their highly scattering
acoustic properties. Although their application as contrast agents is ubiquitous, the size of
microbubbles significantly reduces their circulation time and their capability of extravasating
outside the vascular system1 . In drug-delivery applications, that have longer span of action and
that rely on the preferential accumulation (either passive or active) of drug carriers at the tumor
site, the use of nanosized phase-changing droplets is preferred 2 . A schematic of the construct
proposed in this chapter is presented in figure 2.1

Figure 2-1 Schematic of a dual-loaded nanodroplet’s cross section.
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2.1.1

Core

The choice of the core perfluorocarbon took into consideration several factors including usage in
FDA-approved applications, boiling temperature, cost and ease of synthesis. The base principle
of nanodroplets is the presence of a liquid that can be vaporized by an external energy source.
The higher the boiling point of the core, the more energy needs to be provided for a significant
increase in temperature3,4 . In order to decrease any side effects of the temperature increase on the
tissue or the encapsulated drugs, as well as the depth at which nanodroplets can be vaporized, it
is desired to use a perfluorocarbon that is superheated at physiological temperatures4 . The boiling
temperature of perfluorocarbons increases with the number of carbons in the backbone, as shown
in table 2.1
Table 2-1 Perfluorocarbons used for externally-activated nanodroplets and their boiling points as
reported in literature/supplier websites.
Compound

# Carbons

b.p.

Perfluorobutane

4

-1.7

Perfluoropentane

5
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Perfluorohexane

6

56

In order to be able to conduct the synthesis and purification steps at room temperature, and keep
the cost of the production low, perfluoropentane was chosen for this work. Perfluoropentane is
relatively inexpensive and commercially available, and it does not require special adjustments to
the synthesis method, like low temperature, condensation processes or others 5 . Some batches
using perfluorohexane instead of perfluoropentane were synthesized for comparison purposes,
but were not tested further than size and polydispersity.

2.1.2 Shell
Another essential part of the nanodroplets’ design is the choice of shell material, which can be
formed from lipid mixtures, polymers, proteins or polysaccharides. Out of them, lipids present
several attractive features. Firstly, they are relatively easy to synthesize, the lipids are versatile
and many commercial options exist. Surface properties such as charge are easily tunable by
changes in composition, and targeting moieties can be conjugated on the surface with relative
ease. Further, the elasticity of the shell allows for facile sizing using lipid extruders, generating
narrow size distributions. Another interesting aspect of lipid shell particles, particularly ones
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containing phospholipids, is their ability for “contact facilitated lipid exchange” t hat can allow
delivery of payloads to the cytoplasm by merging of lipid -shell particles with the cell lipid
bilayer6 . For all these characteristics, a lipid shell was used for the development of nanodroplets
presented in this work.

2.1.3 Drug encapsulation
One of the hallmarks of cancer that many others derive from, is the multiple successive
mutations that cells can undergo during their progression. Due to a high proliferation rate,
mutation chances are also large, meaning that cancer cells can respond to alterations in their
environment quickly, by selecting the mutations that favor survival. These factors make tumors
challenging to treat, as acquired resistance to treatments can occur early on in the regime 7 . For
this, the use of multiple therapeutic treatments, often called “combination therapy” is tested and
adopted in several types of cancer7,8 . Combination chemotherapy, the use of two or more drugs,
often allows oncologists to reduce the dosage and increase efficacy by generating a bet ter
response compared to single-agent therapy. However, there are hurdles to be jumped over in the
case of combination therapy as well. Agents have to be chosen in such manner that they target
different disease pathways, to ensure they will not get blocked by the same type of acquired
resistance. Moreover, their effects towards cancer cells should be neutral or synergistic, to enable
a better tumor response. The administration of multiple drugs is not straight forward, as their
different properties are bound to result in dissimilar pharmacokinetics profiles and
biodistributions, and optimized dosage is dependent on a multitude of factors. The choice of
drugs that are used in combination, as well as the administration sequence is often dependent on
the slight differences between the cancer cells and normal cells in the particular case.
Doxorubicin/paclitaxel regimes have been shown to result in better efficacy in the clinic for the
treatment and neoadjuvant therapy of breast cancer9 , while cisplatin/paclitaxel combination
therapy is the gold standard for treating non-small cell lung cancer, and several types of head and
neck cancer10 . Several studies also underline the potential of combination therapy to lower side
effects in normal cells while maintaining a therapeutic effect, such as in the use of low-dose
doxorubicin to produce G1/G2 arrest in non-target cells, followed by paclitaxel to induce mitotic
arrest in the cancer cells that are still dividing 8,11 . This type of strategy could be useful for tumors
that lack p53.
In order to improve and better control the pharmacokinetic profile of drugs in combination
therapy and their ratios in vivo, the idea of employing nanomedicine to co-deliver multiple drugs
emerged 7 . By unifying the pharmacokinetics of the two or more drugs, at a particular
predetermined loading ratio, the degree of synergism can be tuned to achieve improved
therapeutic effects.
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In this work, we produced dual-loaded nanodroplets with a doxorubicin/paclitaxel combination.
Our platform is versatile in terms of the therapeutics to include, as shown by multiple
incorporations of various hydrophilic or hydrophobic compounds, either in the core or the shell
of the nanodroplets, respectively. However, care has to be given to factors such as solubility and
relative solubility of the compounds, as that could guide which combinations will indeed be
useful from a therapeutic point of view. Early in this work, cisplatin/paclitaxel containing
droplets were obtained, however, due to the relatively low solubility of cisplatin in aqueous
media, as well as the difficulties in quantifying the loading and release, it was deemed that this
procedure was not suitable for the respective formulation.

2.1.4 Optical activation and inclusion of dyes
As previously detailed in Chapter 1, optical activation by NIR light relies on the presence of a
dye to absorb the light and convert it into energy in the form of increased temperature and
ultrasound waves. When this energy is sufficiently high, the liquid core of perfluoropentane gets
vaporized in a process called ‘optical nanodroplets activation”. Several agents have been
proposed as absorbers to be encapsulated in perfluorocarbon nanodroplets, including organic
dyes – indocyanine, methylene blue and inorganic materials- PbS, iron-based nanoparticles etc.
In this work, we use Epolight™ 3072, a lipophilic dye with a maximum absorption at 1064 nm,
and a good solubility in organic solvents including chloroform. This property allows for the codissolution of epolight with the lipids during synthesis, as well as easy clean-up of
unencapsulated dye after synthesis due to its separation from the aqueous dispersion media. The
dye is a nickel dithiolene complex, that is not cytotoxic in the concentrations used in this work,
as shown later in this chapter in our in vitro testing.

2.2 Synthesis procedures
2.2.1 Synthesis of Nanodroplets
The dual-drug loaded nanodroplets (DDDs) were synthesized by a double emulsion method. The
first emulsion was synthesized by a thin-layer hydration-sonication method. Typically, a mixture
of dipalmitoylphosphatidylcholine (DPPC, NOF America), 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG 2000, NOF America) and
cholesterol (Alfa Aesar), in a molar ratio of 35:15:50 was added to 3 mL chloroform and
evaporated under vacuum (250 mbar) with a rotary evaporator at 38.5 °C. Paclitaxel (2 mg,
Fisher Scientific) was dissolved together with the lipids in chloroform for co-assembly. To
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enable laser activation capabilities of nanodroplets, a NIR dye, Epolight™ 3072 (Epolin) -with a
maximum absorbance at 1064 nm- was added together with the lipid mixture in chloroform.
After the mixture evaporated and formed a thin film, 3 mL of 2:3 v/v water: Dulbecco’s
phosphate-buffered saline (Corning) were used for rehydration, and the mixture was subjected to
a sonicating bath for 5 minutes at room temperature. Next, the mixture was dispersed with a
sonication probe (QSonica, Q700, 1/8 inch microtip) for 30s continuously, at 27 W/cm2 in an
ice-bath to prevent the sample from over-heating.
The second emulsion was constituted by aqueous doxorubicin solution (Advanced ChemBlocks)
in perfluoropentane (PFP, Fluoromed). The doxorubicin solution (0.25 mL, 7.0 mg/mL) was
added to a mixture of PFP (1.5 mL) and emulsifier (Krytox™ FSL, 20 µL), and sonicated with
the ultrasonic probe under the same conditions described before. Different formulations were
tested before settling for these specific ratios between the drug solution, PFP and emulsifier. A
volume of 200 µL of this emulsion was added to the lipid -paclitaxel mixture and sonicated for an
additional 30s on the same settings as above. For empty nanodroplets, this step consisted of only
adding the PFP, followed by the same sonication regimen.
The nanodroplet mixture was centrifuged with an Eppendorf MiniSpin centrifuge at 43 rcf for
60s, to remove large aggregates and unencapsulated components, such as paclitaxel or Epolight,
that settle out of the dispersion due to poor solubility in water. This was followed by collecting
of the supernatant and two more steps of centrifugation at 2100 rcf , for 60s each. For each of
these steps, the supernatant was discarded and replaced with distilled water, to remove micelles
or unincorporated doxorubicin.

2.2.2 Extrusion of DDDs
After synthesis and washing steps, the DDDs were downsized by extrusion through a miniextruder (Avanti Lipids) with a 0.4 µm polycarbonate membrane for a total of 11 passes. The
sample of nanodroplets was diluted to a 10x dilution prior to the extrusion process. The extrusion
system was prepared by passing distilled water through it for 2 passes, to pre-wet the membrane,
and minimize losses to the droplets’ sample. The process was undertaken at room temperature,
using a volume of 1 mL per batch.
For cell studies, the sample was further filtered through a sterilizing 0.2 µm syringe filter
(Whatman® Puradisc, polyethersulfone) under a biological hood to ensure sterility.
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Figure 2-2 Synthesis schematic of dual-drug loaded, optically activatable nanodroplets.

2.3 Materials
Table 2-2 List of materials and suppliers used for the synthesis of dual-drug loaded nanodroplets.
Product name

Use

Supplier

Dipalmitoylphosphatidylcholine
(DPPC)

Nanodroplet shell

Avanti, NOF

1,2-Distearoyl-sn-glycero-3phosphoethanolamine-Poly(ethylene
glycol)2000 (DSPE-PEG)

Nanodroplet shell

Avanti, NOF

1,2-Dioleoyl-3-trimethylammonium
propane (DOTAP)

Nanodroplet shell

NOF

Cholesterol, 95%

Nanodroplet shell

Alfa Aesar

Perfluoropentane

Nanodroplets core

Fluoromed
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Paclitaxel

Loaded in shell

Doxorubicin

Loaded as emulsion in Advanced ChemBlocks
core

Krytox ™ FSL

Emulsifier for hydrophilic Chemours
drug

Epolight 3072

Dye for NIR activation

Acetonitrile

Used
to
dissolve Alfa Aesar
nanodroplets for paclitaxel
measurements

Fluorescein isothiocyanate DSPE- Nanodroplets shell
PEG 2000 (FITC-DSPE- PEG 2000 )
fluorescently-labeled
nanodroplets
1,1′-dioctadecyl-3,3,3′,3′tetramethylindotricarbocyanine
iodide (DiR)

Fisher Scientific

Epolin

for Nanocs

Loaded
in shell of Biotium
fluorescent nanodroplets

2.4 Characterization
2.4.1 Size characterization
Average nanodroplet diameter and size distribution were determined by a Malvern Zetasizer
Dynamic Light Scattering (DLS) instrument after 100x dilution to ensure the concentration was
low enough for single-scattering events. All samples were subjected to 3 measurements each,
with 0 time delay between measurements, with an automatic number of runs per measurement, as
determined by the instrument. Size is reported as the d -average, together with the standard
deviation of the 3 measurements. Stability of nanodroplets kept at 4 °C was estimated by the
evolution of size in time, as reported by DLS.

2.4.2 Morphology characterization
Nanoemulsions were diluted with distilled water to a final 100x dilution to minimize droplet
overlays. Approximately 3 μl diluted dispersion were applied on a copper grid covered with CFlat™ holey carbon film 1/1 (Electron Microscopy Sciences). Excess liquid was removed from
the grid by blotting with filter paper. The sample was then immediately shock-frozen by
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plunging it into liquid ethane. These sample preparation steps were done using a FEI Vitrobot
(Thermofisher), at 4°C and 100% humidity.
The subsequent fixation of the grid on the sample rod (Gatan Single Tilt Liquid Nitrogen Cryo
Transfer Holder Model 626) and transfer of the rod into the transmission electron microscope
(FEI Tecnai 20) were done under a nitrogen atmosphere at a temperature of 90 K (-183°C). The
instrument was operated at 120 kV and pictures were taken from 5-10 different positions of the
grid to include all particles of the sample (Camera: Gatan OneView CMOS 4K camera).

2.4.3 Drug Loading Measurement
The nanodroplets were dissolved in a 50/50 v/v mixture of acetonitrile (ACN) and water and
heated up to 60°C to ensure the destruction of all droplets. The PTX concentration was
determined by UV-VIS absorption at 229 nm, by means of a previously constructed calibration
curve. Doxorubicin content was measured by a Horiba FluoroMax spectrofluorometer, using an
excitation wavelength of 480 nm and emission at 590 nm, against a previously constructed
calibration curve. All doxorubicin-loaded samples were shielded from light between preparation
and measurement to avoid quenching.
The encapsulation efficiency was determined by the formula:
𝑒𝑒, % =

𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑,𝑚𝑔
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑖𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 ,𝑚𝑔

× 100 (1)

Measurements were realized for single-drug nanodroplets (PTX-NDs, Dox-NDs) as well as DDNDs.

2.4.4 Drug-release study
Nanodroplets were diluted 20x in phosphate-buffered saline (PBS), and samples incubated in a
water bath at 37 °C under gentle mixing to combat any sedimentation. Samples were taken at the
beginning of the study, after 0.5 h and after 1 h. At the 30-min time point, the corresponding
samples (noted as “laser-activated”) were activated by 1064-nm pulsed laser (Opotek Phocus
HE) with a fluence of 15 mJ/cm2 , for a total of 10 s at 10 Hz pulse repetition frequency. Samples
were centrifuged and the supernatant was measured for the amount of drug based on the methods
described above. The pellet was similarly collected to measure the drug left in the droplets. The
amount of unencapsulated drug measured at the initial time point, was subtracted from the
following measurements. For each of the measurements, the same batch of nanodroplets was
divided in two parts- one that was not activated to serve as a control, and one that was exposed to
the laser at the 30 minute time point. For doxorubicin measurements, the samples collected from
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the inactivated nanodroplets were exposed to laser illumination equivalent to the activated
nanodroplets to account for photobleaching effects.

2.4.5 Drug-release in the presence of serum proteins
To study the influence of protein-nanodroplets interactions on the release of drugs of nonactivated compared to activated nanodroplets, three different media were used: distilled water,
10% fetal bovine serum (FBS, Hyclone) solution and 100% FBS. Nanodroplets were incubated
in the respective media for 1 h, at 37 °C, under gentle stirring, followed by centrifugation at 2100
rcf for 90s and replacement of their suspension media with PBS. After 10 minutes in a water bath
at 37 °C, nanodroplets from the “activated” group were illuminated with the pulsed NIR laser.
Control samples followed the same procedure, except for the activation step. The samples were
centrifuged at 2100 rcf for 60s, and the released doxorubicin was measured in the supernatant.

2.4.6 Doxorubicin-release from positively charged nanodroplets
Samples of cationic loaded nanodroplets were obtained by including 1,2-dioleoyl-3trimethylammonium-propane (DOTAP, NOF America) in the shell, in different molar
percentages, as described in table 2.3.
For zeta potential determination, nanodroplets were d iluted in a 0.01 M NaCl (LabChem)
solution and measured with a Malvern Nano Zetasizer for 3 measurements with an automatically
determined number of runs/measurement. Zeta potential is reported as the mean of three
measurements and standard deviation.
The amount of released doxorubicin was measured in the same way as the DDDs described
above in Section 2.4.4.
Table 2-3 Sample formulations for charged nanodroplets with molar percentages of all
components in the shell. The perfluoropentane in the core is kept constant through the samples,
as is the Epolight amount added for the activation capability.
Sample name

DPPC (molar %)

DOTAP (molar %)

Cholesterol (molar %)

1%

49.5

1

49.5

5%

47.5

5

47.5

10%

45

10

45

37

20%

40

20

40

25%

37.5

25

37.5

2.4.7 Ultrasound imaging
Polyacrylamide gel phantoms were obtained as described before 12 . Briefly, a 10%
polyacrylamide gel was prepared from a solution of acrylamide:bisacrylamide (29:1) (Sigma
Aldrich) adding up to 1.5% v/v nanodroplets suspension, and N,N,N′,N′tetramethylethylendiamine (TEMED, Thermofisher) and ammonium peroxydisulfate (APS,
Sigma Aldrich) as initiator system. Each phantom was set on an in-house built platform and
imaged with a L22-8v Verasonics linear array ultrasound transducer connected to a Verasonics
Vantage 256 imaging system. Images were acquired using plane-wave acquisition with five
compounding angles (-18, -9, 0, 9, 18 degrees) before and after the laser pulse(s). Results are
presented as the difference between the average signal after the trigger and the signal before, as
well as the signal magnitude in the region of interest of the scan.
To investigate the correlation between the concentration of nanodroplets in the phantom and the
change in signal magnitude recorded by ultrasound, a series of phantoms with various volumetric
percentages of nanodroplets dispersion were created: 0.1%, 0.25%, 0.5%, 1%, 1.5%. The
concentration, expressed as particles/mL, was determined from the DLS results using the
Malvern Zetasizer’s built-in concentration measurement tool. To avoid any mismatch, the same
sample of nanodroplets was used for the whole series, and four spots on each phantom were
averaged to account for any heterogeneity for each of the studied concentrations. A 6 x 3.25 mm
rectangular region of interest (ROI) was selected for each of the spots on the phantoms, with the
signal being computed as the difference between the average sum of pixel values in the ROI after
activation and the average sum of pixel values in the ROI prior to activation.
To establish the depth of activation, nanodroplet-loaded tissue-mimicking phantoms were
obtained in the same manner, keeping the nanodroplet concentration constant. Raw chicken
breast tissue was used as a breast tissue substitute and cut into thin slices. Slices of increasing
thickness (0 mm, 6mm, 10mm, 16 mm, 18mm, 20 mm, 22mm) were placed between the laser
and the phantom’s top, keeping the distance between laser beam and tissue top edge constant.
The signal of activated nanodroplets was recorded and the thickness increased until no signal
from activation could be detected. A fresh phantom was used for each of the measured
thicknesses to ensure an equal volume of nanodroplets available for activation. Images were
processed by computing the difference between the frame following activation and that before
activation.
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2.4.8 In vitro cell toxicity studies
FaDu cells (ATTC) were used to assess the cytotoxicity of drug-loaded nanodroplets. Cells
were passaged and seeded into 24-well plates (Corning) in Dulbecco’s Modified Eagle Medium
(DMEM, Corning) with 10% FBS, and 1% mixture of penicillin/streptomycin at a 0.04 x 10 6
cells/well density. The cells were left overnight to attach and grow in an incubator at 37 °C and
5% CO 2 concentration, then subjected to various formulations. The studied groups were: nontreated cells for control, inactivated empty nanodroplets, inactivated DDDs, free paclitaxel +
doxorubicin, laser-activated empty nanodroplets and laser-activated DDDs. Nanodroplets were
added to a 250x dilution in the total volume of each well, or around 4.56 x 10 7 nanodroplets/well.
The concentration of loaded paclitaxel was 1.7 μM and that of loaded doxorubicin was 0.28 μM
with respect to the well volume in the wells that were subjected to drug-loaded nanodroplets. For
the free drug formulation, the same concentrations of both paclitaxel and doxorubicin were used.
The working volume throughout the study was kept constant at 1 mL in each well. Each group
was triplicated. After adding the corresponding formulation, the cells were allowed to rest for 10
min in the incubator, followed by the subsequent activation (pulsed laser, 1064 nm, 10s at 10Hz
pulse repetition frequency) of the specified groups in vitro. The cells were then incubated for 4 h,
followed by washing with PBS and a (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (MTT, Alfa Aesar) assay to assess cell viability.
The same procedures were followed for MDA-MB231 cells (ATCC), with the exception of the
activation method, which in this case was pulsed high-intensity focused ultrasound. A 1.1 MHz
transducer (Sonic Concepts H-151) was used at a focal pressure of 9.6 MPa. 10 pulses of 10
cycles each were applied to each of the wells with the help of a polyacrylamide cone, that was
put in contact with the bottom of the well by means of ultrasound gel to ensure the connection.
The polyacrylamide cone used here was obtained using the same recipe as for the phantoms
described in Section 2.4.7, excluding the nanodroplets from the composition. The activation was
confirmed by both the sound of nanodroplets vaporizing as well as small bubbles appearing in
the wells. This added experiment was necessary to confirm the activation method due to the laser
breaking down.

2.4.9 Cell sonoporation experiment
To probe the effect of mechanical events occurring during the phase transition of nanodroplets,
such as cell sonoporation, FaDu cells were subjected to the same doxorubicin concentration (0.2
µg/mL) either as a free drug, together with empty nanodroplets or formulated in a nanodroplet.
The cells were grown in DMEM media with 10% FBS and 1% penicillin/streptomycin in a 24well plate, with a density of 0.04 x 106 cells/well, overnight. Following this incubation, the cells
were subjected to the different formulations, with 3 wells being used for each of the groups:
control (“Cells”), free doxorubicin (“Dox”), free doxorubicin added together with empty
droplets, containing only the optical absorber Epolight (“DOX + Empty NDs”), and
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nanodroplets’ encapsulated doxorubicin (“Dox-DDs). Each formulation was analyzed in the
case of laser-activated samples (1064 nm, fluence 15 mJ/cm2 , for 10 s at 10 Hz pulse repetition
frequency, activated after 10 minutes equilibration time after adding the corresponding
formulations) or inactivated samples. Post-activation, cells were allowed 4 h incubation,
followed by washing steps and the application of the MTT assay. The same protocol to the cell
toxicity study was followed to evaluate the cell viability of the different groups.

2.4.10 In vitro time of incubation influence
The influence of exposure time of cells to loaded nanodroplets was studied by incubating FaDu
cells with loaded nanodroplets for 10 min, 30 min and 1 h, followed by the replacement of the
media and activation of the internalized/bound nanodroplets, and an MTT assay to assess the
effects on cell viability. For each of the time points, the study included control wells that were
subjected to the same incubation regimen but not activated with the laser. The procedures and
parameters for incubation and activation, respectively, were the same as in Section 2.4.8. All
samples and controls were performed in triplicate.

2.4.11 Internalization of nanodroplets study
FaDu cells were plated at a density of 0.5 x 10 4 cells/mL on a MatTek 35mm, collagen-coated
14mm diameter glass well and left to attach overnight. Cells were incubated with FITC-labeled
empty nanodroplets, obtained by the procedure described before by replacing 10% of the DSPEPEG with a FITC-DSPE PEG (Nanocs). Two samples were included, one in which cells were
incubated with nanodroplets for 10 minutes, and another in which the incubation time was 1h.
The final dilution of nanodroplets in both samples was 100x compared to the stock solution of
nanodroplets, and the same batch was used for both samples. After incubation, the media was
aspirated, and cell layer washed with fresh PBS 3 times. A 300 mM solution of 4′,6-diamidino-2phenylindole (DAPI, Thermofisher) was used to stain the nuclei as described in the supplier’s
protocol13 . Next, a Cell Mask™ Deep-red membrane stain (Thermofisher) was used to stain the
cell plasma membrane following the supplier’s protocol14 . The staining steps were followed by
washing steps and a final cell fixation procedure with formaldehyde (Thermofisher) 3.5% w/v in
PBS. Confocal images were acquired right after cell fixation, with a ZEISS LSM 800 laser point
scanning confocal microscope with Airy scan enhanced resolution, at a magnification of 20x. A
diode laser at 405 nm wavelength, 5 mW together with a 420/450 nm emission filter was used
for DAPI imaging, 488 nm, 10 mW and a 530/550 nm emission filter for FITC, and a 640 nm, 5
mW laser and a 670/710 emission filter for the plasma stain.
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2.4.12 Nanodroplets biodistribution and tumor accumulation
To assess the biodistribution of nanodroplets, a Nu/Nu mouse model (Charles River) was used
and inoculated with hind side tumors by subcutaneous injection. MDA-MB231 cells, a triple
negative breast cancer cell line was employed. The cells were grown in 10% FBS, 1%
Penicilin/Streptomycin enriched DMEM media, until a 90% degree of confluence, they were
detached using trypsin 0.5% (Corning) and counted with a hemocytometer. After centrifuging
the cells, the media was replaced with PBS and the cells resuspended by gentle mixing. The cell
suspension was then mixed in a 1:1 volume ratio with Matrigel (Corning), and injected in the
hind flanks of mice, with each flank receiving approximately 1.5 x 10 6 cells, in a 100 μL total
volume. Tumors were allowed to grow for three weeks, until they reached a size of
approximately 20 mm3 , as measured by ultrasound (Vevo 770, 40 MHz transducer).
To obtain fluorescent nanodroplets that can be visualized with NIR fluorescence, 40 µL of a 1
mg/mL DiR dye solution in chloroform was added together with the lipids in the same amounts
mentioned in Section 2.2.1. The Epolight was omitted, as nanodroplets were to be activated
acoustically. Instead of doxorubicin, in the core emulsion, only distilled water was added,
keeping the other elements identical to those in Section 2.2.1. All the rest of the synthesis and
washing steps were the same as for dual-drug nanodroplets.
DiR-loaded nanodroplets obtained this way were employed and NIR fluorescence imaging (LiCor Pearl Impulse) was used, imaging the mice prior to activation, immediately after the
activation, and for several timepoints afterwards. The tumor to be activated was assigned
randomly, and a 515 kHz annular HIFU was used to activate the tumor, immediately after
injection, for a total duration of 10 minutes, with HIFU pulses at every 20 s, 10 cycles/pulse and
a peak focal pressure of 5.7 MPa.
At 2h post-injection, the mice were sacrificed by cervical dislocation and both tumors were
excised and measured in fluorescence using the same settings as the whole-body imaging. For
two of the mice in the study, the main organs- liver, spleen, kidneys, heart, lungs- were excised
and imaged alongside the tumors. The percentage of signal from the total signal across the
organs was computed for all the organs, as well as the tumors, using fluorescence intensity as a
proxy for nanodroplets’ dose.

2.4.13 Dual-drug loaded nanodroplets in vivo efficacy
A similar model of triple negative breast cancer as described in the previous sections was
employed. Each mouse was inoculated with two hind flank tumors by injecting a 1:1 volumetric
mixture of MDA-MB231 cells in Matrigel, with an approximate number of cells of 1.5x10 6 per
flank. The tumors were allowed to grow for around 3 weeks, or until they reached a volume of
approximately 20 mm3 , as measured by the Vevo 770 system.
Two groups of mice were investigated: dual-drug loaded nanodroplets and empty nanodroplets.
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For each formulation used, one of the tumors was subjected to activation, while the other served
as internal control. This allowed us to discern between effects from the on-demand activation
and spontaneous activation events that are uncontrolled.
The mice received an injection of 100 μL (with a concentration of 250 μg/mL PTX, and 70
μg/mL DOX, at a 5% v/v PFP concentration). Following tail vein injections of nanodroplets, the
mice were setup on a custom-built platform and the tumor to be activated was aligned with the
two transducers arranged in a co-axial geometry: a 32x32 matrix array transducer (7.5 MHz,
Verasonics) for imaging, and a single-element HIFU transducer for activation. The two
transducers were coupled by a polyacrylamide cone (obtained with the same recipe as described
in Section 2.4.7, excluding the droplets) with an inner indent to accommodate for the imaging
transducer. Ultrasound gel (Parker Labs) was added to the indent to ensure contact between the
imaging transducer and the cone, as well as on top of the tumor to ensure contact between the
mouse and the imaging-activation setup. The activation sequence consisted of HIFU pulses (515
kHz, 5.7 MPa focal pressure, 10 cycles) spaced at 20s, for a total duration of 10 minutes (Fig 2.3
A). The activation sequence was started immediately after the tail vein injection. Mice were
anesthetized by isofluorane (VetOne), at a 2% concentration in oxygen, with a flow rate of 1.5
L/h for all the procedures and measurements.
The tumor size was measured periodically, together with the weight of the mice, and animals
were sacrificed after 21 days since injection (Fig. 2.3 B), or when meeting the euthanasia
criteria- loss of more than 10% body weight or tumor burden larger than 1.5 cm. A 40 MHz
single-element ultrasound transducer mounted on a motorized stage was used for tumor size
measurements, raster scanning the tumor across the width (xz axis) across 10 mm, with a step of
0.1 mm. A cross-section of the tumor was also acquired. The tumor volume was computed by:
𝑣=

4𝜋 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑒𝑛𝑔𝑡ℎ
3

(

2

)∙(

𝑤𝑖𝑑𝑡ℎ
2

)∙ (

𝑑𝑒𝑝𝑡ℎ
2

) (2)

where the average length is obtained by an average of the length across three slices, and the
width and depth are obtained from the orthogonal slice (Fig. 2.3 C).
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Figure 2-3 A. Schematic of activation and ultrasound acquisition regimen showing the total
duration and the spacing of HIFU pulses; B. Timeline of tumor size measurements and spacing
for the duration of the study, beginning once both tumors on a mouse reach at least 20 mm3
volume; C. A mouse in the prone position showing the directions of measuring with the
ultrasound transducer: along the yz axis for the length of the tumor, and an orthogonal frame of
the tumor, on the xz axis, used to measure the depth and width of the tumor, respectively.

2.5 Results
2.5.1 Nanodroplets Synthesis and Size Characterization
The average hydrodynamic diameters of the nanodroplets as measured by dynamic light
scattering were 195.70 ± 27.38 nm and 337.40 ± 50.07 nm diameter for extruded nanodroplets,
and non-extruded nanodroplets, respectively immediately following the synthesis and washing
steps (Fig. 2.4 A).
Size was also used as an indicator of nanodroplets’ stability, with coalescence and aggregation
leading to larger sizes. Dual-drug loaded nanodroplets were dispersed in distilled water stored in
the refrigerator at 4 °C, and measured periodically over the course of 8 days (Fig. 2.4 A).
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Nanodroplets stored in this manner showed good stability over the time of the experiment, with
size slightly increasing in the case of both extruded and non-extruded nanodroplets. On the other
hand, the derived count rate of the two samples shows more of a pronounced difference in
evolution. In the case of extruded nanodroplets, the derived count rate showed a 5% decrease
between the day 0 and day 8 timepoints (Fig. 2.4 B), while the non-extruded sample decreased
by 78% compared to the initial timepoint. These measurements highlight the need for the sizing
procedure, especially when longer-term storage is considered. The intensity-weighed distribution
of nanodroplets (Fig. 2.5) from both samples showed a widening of the peaks, as well as the
appearance of smaller peaks, and larger peaks which might indicate a disproportionation process
such as Ostwald ripening happening.
In order to simulate the conditions nanodroplets would be subjected to during circulation,
extruded nanodroplets were incubated with a 40 mg/mL bovine serum albumin solution at 37 °C,
with DLS measurements taken over the course of 26.5 hours. The size trended upwards for both
samples, most likely due to the coalescence or agglomeration of nanodroplets (Fig. 2.4 C).
However, the size of nanodroplets after 1 day was still in the submicron range indicating a good
potential for circulation times and accumulation in leaky tumor tissue 15 . The different media of
incubation did not generate a statistically significant difference in the mean size of nanodroplets,
due to the rather large variance between measurements. The derived count rate (Fig. 2.4 D)
shows a large decrease for the BSA-incubated nanodroplets compared to the ones dispersed in
water. This could be a result of foam formed during the mixing of the BSA sample, that raises to
the top of the dispersion and is not present in the detection window. One thing to note is that the
BSA solution itself contributes to the count rate, as micelles or proteins agglomerates are
detected by the DLS alongside the nanodroplets peaks, as can be seen in the intensity-weighed
distribution histograms (Fig. 2.6).
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Figure 2-4 A. Size change of extruded vs non-extruded nanodroplets stored at 4 °C as a water
dispersion; B. Derived count rate change of extruded compared to non-extruded nanodroplets
stored at 4 °C; C. Size evolution of nanodroplets incubated at 37 °C in water an d bovine serum
albumin solution. D. Derived count rate change of nanodroplets incubated at 37 °C in water and
bovine serum albumin solution- 40 mg/mL Error bars show the standard deviation obtained from
triplicate measurements.

45

Figure 2-5 A. Intensity-weighed size distribution of extruded nanodroplets over several days
incubated at 4°C. B. Intensity-weighed size distribution of non-extruded nanodroplets over
several days incubated at 4°C.

Figure 2-6 A. Intensity-weighed size distribution of nanodroplets dispersed in water and kept at
37 °C over time; B. Intensity-weighed size distribution of nanodroplets dispersed in a BSA
solution of 40 mg/mL concentration, and kept at 37 °C over time; C. Intensity-weighed size
distribution of the BSA solution of 40 mg/mL alone.
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To study the morphology of nanodroplets and confirm the dual-emulsion structure proposed in
the schematic in Fig. 2.1 cryo-TEM was used to capture the nanodroplets. As Fig. 2.7 shows, the
dispersion of nanodroplets had a relatively narrow size distribution. Despite the contrast between
the core emulsion and the surrounding perfluoropentane not being extraordinarily high, the cryoTEM analysis captured the core-shell structure of the nanodroplets, as indicated by the red
arrows in Fig. 2.7.

Figure 2-7 TEM images of dual-drug droplets dispersion. Arrows indicate the dual emulsion
morphology present in the sample.
2.5.2 Nanodroplets Drug Encapsulation and Release
Both paclitaxel and doxorubicin are common chemotherapeutics, which are used either as
monotherapy or in combination in the treatment of solid tumors. Both drugs have side effects,
such as neurotoxicity or cardiotoxicity, that limit their systemic use 16 . Moreover, the two have
different solubilities in aqueous media and have distinct mechanisms of cytotoxicity 11 making
them good candidates for co-encapsulation in the same nanocarrier. Loading both these drugs in
nanodroplets bypasses the issue of different pharmacokinetic profiles 17 , ensuring the co-delivery
at the same time and place.
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Figure 2.8 presents the nanodroplets captured with bright field microscopy before activation
(“0”) and 5 minutes after sitting on the coverslip without any intervention (“5-“). The next image
shows the same droplets immediately after activation with a NIR pulsed laser (“5+”), as well as
the progression of microbubble size after 5 minutes after activation (“10”). The images showcase
the transition of the core from liquid to gas as microbubbles are formed upon exposure of the
sample to laser. The microbubbles increase in size after a few minutes, a process that could be
explained by the recently described phenomenon of nanodroplets enhancing microbubble
inflation in mixtures of the two18 .

Figure 2-8 Brightfield image of droplets prior to activation (0), 5 minutes after the initial time
point (5-), immediately after activation (5+), and 5 minutes after the moment of activation (10).
Dual-drug loaded nanodroplets were destroyed in acetonitrile-water 1:1 vol. mixture to dissolve
all loaded drugs. Encapsulation efficiencies were measured to be approximately 80% for
paclitaxel and 60% for doxorubicin (Fig. 2.9 A), corresponding to a loading of 360 ± 67 µg/mL
of paclitaxel, and 40 ± 7.9 µg/mL for doxorubicin (Fig. 2.9 B). These translates into a loading of
0.36 mg paclitaxel/mg particles and 0.04 mg doxorubicin/mg particles. While this study kept the
parameters constant, as to get the same ratio between loaded paclitaxel and loaded doxorubicin,
the relatively simple synthesis method allows for this ratio to be modified. This allows for
versatility in the effects of the nanodroplets, as different types of cells have been shown to have
different optimal ratios for maximum treatment efficacy 17 .
The triggered release of paclitaxel upon nanodroplet vaporization was shown by measuring the
release profile with and without external activation for samples kept at 37 °C (Fig. 2.9 C). The
activated sample was exposed to 5 s of pulsed laser irradiation (with 10 Hz pulse repetition
frequency) at the 30-min time point, a small volume was taken out to measure drug release, and
the rest of the sample was kept at 37 °C for an additional 30 min, for a total experiment time of
60 minutes. While the initial samples showed a relatively small amount (~3% with respect the
total loaded paclitaxel) of unencapsulated paclitaxel present in the supernatant, after 30 min, both
the non-activated and the activated samples had a 10-fold increase in the amount of released
paclitaxel. In the case of the non-activated sample, this might be from spontaneous droplet
activation, from reorganization of the lipid membrane upon coalescence of droplets, events that
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are in line with the gradual increase in size and widening of the peak in the size-distribution
observed in DLS measurements. On the other hand, the laser-triggered samples released nearly
50% more paclitaxel than the non-activated control. After an additional 30 min at 37 °C, both
samples continued to increase the amount of released paclitaxel in a similar fashion, which is
expected due to no additional activation of the samples being performed.

Figure 2-9 A. Encapsulation efficiency of paclitaxel and doxorubicin in DDD; B. Loading
efficiency for paclitaxel and doxorubicin in double-drug loaded nanodroplets; C. Laser-triggered
paclitaxel release from activated DDDs compared to a non-activated control; D. Laser-triggered
doxorubicin release from DDD compared to non-activated control; E. Doxorubicin release
comparison of nanodroplets pre-incubated with FBS solutions of various concentrations (0-100%
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volume). Error bars represent the standard deviation of triplicate experiments; F. Doxorubicin
release from nanodroplets with different zeta potentials, after incubation of 30 minutes at 37 °C
with or without laser exposure.

In the case of doxorubicin, a similar experiment was performed, with a batch of nanodroplets
being divided into activated and non-activated samples. The “activated” sample was subjected to
laser-exposure at the 30-min time point, at which point a small volume of it was removed to
measure the released doxorubicin, with the rest of the sample kept at 37 °C for an additional 30
minutes. To ensure a fair comparison of the activated and non-activated samples, after taking
samples for each time point and separating the released doxorubicin in the supernatant, the nonactivated samples were subjected to an equivalent laser exposure. This is to correct for
photobleaching effects on doxorubicin due to the laser exposure. Figure 2.9 D summarizes the
experiment, showing a relatively slow evolution of the released doxorubicin for control droplets,
and a jump of over 33% in the amount released from the activated sample immediately after laser
activation.
A third experiment related to drug-release was included, investigating the influence of protein
interactions over the release of drugs (Fig. 2.9 E). Doxorubicin was measured in this situation,
due to the ease of measurement compared with paclitaxel given its solubility in aqueous media.
While passive delivery of drugs has been shown to be impeded by the hard protein corona
formed around nanoparticles19 , we hypothesized that the nanodroplets would be able to
overcome the barrier due to the relatively strong mechanical forces generated during activation,
that have been shown to be powerful enough to cause cell membrane permeabilization 20–22 .
During the experiment, three different conditions of incubation were tested: distilled water, 10%
FBS solution, and 100% FBS solution. After a 1-h incubation in their respective media, droplets
were resuspended in water and kept for 30 min at 37 °C. The passive and laser-activated
doxorubicin release were measured and compared. The droplets that were kept in water,
therefore forming no protein corona, showed results in line with the previous experiment (Fig.
2.9), with some doxorubicin being released passively and a jump in the amount released after
laser activation. The effect was more pronounced in the 100% FBS solution. Moreover, laseractivation of the nanodroplets increased the amount of drug release in all cases, with the greatest
effect observed in the 100% FBS case. This might be an effect of droplets being closer to one
another in dispersion when the protein coronas are larger, allowing for a more efficient transfer
of the energy across the droplet population in the sample. This might result in the activation of a
higher number of droplets compared to water samples where movement is unencumbered.
Additionally, the increased interactions between nanodroplets can cause a broadening of the size
of nanodroplets, which relates inversely with the energy needed for activation 3 . Lastly, proteins
in the serum might interact with and destabilize the lipid layer of nanodroplets, contributing to
the increased passive release of the drug or change the surface charge of the nanodroplets,
decreasing the electrostatic interactions between the released doxorubicin and the
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nanodroplets/microbubbles present in dispersion. Increasing the zeta potential of nanodroplets by
using an amine functionalized DSPE-PEG was shown to increase the amount of doxorubicin that
is measured in the supernatant after release (Fig. 2.9 F), which supports the hypothesis that
surface charge plays an important role in the interaction between nanodroplets and microbubbles
and released doxorubicin, impacting the amount of drug that gets detected. This might also
explain the disparity between the percentages of released drugs for paclitaxel and doxorubicin.
This aspect is explored further in section 2.5.3 in order to optimize the composition of
nanodroplets designed for doxorubicin encapsulation and delivery.
2.5.3 Optimizing doxorubicin-release by charged nanodroplets
The influence of the surface charge on the measurement of released doxorubicin after laser
activation became apparent in the case of the dual-drug loaded nanodroplets. While the negative
charge of those nanodroplets aid in lowering their interactions with negatively-loaded serum
proteins23 , the same property makes the partially positively charged doxorubicin to remain
associated with the membrane after activation. This hypothesis was tested by replacing a part of
the DSPE-PEG 2000 with a positively charged amine terminated DSPE-PEG 2000 -NH2 to increase
the overall surface charge of nanodroplets. The release study showed an increase in the
doxorubicin in the supernatant after laser exposure, in line with our expectations (Fig. 2.10 A).
To further investigate the effect of the charge on doxorubicin release upon activation,
nanodroplets with positive charge were obtained by incorporating DOTAP into the composition.
The charge increased with the molar percentage of DOTAP used in the f ormulation (Fig. 2.10
B), and similarly, the difference between the percentage of the loaded drug being release by
activation when compared to control, non-activated samples, increased with the zeta potential
(Fig. 2.9 C). While these nanodroplets were not further tested, the ease of tuning the charge
could be explored further to tune the biodistribution of nanodroplets, and allow for more efficient
drug release.
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Figure 2-10 A. Release of doxorubicin from dual-drug loaded nanodroplets with a negative
surface charge; B. Zeta potential of nanodroplets formulated with DOTAP, a positively charged
lipid; C. Doxorubicin-release after activation of positively charged loaded nanodroplets.
2.5.4 Ultrasound Imaging
The ultrasound contrast capabilities of the droplets before and after activation were investigated
in tissue-mimicking polyacrylamide phantoms. A custom ultrasound imaging sequence which
consisted of one frame before activation and 15 frames immediately after activation was used.
After a single laser pulse, the laser focal spot showed increased contrast compared to the initial
liquid droplet state (Fig. 2.11 A, B). This is because of the strong acoustic impedance mismatch
between the gaseous microbubbles and aqueous background. To obtain the total ultrasound
amplitude, a rectangular area surrounding the laser illumination spot was selected as a region of
interest (ROI) and the magnitude of pixels in the region was computed as the sum of all pixel
values for each frame and denoted the ‘signal magnitude’. Further, the signal magnitude in the
ROI was divided by the signal magnitude of the background to calculate the signal-tobackground ratio. The results show a strong increase in ultrasound signal-to-background ratio
immediately following laser activation of the nanodroplets (Fig. 2.11 C). The ratio remains
relatively constant for the next 14 frames, indicating that the microbubbles are stable contrast
agents for imaging. To obtain the differential signal magnitude, the ultrasound frame
immediately preceding the laser activation was subtracted from the ultrasound frame
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immediately succeeding activation (Fig. 2.11 D), and the sum of all pixel values in the same ROI
computed and denoted ‘differential signal magnitude’.

Figure 2-11 A. Ultrasound B-scan frame of DDD-laden polyacrylamide phantom prior to
activation; B. Ultrasound B-scan frame after 1 laser pulse with visible microbubbles in the laser
focal spot (red circle); C. Graph of total intensity in the selected region of interest against frame
number, showing a sharp increase of signal at the moment of activation (frame #2); D.
Ultrasound difference frame between the frame acquired immediately after activation (#2) and
the frame acquired before (#1).
To assess the depth of activation for our nanodroplets, a phantom experiment was set up using
fresh raw chicken breast tissue as a stand-in for human tissue. Thin slices of chicken were
measured by a caliper and added on top of nanodroplets-laden polyacrylamide phantoms and
pulsed laser was applied to activate the droplets, keeping the laser-top of the tissue distance
constant between the different groups. In this way, increasing the thickness of the chicken breast
increases the depth at which the droplets are relative to the laser. The results showed that after
18-19 mm depth, no more signal was detected from the activation of droplets, giving up an
estimation of the depth of activation in tissue (Fig. 2.12).
To investigate a dependency of the differential signal magnitude in the ROI on the concentration
of nanodroplets in the phantom, an experiment was performed using a similar imaging and
processing setup as the one described above. The main difference was the laser exposure time
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was extended to 5 s to ensure activation of the entire population of nanodroplets. Dual-drug
loaded nanodroplets were dispersed in polyacrylamide phantoms with concentrations ranging
from 0.1% to 1.5% v/v. This corresponds to a 2x10 7 -1.5x108 particles/mL concentration range, as
determined from DLS measurements. The main rationale behind the experiment is to establish
that the differential ultrasound signal magnitude is linearly correlated to the number of activated
nanodroplets. Thus, the concentration of released drug could be estimated from the images. In
the studied range, the phantoms showed a linear dependency of the normalized different ial signal
(Fig. 2.13). The normalized differential signal was obtained by computing the differential signal
magnitude in the ROI as described before and dividing it by the area of the ROI. With the
increase of nanodroplets per unit volume in the focal spot, the normalized differential signal
magnitude increases as more microbubbles are created during the activation. The relation
between the nanodroplets concentration, and implicitly the concentration of released drugs, and
the differential signal is linear in the studied range (R 2 = 0.9490). When increasing the
concentration of nanodroplets in the phantom above 1.5% v/v, a shadowing effect formed due to
the high concentration of microbubbles blocking the signal transmission and reflection. This
caused the detected differential signal magnitude in the ROI to drop. Thus, the linearity of
imaging signal is not reliable for very high concentrations of nanodroplets. It is worth noting that
in order to find the range of linear response and obtain a similar accuracy of ultrasound
measurement to the one in our study, a calibration process might be involved. This calibration
would take into account the nanodroplet characteristics, the ultrasound imaging setup parameters
and the imaging depth. Moreover, as noted in the drug release experiments, the amount of drugs
being released by activation is not necessarily 100% of the drugs encapsulated, with other
interactions of the nanodroplets and microbubbles matrix and the released drug being a possible
factor. Additional work is needed in order to establish the correspondence between the activated
nanodroplets and the amount of drugs being released in tissue-mimicking phantoms, which
would allow the translation of the ultrasound magnitude to the local concentration of drugs.
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Figure 2-12 US differential magnitude frames from the activation of a nanodroplets-loaded PAA
phantoms through raw chicken breast of varying thickness: 0 mm- 22 mm.
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Figure 2-13 Graph showing the linear dependency of the differential ultrasound magnitude in the
ROI with the concentration of nanodroplets in the phantom. Error bars represent the standard
deviation of triplicate experiments.
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2.5.5 Nanodroplet Cytotoxicity
Dual drug-loaded droplets were tested for their cytotoxicity on FaDu cells using an MTT assay.
FaDu cells are a well-established squamous head and neck cancer in vitro model, and both
paclitaxel and doxorubicin are used in therapeutic regimens for this type of disease in
combination with one another24 or other chemotherapeutics25 . We compared the effect of
incubating cells with drug-free nanodroplets against that of paclitaxel and doxorubicin loaded
DDDs (Fig. 2.14 A). Drug-free nanodroplets, either activated or non-activated, showed no
significant cytotoxic effect compared to the control cell group. There was also no significant
difference between the activated and non-activated empty droplets, showing the mechanical
effects of the expansion experiences during activation did not considerably affect cell viability.
In contrast, activated drug-loaded nanodroplets showed significantly lower cell viability than
inactivated drug-loaded nanodroplets (p = 0.0019), supporting the hypothesis that NIR activation
enables on-demand release of the two drugs. Moreover, compared to cells that were subjected to
a combination of free doxorubicin and paclitaxel in the same concentrations as the loaded
nanodroplets, the activated DDDs showed significantly greater cytotoxicity (p = 0.0012).
We hypothesized that the difference in cytotoxicity between free drugs and droplet -encapsulated
drugs stemmed from the release of the drugs in the intracellular space, increasing their efficacy,
especially in the case of doxorubicin, which acts by intercalation within DNA strands and
inhibition of topoisomerase-II 26 . This would imply that the time between the start of incubation
of cells with droplets and their activation would influence their cytotoxicity based on the length
of time of the internalization of droplets. To test this hypothesis, the DDDs were activated after
either 10 min, 30 min, or 1h of incubation with FaDu cells. All samples were left for their
respective incubation times, media removed and replaced with fresh media, then subjected to
pulsed laser activation, for a total of 10s at 10 Hz. All groups had a non-activated counterpart to
compare to the effect of passive release from inactivated droplets. After 10 minutes of
incubation, the DDDs did not show a significant effect on cells for inactivated droplets but did
show a reduction in the cell viability in the case of activated droplets (Fig. 2.14 B). All other
groups, inactivated and activated, showed statistically significant differences with respect to the
cell control. As observed in the previous experiment (Fig. 2.14 A), all groups showed a
significantly greater cytotoxicity when the laser activation stimulus was applied. Moreover, there
were significant differences between the activated 10 minutes group and the activated 30 minutes
or 1h groups. This is in line with our expectations given the above stated hypothesis.
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To further support the hypothesis of time-dependent droplet localization, we studied the
internalization of droplets following a 10 minutes internalization compared to 1h internalization
with confocal fluorescence microscopy. Our results showed a large difference in the number of
droplets present in favor of the 1h incubated sample (Fig. 2.15 A-B). Even though the
nanodroplets seemed to be mostly bound to the cell membrane for the 1h incubation time sample,
a fraction of them were situated inside the cytosol, in contrast with the 10 minutes sample where
no such examples could be visualized.

Figure 2-14 A. Cytotoxicity of activated nanodroplets compared to control, empty nanodroplets,
free drugs (paclitaxel - PTX and doxorubicin - DOX) and inactivated nanodroplets on FaDu
cells. Symbols express the results of student t-tests between several groups; B. Comparison of
time of activation impact on cytotoxicity. Statistically significant differences between the groups
as revealed by student t-test are indicated; C. Cytotoxicity of various doxorubicin formulations:
free drug, encapsulated in nanodroplets, co-delivered with empty nanodroplets to showcase the
impact of the activation events on drug internalization. Statistically significant differences are
indicated between the groups when relevant. Error bars represent the standard deviation of
triplicate experiments; D. Cytotoxicity of activated nanodroplets compared to control, empty
nanodroplets, free drugs (paclitaxel - PTX and doxorubicin - DOX) and inactivated nanodroplets
on MDA-MB231 cells.
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Beyond the intracellular localization of nanodroplets at the time of activation compared to
extracellular in the case of cells incubated for 10 minutes, mechanical effects of the activation
are another factor likely to influence the effect of drugs on cells. Previous studies have shown
that cells experience permeabilization of the membrane – and potentially of the nuclear
membrane – when exposed to ultrasound waves, such as ones arising from the acoustical
activation of nanodroplets20–22,27 . To investigate whether the mechanical effects of the activation
play a role in the case of our nanodroplets we designed an experiment to compare cells that were
incubated with either doxorubicin, doxorubicin and empty nanodroplets, or doxorubicin-loaded
nanodroplets (Fig. 2.14 C). Doxorubicin was particularly selected as the drug of choice in this
situation due to its mechanism of action that involves localization in the cell nucleus 26 , and due
to its lower concentration in the nanodroplets that allowed us to increase the number of
nanodroplets used in the study without decreasing the population of cells drastically. This test
revealed that empty nanodroplets alone did not significantly affect cell viability, while the
doxorubicin and empty nanodroplets mixture slightly improved the cytotoxicity of the drug.
However, the cells in the drug and activated empty nanodroplets group did not differ
significantly from the non-activated equivalent. This indicates that the mechanical effects of the
activation are not strong enough to make a difference in this case. In contrast to sonoporation
studies28 – which use minutes-long ultrasound exposure to disrupt cell membranes – the pressure
wave produced during the vaporization event only persists on the microsecond timescale. Thus,
it is unlikely that drugs external to the cell will be able to experience a strong increase in uptake
with this stimulus. Moreover, the activated drug-loaded nanodroplets was the most successful
formulation at reducing the cell viability, underlining once more that the spatial co-localization
of the nanodroplets and the drug, but also the simultaneous drug release and mechanical effects
of activation are needed for an increase in efficacy of the drug.
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Figure 2-15 A. Maximum intensity z-projection of confocal fluorescence images of FaDu cells
incubated with FITC-labeled nanodroplets (green) for 10 minutes. Cells were counterstained with
DAPI (blue) and CellMask™ Deep Red (red) for nuclei and plasma membrane, respectively; B.
Maximum intensity z-projection of confocal fluorescence images of FaDu cells incubated with
FITC-labeled nanodroplets (green) for 1h. Cells were counterstained with DAPI (blue) and
CellMask™ Deep Red (red) for nuclei and plasma membrane, respectively.

2.5.6 Preliminary in vivo biodistribution studies
Nu/Nu female mice with two hind-flank tumors were administered DiR-loaded nanodroplets
through a tail vein injection, followed by activation with high-intensity focused ultrasound of one
of the tumors.
The fluorescence signal in mice was followed prior to the injection, as well as post injection and
activation at 30 min, 1h and 90 min. Another image was taken the next day, at approximately
20h from the injection + activation event. The mice included in this study showed relatively
localized activated spots after activation, due to the small focus of the HIFU-transducer.
In a small additional study, mice were given an iv-injection as described before, one of the
tumors was sonicated, and at the 2h timepoint, the mice were euthanized and dissected, with their
main organs excised and imaged for fluorescence signal (Fig. 2.16 A-B). This showed the
distribution of the signal in the main organs, with a majority of fluorescence being in the liver
and spleen, while tumors seemingly got around 3% of the signal at this timepoint. This, indeed,
underlines an issue that many nanoparticle systems suffer from, which is the low amount of the
dose that reaches the tumor. While the activation seems to have made a positive difference in the
amount of signal we recorded, for both these mice that got all the organs excised, as well as two
other mice whose tumors were excised following identical procedures (Fig. 2.16 C-D), the total
amount of nanodroplets that gets inside the tumor being so low is a concern. For this reason, in
the case of drug-loaded nanodroplets, we allowed the tumors to grow more before the injection,
to hopefully give time for vasculature to develop further.
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Figure 2-16 A. The distribution of fluorescent droplets in 2 mice euthanized 2h post tail-vein
injection with DiR-loaded nanodroplets; B. Example of excised organs from a mouse that had
received a tail-vein injection with DiR-loaded nanodroplets C. The fluorescence intensity in
excised tumors comparing the activated and non-activated tumors of mice injected with DiR
loaded nanodroplets; D. Example of excised tumors showing the difference in fluorescence
signal between the activated tumor and non-activated one.

2.5.7 In vivo dual-drug nanodroplets evaluation
To understand the effect that the nanodroplets have in the animal model, a study was setup to
compare mice receiving dual-drug nanodroplets with mice receiving non-loaded, or empty
nanodroplets. The model was the same as described in the fluorescent droplets study, with two
hind tumors one of which was activated with high intensity ultrasound, and the other used as
internal control. The tumor size was followed periodically after the injection and activation for
both groups, and the weight of mice was also recorded at several timepoints to ensure that the
treatment were not negatively affecting the mice. In the case of dual-drug loaded nanodroplets, a
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one-dose regimen was used. Empty nanodroplets were administered at a similar PFP
concentration.

Figure 2-17 A. Tumor growth rate of both activated and non-activated hind leg tumors on mice
receiving DDDs injection (day 0); B. Aggregate tumor growth rate for activated tumors
compared to non-activated counterparts on mice that received a DDDs injection; C. Tumor
growth rate of both activated and non-activated hind leg tumors on mice receiving empty
nanodroplets injection (day 0); D. Aggregate tumor growth rate for activated tumors compared to
non-activated counterparts on mice that received an empty nanodroplets injection; E. Weight
evolution of mice receiving either DDDs or empty nanodroplets injections on day 0, expressed as
relative ratio with respect to the mice’s weight on day 0.
Over the duration of the study, the dual-drug nanodroplets receiving mice showed a delay in the
tumor growth rate compared to the non-sonicated counterparts (Fig.2.17 A-B), as shown by a
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non-parametric Wilcoxon test (p =0.0039). Performing paired t-tests between the data for the 5
mice at each timepoint showed a statistically significant difference between the tumor volumes at
days 2 (p = 0.034 ), 5 (p = 0.009), 7 (p = 0.0002). This is not unexpected, as the effect of drugs is
expected to occur in the first few days after administration and taper off, with clinical regimens
usually dosing paclitaxel and doxorubicin over an interval from 3h-24h and repeating the
treatment every two or three weeks, depending on the type, location and aggressiveness of the
tumors in question. Therefore, we expect that a repeated dosage, of nanodroplet -encapsulated
drugs could be most beneficial, in not only slowing the rate of growth, but actively reducing the
size by effectively attacking the tumors. The evolution of the weight of mice in both groups was
similar, with no obvious difference being noticeable between the groups (Fix 2.17 E).

Figure 2-18 A. High-frequency ultrasound frames of mouse tumor imaged before and after
nanodroplets injection and HIFU activation; B. Ultrasound frames taken at various points during
the circulation of nanodroplets and activation with HIFU overlayed with the differential signal
from co-registered frames before and immediately after HIFU pulse. The yellow dashed circles
indicate the location of the tumors.

Example ultrasound frames of sonicated tumors before and after activation showed regions of
contrast (Fig. 2.18A). However, since the images were not co-registered, the processing proved
difficult beyond qualitative assessments. Ultrasound images were also recorded during the
activation of nanodroplets post-injection, using a matrix array transducer, in the hopes of
identifying any correlation between the amount of signal detected and the tumor response.
However, although we can observe a difference from the activation of nanodroplets in the
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tumors, the images obtained during activation lacked the required resolution for confident
quantification (Fig. 2.18 B). Integration of the high-frequency ultrasound imaging system with
the HIFU transducer, or even switching to a laser-activated nanodroplet that is more easily
adjustable, could be beneficial to allow for quantitative ultrasound results.
An interesting follow-up direction to consider is the estimation of vascular development during
the course of treatment, factor that could be incorporated with the ultrasound study or by
photoacoustic means. Other studies have looked at the effects of ultrasound, alone or together
with agents like nanodroplets or microbubbles of vasculature during different types of
treatments29–32, but a more complete characterization of treatment dynamics is needed.
This is especially important for nanoparticle systems, which, as we have seen in our own
experiments highlighted above, have modest percentages of accumulation in the tumor, and
depend on the vasculature being developed to be useful across the tumor volume. As
chemotherapeutics can have adverse effects on the development of new vasculature, or affect
existing vasculature, the regimen of treatment has to take that into account to yield optimum
results.

2.5 Conclusions
In this chapter, we report the construction and characterization of phase-changing nanodroplets
loaded with both paclitaxel and doxorubicin for laser-triggered drug-releasing capabilities. The
two chemotherapeutics are concurrently loaded into a core-shell nanodroplet structure, with a
perfluoropentane core and a biocompatible lipid shell. Due to the incorporation of a NIR
absorbing dye in the shell, the core of the nanodroplet transitions from a liquid to a gaseous
phase when exposed to a pulsed NIR laser. This activation results in expulsion of the loaded
drugs, and the emergence of microbubbles, which provide high ultrasound contrast. This contrast
can be used as a spatially resolved estimation of released drug concentration. In our study, we
show that there is a range in which the dependency of the total ultrasound image amplitude and
the concentration of activated nanodroplets follows a linear relation. These results contribute
towards establishing an ultrasound-based approach to monitoring chemotherapeutics delivered to
a specific location.
We characterized the cytotoxicity of the DDDs, noting an enhancement in the effect of triggered
nanodroplets compared to free drug formulations. The relatively low effects of non-activated
loaded nanodroplets indicate a good stability and control over the drug-release process. The codelivery of two drugs with the same vehicle overcomes the barriers imposed by their different
pharmacokinetic profiles, especially given their difference in solubilities.
In vivo preliminary studies show that activated dual-drug nanodroplets slowed down tumor
growth compared to tumors that have not received activation, and empty nanodroplets have no
positive or negative effects on tumor growth regardless of activation status.
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However, in order to fully take advantage of the image-guided capabilities of the platform, the
activation process has to allow for better ultrasound resolution, in order to identify the tumor
more easily, and be able to quantify the magnitude of the differential signal after activation. A
setup that integrates the high-frequency US system and the HIFU activation might be able to
achieve that. This will also ensure that the images are co-registered and can be processed easily.
Further, post-processing methods like ones designed for the high accuracy and high sensitivity
detection of microbubbles could aid in increasing the spatial resolution beyond the acoustic
diffraction limit 33 .
Moreover, work remains to be done towards increasing the amount of nanodroplets that
extravasate into the tumor. While intratumoral injections could be a solution for rodent studies,
that is not likely to be a long-term option for the nanodroplets’ translation. Therefore, more work
on the timing of the tumor sonication, as well as studying whether the HIFU regimen used is
sufficient to cause temporary endothelial disruption, and ways to maximize that, are required.
Overall, our work proposes a nanocarrier design with on-demand drug-release for enhanced
efficacy combination therapy that can be monitored by ultrasound imaging. Due to accessibility
of ultrasound imaging, as well as its good spatial and temporal resolutions, we believe this could
be a useful alternative to more complex imaging techniques currently employed. Based on the
preliminary data shown here, we expect the formulation to be promising for the proposed
application.
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Chapter 3 : Nanodroplets for Encapsulation and Ondemand Release of Large Molecules for
Immunotherapy for Breast Cancer
This chapter describes the design and development of nanodroplet formulations for the coencapsulation of chemotherapeutics and immunotherapy agents. These constructs are designed to
serve as combination therapy for neoadjuvant therapy of locally advanced or metastatic triple
negative breast cancer. Two different manners of encapsulating an anti-PD-L1 antibody
(Atezolizumab equivalent) into droplets are explored: i) by electrostatically binding onto the
anionic shell of droplets or ii) into the perfluorocarbon core as emulsion. The construct is tested
in vitro for encapsulation efficiency, and stimulus-triggered release, as well as for biologically
activity in a PD-1/PD-L1 interaction assay and on a triple negative breast cancer cell line.

3.1 Introduction
3.1.1 Neoadjuvant therapy for breast cancer
Neoadjuvant chemotherapy (NACT) was introduced in 19701 as a potential method to downsize
locally advanced cancers, considered inoperable, in an effort to make them operable. The
application of NACT was extended to operable, early breast cancer, aiming to allow breast conserving surgery as opposed to full mastectomies, being widely used today in the clinic2 . The
main benefits being quoted in favor of NACT is its potential to eradicate micrometastases more
efficiently than adjuvant chemotherapy 3 , and decrease the toxic side-effects of the
chemotherapy1 , as well as reduce tumor cell shedding during surgery 4 . Moreover, patients’
response to NACT might provide useful insight into the local chemosensitivity of the tumor,
helping guide subsequent treatment regimes5 . This is particularly useful in HR-negative tumors,
generally associated with a high risk of distant recurrence. However, as administration of
neoadjuvant chemotherapy implies a delay in the surgical treatment, close consideration must be
given to early prediction of the tumor’s response to NACT6 , to avoid increased risks of
metastatic spread.
A meta-analysis of NACT clinical trials involving 4756 women across 10 clinical trials by the
Early Breast Cancer Trialists' Collaborative Group looked at the local and distant recurrence for
both responders and non-responders7 . Their study concluded that NACT behaved similarly with
adjuvant chemotherapy in reducing the risk of distant recurrence and death from breast cancer.
Notably, they also underline that NACT was associated with higher local recurrence than the
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corresponding adjuvant chemotherapy, suggesting potential strategies for improvement would
rely on better tumor localization after NACT administration.
In terms of chemotherapeutics being used, their study, as well as other reviews on the topic,
revealed an improvement in the frequencies of clinical response and breast -conserving therapy
for the trials that used a combination of anthracycline and taxane compounds 8,9 . Furthermore,
several clinical trials propose the use of nano-formulated drugs (such as albumin bound
paclitaxel)10,11 , concluding that the side effects experienced by patients undergoing neoadjuvant
chemotherapy are lower, while maintaining treatment efficacy 12 . As toxicity is a high concern for
elderly patients13 , who are usually underrepresented in the breast cancer clinical trials 13,14 ,
research focusing on diminished systemic toxicity by employing nanoparticle-based drug
formulations have emerged. Nanomedicine holds a promise in the field of neoadjuvant
chemotherapy, as it can reduce toxicity in the case of using locally activated nanoparticles 15,16 , as
well as provide monitoring and prognosis information, by the employment of theranostic
nanoparticles17,18 .

3.1.2 Immunotherapy and combination therapy in the treatment of cancer
In addition to surgery, chemotherapy and radiation, immunotherapy has emerged as the fourth
pillar of cancer treatment. The principle behind immunotherapy is taking advantage of the host’s
own immune system to fight off the cancer. The most commonly used type of immunotherapy is
administering immune checkpoint inhibitors (ICIs), that target specific pathways in immune
activation to establish a pro-immunogenic tumor microenvironment 19 . ICIs targeting cytotoxic T
lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed
cell death ligand 1 (PD-1/PD-L1) are currently the standard of care for several diseases,
including advanced melanoma, non-small cell lung cancer, urothelial cancer, renal cancer,
refractory Hodgkin lymphoma and triple negative breast cancer, to mention just a few 20–22 . The
PD-1 receptor is expressed on the surface of T cells following T cell receptor (TCR) signaling
and cytokine stimulation23 . When this expression is persistent, the T cells enter what is called an
exhausted state, where their effector function is lost. PD-1 can bind to two receptors, PD-L1 and
programmed cell death ligand 2 (PD-L2) on tumor cells, that generates a cascade of inhibitory
signals for tumor-infiltrating lymphocytes proliferation and cytokine production23,24 . This finally
results in tumor cells escaping the immune system. By blocking this interaction at the tumor site,
either by inhibiting the PD-1 on T cells or the PD-L1 receptor on cancer cells, PD-1/PD-L1 ICIs
upregulate the inherent immune activity on tumor cells22,25,26 (Fig.3.1 A).
Despite great results shown in employing immunotherapy particularly for “liquid” tumors, the
clinical application of immunotherapy still faces several hurdles. These include off -target
toxicity as a result of systemic administration, as well as low immune response due to tissue
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heterogeneity and the complex tumor immune microenvironment 27–29 . While the toxicity is still
unaddressed, efforts to increase the response of patients to immunotherapy rely on combining
this type of therapy with other established methods, such as chemotherapy, radiation therapy or
emerging phototherapies19,29–31 .
TNBC is generally regarded as having a tumor-infiltrating lymphocytes enriched
microenvironment which makes it a prime candidate for immunotherapy 32,33 . However, the
observed benefits of ICI monotherapy have been modest at best, calling for a shift in focus on
combination regimens and more targeted treatment options 26,33,34.
The rationale behind combining cytotoxic agents with immunotherapy agents such as ICIs, relies
on the chemotherapeutics immunomodulatory properties30 (Fig.3.1). The destruction of cancer
cells by such agents generated a tumor-associated antigen release phenomenon, which has been
shown to stimulate a localized potent immune response 35 . In addition to this, chemotherapeutics
can synergize with immunotherapies by changing the ratio of immune cells present at the tumor
site, for example by depleting immunosuppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs), to enable expansion of tumor-specific effector T cells20,30 . In
the case of triple negative breast cancer, the combination of nab-paclitaxel and the anti-PD-L1
antibody atezolizumab is used as a first line therapy, based on its superior efficiency to
chemotherapy alone21,36 .

Figure 3-1 Schematic of the interplay of different type of cells involved in tumor
immunogenicity and their interactions. The effects of some commonly used ICIs are shown near
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the corresponding interaction that they inhibit. Some commonly used chemotherapeutics are
included and their downregulating effect on some tumor immune suppression promoting cells
(i.e myeloid-derived MDSC, TAM, Tregs) indicated by red downward arrows 30 .
Other combinations of immunotherapy targeting the PD-1/PD-L1 pathway and
chemotherapeutics are currently being investigated. Preclinical and clinical studies have looked
at low-dose chemotherapy or irradiation used in conjunction with PD-1/PD-L1 inhibitors.
Examples of chemotherapeutics that have been investigated for their stimulatory effect on the
immune response include cyclophosphamides that can deplete Tregs 37,38 , cisplatin that can
upregulate major histocompatibility complex class I expression, while doxorubicin has been
shown to deplete MDSC 39 and induction of immunogenic cell death 38 . A summary of ongoing
trials in triple negative breast cancer combination therapies is presented in table 3.1
Table 3-1 Ongoing trials investigating the efficacy of anti PD-1/PD-L1 combination therapies in
TNBC.
Trial Name
Regimen
Chemotherapy combination trials
KEYNOTE-355
Chemotherapy
(carboplatin
+
gemcitabine or nab-/paclitaxel) ±
pembrolizumab
IMpassion 131
Paclitaxel ± atezolizumab
IMpassion 132
Chemotherapy
(carboplatin
+
gemcitabine, or capecitabine) ±
atezolizumab
Targeted therapy combination trials
ETCTN
Olaparib ± atezolizumab BRCAmpositive
DORA
Olaparib ± durvalumab sporadic or
germline BRCAm
IPATunity130
Paclitaxel ± ipatasertib (AKTi) ±
atezolizumab
BEGONIA
Paclitaxel
+
durvalumab
±
capivasertib (AKTi) or danvatirsen
(STAT3i) or oleclumab (anti-CD73)
InCITe
Avelumab + binimetinib (MEKi) or
utomilumab (IgG2 antibody) or antiOX40 antibody
DFS = disease free survival

70

Lines or Stage

N

0 (DFS ≥ 6 months)

847

0
0 (DFS <12 months)

600
350

Any

72

≤2

60

0 (DFS ≥ 12 months)

450

0

120

0-3

150

3.1.3 Combination chemotherapy and immunotherapy regimes as neoadjuvant treatment
of TNBC
The success of the combination therapy for advanced disease has generated interest towards
testing of the same type of treatment for neoadjuvant regimens. A recent phase III clinical study
testing the PD-1 inhibitor Pembrolizumab confirmed the benefit of adding immunotherapy
compared to standalone “classical” NACT, seeing an improvement particularly in high-risk
populations of patients with positive lymph nodes or higher disease stage (≥ stage II)40,41 .
Despite promising results in terms of efficacy, immunotherapy, either used as a monotherapy or
a combination with chemotherapy, still has challenges associated with it. Traditionally,
immunotherapy, like chemotherapy, suffers from off-target toxicities due to the systemic
administration42 . Around 90% of patients receiving a combination of PD-1/PD-L1 checkpoint
inhibitors and chemotherapy report experiencing grade 3 or higher side-effects, which are
considered severe, life-threatening effects, requiring hospitalization 40 . During the use of
pembrolizumab and chemotherapy for TNBC neoadjuvant therapy, around 25% of patients
discontinued treatment due to toxicity, compared to only 13% in the control arm, which were
subjected to the chemotherapy regimen alone 41 . A meta-analysis looking at inhibitor-related
toxicity found non-overlapping toxicities of checkpoint inhibitors compared to the side effects of
chemotherapies or targeted therapies43 . When used in combination, the inhibitors show shared
adverse effects, indicating a synergistic toxicity.
To overcome these challenges and expand the usefulness of combination therapies including
immunotherapy, research has turned to nanomedicine delivery systems44 . Although for the
longest time nanomedicine was focused on design to ensure immune evasion, deployment of
nanotherapeutics for immuno-oncological purposes has begun to take shape45 . These are
designed to enhance the effectiveness of immunotherapeutic agents by targeting them to the
tumor site and minimizing off-side effects, in a similar manner to ones used for nanoformulated
chemotherapeutics. Examples of nanomaterials explored for immunotherapy include polymeric
nanoparticles (such as PLGA spheres), polypropylene sulfide nanoparticles, nanogels, metalorganic frameworks46 , or inorganic nanoparticles like iron nanoparticles, gold nanoparticles or
mesoporous silica nanoparticles44 . Moreover, several of these systems have the advantage of
possessing imaging capabilities18,47 , making them prime candidates for combined,
nanotheranostic solutions. This is advantageous, as non-invasive imaging during treatment,
particularly during neoadjuvant regimens, is essential to early identification of non-responders,
that allows for faster turnaround of clinical decisions.
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3.1.4 Monitoring tumor progression
During the neoadjuvant treatment, patients are normally monitored by assessing morphological
changes in primary tumor and lymph nodes13 . However this method could be unreliable, as it is
highly subjective, and it could be inaccurate due to therapy-induced fibrosis48 . Another
commonly employed modality, mammograms, have difficulty distinguishing between scar tissue
and viable tumor, failing to determine the proportion of malignancy vs. fibrosis or nonviable
residual tumor tissue48 .
While no gold standard exists for imaging surveillance during therapy, the International
Consensus Conference on the use of neoadjuvant systemic therapy suggests magnetic resonance
imaging (MRI) or ultrasound as preferred modalities2 . Many clinical studies have proposed MRI
as a means to predict response after neoadjuvant chemotherapy, with many clinical studies
showing good results in terms of accuracy49–52 . An improved dynamic contrast enhanced MRI
technique uses sequential imaging after a contrast agent injection to assess the tumor perfusion 51
was also proposed. However, these methods are costly from a financial and a time perspective,
therefore being limited in use. Diffuse optical spectroscopy was also proposed as a more
affordable option and investigated in animal models53 . However, this method suffers from lower
resolutions than other imaging techniques, and it does not directly measure the tumor parameters
that are used in assessing the progression (size, morphology, heterogenicity), but rather relies on
endogenous contrast generated by hemoglobin in the tumor’s vasculature. While the information
about tumor vasculature progression is important in monitoring and predicting a treatment
response54 , it needs to be complemented by other parameters, potentially identified with different
imaging techniques.
Studies have shown that the combination of mammography and ultrasound, the two most
commonly available techniques in the context of breast cancer treatment, correlated better with a
pathological complete response (pCR) at the end of the regime than just physical examination
alone55 . Although ultrasound alone might suffer from interference from any fibrosis in the tumor
tissue, quantitative ultrasound methods for processing the data have demonstrated promising
accuracies in early prognosis of pCR 56 . With these methods relying on size-changes in the tumor
during treatment, the issue of early prognosis using affordable means, such as ultrasound
imaging, remains a challenge.
An imaging tool to allow the prediction of responses across patients ever since the administration
of the first NAC treatment course would have a great impact in informing changes in systemic
therapy for poor responders and in avoiding unnecessary morbidity and high-treatment costs.
Therefore, a type of image-guided neoadjuvant therapy might be beneficial in closing this gap.
Particularly interesting for their potential for image-guided drug delivery are phase-changing
nanodroplets. These are nano-sized carriers that have liquid perfluorocarbon (PFC) cores
stabilized by a lipid, protein or polymeric shell57 . Their core can be externally vaporized,
triggering the transition from a nanodroplet to a microbubble. The PFCs used in such
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applications have boiling points lower than the body temperature causing them to be superheated
during circulation and hence susceptible to vaporization in the presence of pulsed ultrasound
with pressures lower than those normally used for therapeutic purposes 58 . Phase-changing
nanodroplets have been shown to offer both ultrasound and photoacoustic contrast 59 , allowing
for a combined imaging technique that would give information on the size of the tumors, as well
as their vasculature. This makes them ideal candidates for a comprehensive assessment and
prognosis of neoadjuvant treatment outcome.
In this work, we focus our attention to the design and development of nanodroplets that can fill
the gap currently still existing in the image-guided neoadjuvant combination therapy space.
Tuning the formulation of nanodroplets in order to modify their charge, we propose a platform
that can encapsulate both chemotherapeutics as well as large molecules, and achieve on demand
simultaneous release of both agents. Nanoparticles’ charge is important in their biological
activity, with extensive research dedicated to studying how different charges impact
nanoparticles circulation times, their interactions with the immune system, their stability in vivo,
or their capability to bind to the cell membrane and deliver their payload 60,61 .
Perfluorocarbon core nanodroplets, a relatively new platform being explored for imaging,
therapeutic or theranostic purposes, have not properly been explored in terms of influence of
charge. In this study, we show the synthesis and characterization of perfluoropentane
nanodroplets either cationic or anionic, and the possibility to use that charge to generate
electrostatic interactions with large molecules. This allows the encapsulation of biomolecules
such an antibodies, like the anti-PD-L1 antibody used herein.
Moreover, as shown in Chapter 2 both the core and the shell of nanodroplets can be employed to
load small molecules, capacity which we take advantage of to create an all-in-one combination
chemotherapy and immunotherapy platform. These nanodroplets, loaded with a small molecule
and a large molecule, can release their payload after activation with focused ultrasound and
generate microbubbles visible with great contrast in ultrasound.

3.2 Methods
3.2.1 Synthesis
Cationic nanodroplets were synthesized by mixing 2-dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC, NOF America), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE, NOF
America), 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP, NOF America) and
Cholesterol (Alfa Aesar) were mixed in 5 mL chloroform in the molar ratios described in Table
3.1. The lipid mixture was evaporated in a rotary evaporator (Heidolph HEI-Vap) under a 250
mbar vacuum at 39°C until the formation of a thin film. The film was then rehydrated with 3 mL
distilled water, sonicated in a water bath to form and disperse the liposomes, and transferred to a
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15 mL centrifuge vial. The perfluoropentane (200 µL) was added to the liposomes, followed by
sonication with a QSonica Q700 1/8 inch microtip probe sonicator (20 s total “On time” with 1s
on and 3s between pulses at 1% amplitude, followed by 5 s total “On time”, with 1s on and 10s
between pulses at 25% amplitude). At the end of the synthesis, nanodroplets were centrifuged
(Eppendorf MiniSpin) and washed several times to remove unincorporated lipids: first at 43 rcf
keeping the supernatant, then two times at 2100 rcf keeping the pellet and replacing the solvent
with fresh distilled water. The nanodroplets were kept on ice until the incubation with antibodies.
A fluorescently-labeled secondary antibody (CF647 goat anti-mouse IgG(H+L), Biotium) with a
negative charge was used as received from the supplier for this proof-of-concept nanodroplets,
and 200 µL of nanodroplets stock was mixed with 10 µL antibody solution, with a final antibod y
concentration in the mixture of 95 µg/mL.
Anionic nanodroplets were obtained in a similar manner, the difference being having replaced
the DOTAP lipid with a negatively charged 1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol
(DMPG, NOF America), and the various ratios of the lipids described in Table 3.2. After
following the same protocol for synthesis and purification of the droplets, 200 μL of anionic
nanodroplets stock were mixed with a 20 µL antibody solution volume, used as provided by the
respective suppliers. Two different antibodies were used for incubation obtaining two types of
samples: a fluorescently labeled anti-PD-L1 antibody (AlexaFluor 647 conjugated Human PDL1/B7-H1 durvalumab biosimilar, R&D Systems) with final concentrations in the range of 66
µg/mL, and a non-fluorescently tagged anti-PD-L1 antibody (Human PD-L1/B7-H1
atezolizumab biosimilar, bioXcell) with concentration of 500 µg/mL. For both of these types, the
mixture of antibodies and nanodroplets was incubated for 1 h at 4 °C with gentle mixing. The
incubation was followed by three centrifugation steps at 2100 rcf, to remove the unbound
antibody. The supernatant was kept at each stage, and measured, to account for the
unencapsulated amount.
Table 3-2 Formulation of nanodroplets, expressed as molar ratio of lipid and lipophilic
components.
Cationic Droplets
Sample name
DPPC

DOPE

DOTAP

Cholesterol

9-1-1-0

9

1

1

0

3-1-1-0

3

1

1

0

3-1-1-1.5

3

1

1

1.5

0-1-2-1.5

0

1

2

1.5
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Anionic Droplets
Sample name
DPPC

DOPE

DPMG

Cholesterol

Type A (5%)

7.9

1

1

0

Type B

7.9

1

1

1

Type C

7.9

0

1

1

10%

7.9

1

0.5

0

18%

7.9

1

2

0

Sample name

Nanodroplets with physically entrapped antibodies

DPPC

DSPE-PEG 2000

Cholesterol

Paclitaxel (with
respect to total
lipids)

ITD

35

15

50

0

ICD

35

15

50

45

3.2.2 Size and zeta potential determination
After synthesis nanodroplets were diluted to a 50x dilution in distilled water for size
measurements, and in 0.01 M NaCl solution for the zeta potential measurements. A Malvern
Nanozetasizer instrument was used to measure the size and zeta potential of the particles. All
measurements were done in triplicate, with an automatic number of runs per measurement
determined by the equipment software based on concentration of the sample.

3.2.3 IgG binding determination
After incubating nanodroplets with the corresponding antibody, the size and zeta potential were
measured, and compared to nanodroplets without the antibody. The measurements were done
with the same settings, and the change in zeta potential was deemed to indicate the electrostatic
interaction between the nanodroplets and the antibody molecules.
To quantify the amount of antibody encapsulated in nanodroplets sample, a micro- bicinchoninic
acid (BCA) protein assay kit (Micro-BCA™ kit, Thermofisher) was used. Nanodroplets were
dissolved in a mixture of 50:50 ethanol:water and measured against a previously constructed
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calibration curve. A sample of nanodroplets that were not incubated with antibodies was
measured as well, to correct from any interference from the carrier.
In the case of fluorescently tagged antibodies, a FluoroMax fluorospectrometer was used to
measure the nanodroplets before and after incubation, as well as the supernatant collected during
the washing steps following incubation. The fluorescent antibodies used here were AlexaFluor
647 conjugated Human PD-L1/B7-H1 durvalumab biosimilar, R&D Systems, and the
measurement settings used in the fluorospectrometer were 650 nm/ 670 nm for excitation and
emission, respectively. To get insight into their co-localization with droplets, fluorescence
imaging by a Leica DMI8 fluorescence inverted microscope, with a Y5 filter, was used to
visualize nanodroplets-antibody constructs.

3.2.4 IgG release
For fluorescently tagged antibodies, the release of antibody from the nanodroplets upon
activation was measured employing the same measurement method as for the loading. After
activation, nanodroplets were centrifuged at 2100 rcf for 60s and the supernatant was collected
and measured with the fluorospectrometer.
The micro BCA assay kit was used to measure the amount of antibody in the supernatant from
the release experiment, as well as the antibody left in the nanodroplets. The percentage of
released antibody was computed by the ratio of antibody in supernatant/total antibody amount
(supernatant + pellet).

3.2.5 Anti PD-1/PD-L1 activity of IgG-laden nanodroplets
A competitive ELISA assay from BPS Bioscience was run to measure the activity of the released
antibody of inhibiting the PD-1/PD-L1 interaction. A number of wells corresponding to the
number of samples were selected in a 384 white opaque well plate. Each sample was done in
triplicate, and groups’ placement on the well plate was chosen to allow for at least 3 empty wells
in either direction to minimize bleed-over luminescence signal. The wells were coated with PDL1 antibody by adding a 25 μL volume/well of a 2 μg/mL solution of PD-L1 and left overnight
at 4 °C to allow for adsorption of the protein on the wells. After the coating procedure, the plate
was washed with the immunobuffer provided in the kit 3 times, and 50 μL blocking buffer,
provided in the kit, were added to each well and left to incubate at room temperature with mild
shaking, for 1 h. After blocking, 3 washing steps with immunobuffer were performed, and the
master mixture added to each well as described by the supplier’s protocol. The groups in the
assay were: a positive control ( no inhibitor agent), a ligand-control (no PD-L1 coating), a blank
(no PD-1-biotin added), and testing groups with empty nanodroplets, loaded nanodroplets, and
activated loaded nanodroplets. For the testing groups, 3 μL of the corresponding agent was added
(nanodroplets were added either at the stock concentration or 10 x dilution, unless otherwise
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specified). All groups except blank received a 10 μL volume of a 0.5 μg/mL PD-1-biotin
solution. The blank group wells had 10 μL immunobuffer added instead. After all the additions,
the plate was incubated with mild shaking at room temperature for 2 h. After this incubation, and
3 washing steps, the wells were blocked again by adding the blocking buffer for 10 minutes,
decanted to remove the supernatant and 50 μL of a streptavidin-horseradish peroxidase (HRP)
solution was added to all the wells, and incubated at room temperature for 1h with slow shaking.
Following 3 washing steps with immunobuffer, another blocking step was done for 10 minutes,
and the supernatant removed a last time. The HRP substrate, made up from two components as
provided by the suppliers, was added to the plate ( 50 μL /well) and the luminescence measured
by a SpectraMax i3 reader as soon as possible.
3.2.6 a-PD-L1 staining of cells
MDA-MB 231 cells (ATCC), a triple negative breast cancer cell line overexpressing PD-L1 on
their surface, was used as a model here. Cells were plated on 35 mm VWR confocal Petri Dishes
with a 20 mm glass bottom at a cell density of 0.5 x 104 cells/plate in Dulbecco’s Modified Eagle
Medium (Corning), and left to attach overnight in an incubator at 37 °C and 5% CO 2
concentration. Secondly, cells were fixed on the dish using a paraformaldehyde (Thermofisher)
solution of 3.5% in PBS for 10 minutes at room temperature. This was followed by 2 washing
steps with PBS. A blocking buffer made up from a 5% w/v bovine serum albumin (Sigma
Aldrich) solution in PBS was used for a 30 minutes incubation at room temperature. This is
needed in order to block non-specific binding. After washing with fresh PBS 2 times, the cells
were incubated either with a solution 10 μg/mL of either the fluorescent IgG (AlexaFluor 647
conjugated Human PD-L1/B7-H1 durvalumab biosimilar, R&D Systems) or fluorescent nonspecific antibody (CF® 647 conjugated goat anti-mouse IgG, Biotium) for 1h at 4°C. After 3
washing steps with fresh PBS, the two samples were imaged with a Leica DMI8 inverted
fluorescence microscope with a Y5 filter. The exposure time for fluorescence was 2.5 s, while
the brightfield images were acquired using the “auto” settings in the microscope’s software.

3.2.7 Surface PD-L1 targeting of IgG-laden nanodroplets
Three 35 mm VWR confocal Petri Dishes with a 20 mm glass bottom at a cell density of 0.5 x
104 in Dulbecco’s Modified Eagle Medium were used, and cells were left to attach overnight in
an incubator at 37 °C and 5% CO 2 . The dishes were assigned to one of the groups: one as a
control and two containing a-PD-L1 nanodroplets (electrostatically bound, denoted “eITD”)
either activated using high intensity ultrasound or not. The cells were incubated with eITDs for a
final dilution of nanodroplets of 50x from the stock for 1h, followed by 3 washing steps with
fresh PBS. The activation with pulsed HIFU (1.1 MHz, focal pressure 9.6 MPa, 10 pulses of 10
cycles each) was applied to the dish 20 minutes after adding the nanodroplets to the dish. Care
was taken that the pulses were not aimed directly at the cells to avoid detachment from the dish.
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This was followed by staining of the cells with AF647-labeled a-PD-L1 as described in the
section above, with a concentration of 5 μg/mL.
3.2.8 Obtaining of Nanodroplets with dual immuno- and chemo- therapy functionality
A double emulsion method was employed for obtaining droplets encapsulating paclitaxel inside
the shell, followed by adding the core emulsion containing a-PD-L1 antibodies. To synthesize
ICDs, 2 mg paclitaxel was added to the lipid shell during liposome formation. The core emulsion
was obtained by adding 300 μL PFP, 10 μL Krytox FSL (Chemours) and 50 μL of a-PD-L1 5
mg/mL solution. Following the rehydration of the lipid layer with 3 mL, the core emulsion was
added and sonicated together with the shell. After several washing steps, the resulting
nanodroplets contained paclitaxel distributed through the shell, and a-PD-L1 antibodies inside
the core.
3.2.9 Measurement of PD-L1 expression on the surface of cells
MDA-MB 231 cells were used similarly as described above. The cells were plated on tissue
culture treated 35 mm Petri Dishes and left overnight to attach and grow, in an incubator at 37 °C
and 5% CO 2 concentration. Across different studies, the cells were incubated with various agents
for a 24 h long period of time: paclitaxel (1 μM, Fisher Scientific), doxorubicin (0.19 μM,
Advanced ChemBlocks), dual-drug loaded nanodroplets (up to a dilution corresponding to the
free drugs’ concentration; nanodroplets synthesized as described in Chapter 2, Section 2.2.1) , aPD-L1 loaded nanodroplets (denoted ITD, a 20x dilution from the stock concentration in the
final dish volume), paclitaxel and a-PD-L1 dual-loaded droplets (denoted ICD). After the
incubation time, cells were washed with PBS, trypsinized with trypsin 0.5 % (Corning, 0.5 mL in
each dish, or enough to cover all the surface of the dish), centrifuged and the pellet was washed
again, replacing the media with fresh one. All cells were counted with the help of a
hemocytometer, and the volumes of suspension added in the final samples were adjusted as to
obtain an equal concentration of cells/mL. The same volume (200 μL) of the cell suspensions
were added to low-protein binding 1.5 mL centrifuge vials (Eppendorf). All samples had an
antibody solution added, at a 5 μg/mL final concentration of AF-647 labeled anti-PD-L1 (R&D
Systems) and incubated for counterstaining in the incubator at 37 °C, with mild shaking, for 1h.
After the incubation time elapsed, the samples were centrifuged at 2100 rcf for 60s 3 times in
total, each of the times keeping the cell pellet and adding fresh solvent, fresh cell media for the
first wash, then fresh PBS for the subsequent 2 washes. The cleaned sample was imaged with a
Leica DMI8 inverted fluorescence microscope with a Y5 filter, with the exposure time of 2.5s.
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3.3 Results and Discussion
3.3.1 Synthesis of charged nanodroplets
Various formulations of nanodroplets were investigated by changing the component lipids with
charged counterparts, such as DOTAP for cationic nanodroplets, or DMPG for anionic ones
respectively.
The proof of concept experiments to obtain cationic nanodroplets show that the studied
formulations had highly positive zeta potential (Fig. 3.2 A), that decreased after mixing with
slightly negatively charged goat anti-mouse IgG. In terms of size, the nanodroplets obtained had
sizes in the range of 200-600 nm after synthesis. The interaction with the fluorescently labeled
IgG was reflected not only in the change of zeta potential, but also could be observed from
fluorescence measurements (Fig. 3.2C) and fluorescence microscopy of nanodroplets after
mixing and washing steps (Fig. 3.2 D).

Figure 3-2 A. Zeta potential of two different cationic nanodroplets formulations before and after
1h incubation with a negatively charged secondary IgG; B. Size evolution of the two cationic
nanodroplet batches over 60 minutes of storage in a water bath at 37 °C; C. Darkfield and
fluorescence images of cationic nanodroplets batch containing cholesterol and Y5-labeled
secondary IgG; D. Fluorescence measurement of nanodroplets and IgG mixture after washing
steps and the washed out supernatant of unencapsulated antibody.
The choice of formulation to study more closely was made based on the potential for
electrostatic interactions between the nanodroplets and various antibod ies used for inhibiting the
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PD-1/PD-L1 interaction, especially ones used in the clinic for treatment of TNBC –
Pembrolizumab and atezolizumab.
Although the cationic nanodroplets synthesis was successful and showed the interaction with the
proof of concept antibody as shown above, the decision was made to investigate a different
direction. This was due to Pembrolizumab’s isoelectric point being very close to body pH (pI =
7.4-7.5 compared to pI ~ 6.5 for the placeholder antibody used above) (Fig. 3.3), thus we expect
the interaction between it and cationic nanodroplets would not be very strong. Therefore, the
choice was made to continue with the atezolizumab option (pI = 8.8), and the anionic
nanodroplets. However, the cationic nanodroplets could still be explored for other proteins, that
have lower pIs, such as some cytokines, siRNA or proteins, all of which can have therapeutic
applications. This is beyond the scope of this project, and therefore was not explored further
within. Additionally, chapter 5 introduces cationic nanodroplets in the context of small molecule
loading and release for an analysis on the role of surface charge on drug carrying and delivery
capabilities.
Table 3-3 Iso-electric point of various clinically used antibodies. Data from 62
Antibody commercial name

Iso-electric point (pI)

Eculizumab

6.1

Infliximab

7.6

Cetuximab

8.8

Bevacizumab

8.3

Atezolizumab

8.6

Denosumab

8.9

Adalimumab

8.9

Ixekizumab

8.1

Ipilimumab

9.2

Nivolumab

8.0

Pembrolizumab

7.6
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Rituximab

9.4

Trastuzumab

9.1

Reslizumab

7.1

3.3.2 Synthesis and characterization of anionic nanodroplets containing electrostaticallybound aPD-L1 (eITD)
Several formulations were tested for anionic droplets to optimize for zeta potential as well as
interaction intensity with an anti-PD-L1 antibody. A fluorescently labeled antibody was used for
the initial testing to make the measurement of loaded nanodroplets easier.
Based off the cationic nanodroplet formulation, we have exchanged the charged lipid used in that
case – DOTAP- with a negatively charged lipid- DMPG- and kept the rest of the elements the
same. We obtained negatively charged nanodroplets with all four elements (DPPC, DOPE,
DMPG, Cholesterol) as well as a couple formulations excluding one of the lipids at the time to
study their role on zeta potential, size, stability and interaction with IgG. Excluding cholesterol
from the formulation seemingly increased the size of nanodroplets obtained (Fig. 3.3 A), while
exclusion of DOPE showed the most bearing on nanodroplet stability, with the size after 24h
increasing x times, and the count rate decreasing more than the other formulations studied here.
In terms of zeta potential, the samples did not differ much, with the two samples having only
three lipids registering slightly lower zeta potentials, probably due to a relatively higher
percentage of DMPG, as the total mass of lipids was kept constant across samples (Fig. 3.3 C).
In term of antibody interaction, while all samples showed electrostatic interactions with the IgG,
the two samples containing cholesterol recorded much lower amounts of “encapsulated”
antibody compared to the formulation without. The same results were clear from fluorescence
imaging of nanodroplets after incubation (Fig. 3.4), although due to the apparently different
nanoparticle concentration available in the field of view, the images were used only as a
qualitative guide rather than a quantitative measurements. While it is not clear what the
mechanisms behind cholesterol-containing droplets lowering nanodroplet-antibody interactions
are, previous studies looking at the role of cholesterol in the composition of liposomes note that
it decreases the microviscosity of the double layer63,64 , making the membrane more flexible, and
it decreased the interaction with serum proteins65 . It is possible that the same type of interactions
decreases the amount of antibody that can be adsorbed.
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Figure 3-3 A. Size of anionic nanodroplets of different types after synthesis (initial) and 24h of
storage at 4°C; B. Derived count rate of 100x dilution samples of anionic nanodroplets of
different types after synthesis (initial) and 24h storage at 4°C; C. Zeta potential of anionic
nanodroplets of different types after synthesis (NDs) and after 1h incubation with anti-PD-L1
antibody at 4°C and washing of excess mAb (NDs + IgG); D. Loading efficiency of antibody vs
type of nanodroplets after 1h incubation at 4°C. The measurement was done by subtracting the
fluorescence of washed out fluorescently-labeled antibody from the fluorescence of the initial
antibody solution.
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Figure 3-4 Brightfield and fluorescence images of anionic nanodroplets of different formulations
after incubation with fluorescently labeled anti-PD-L1 antibody for 1h at 4°C, and several
washing steps.

3.3.3 Optimization of eITD composition
Based on these results, we have decided to use a formulation without cholesterol. To optimize
the formulation, the molar percentage of DMPG was varied to evaluate the effect of the
composition on charge and on the interaction with the antibody. Charge is an important
physicochemical characteristic of nanoparticles that influences how nanoparticles behave in
vivo. Previous studies have shown that higher charge density makes nanoparticles more likely to
be opsonized quickly66 , reducing their circulation time, and implicitly affecting their ability to
reach the tumor site and accumulate. Thus, for our design we aim to obtain nanodroplets with a
high enough charge density to be able to capture a large amount of antibody, and that after the
interaction the overall charge would be low enough to not suffer from fast opsonization ( -15 mV
< zeta < 15 mV). Varying the molar percentage of DMPG did not show statistically significant
differences in the size and stability, as can be observed from the similar drops in derived count
rate after 24h (Fig. 3.5 B). While the zeta potential does not seem to decrease when further
increasing the ratio of DMPG, one has to note that the 18% sample showed a bi-modal
distribution of the potential (Fig. 3.5 E). This might indicate that the lipids are not uniformly
distributed across the nanodroplets population, with potential pockets of negatively charged lipid
concentrated on some of the nanodroplets. This might be due to the difference in solubilities
between the anionic lipid that is partially soluble in water, and DPCC and DOPE, that are not .
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This seems to influence the perceived increase in the zeta potential after the interaction with
antibodies (Fig. 3.5 C), and it also impacts the efficiency of this interaction, making the sample
have a rather small loading efficiency (Fig. 3.5 D). For showcasing the loading and triggered
release of mAb from nanodroplets, eITDs of the different compositions were measured with a
microBCA kit, measuring the total amount of protein in the incubating antibody solution, and the
amounts of protein in eliminated in the washing steps. The amount loaded was obtained from the
difference of the two, as the lipids interfere with the assay, and no method that would completely
destroy the nanodroplets maintains the integrity of the antibody. The nanodroplets were activat ed
using continuous focused ultrasound at 50mVrms for 5s, centrifuged and the separated from the
supernatant. The concentration of protein in the supernatant was measured with the same
method, and the percentage of released antibody obtained by dividing the amount of antibody
release to the total amount loaded. This study revealed that there seemed to be a trade-off
between the amount of antibody the eITD can load and the efficiency of triggered release (Fig.
3.5 E-F). This traces back to the content of anionic lipid, and implicitly the charge of droplets
that are incubated with the positively charged antibody – a larger overall charge indicates a
higher number of regions where antibody molecules can electrostatically bind to.

Figure 3-5 A. Size of anionic nanodroplets with varying % of DMPG after synthesis (initial) and
24h of storage at 4°C; B. Derived count rate of 100x dilution samples of anionic nanodroplets
with varying % of DMPG after synthesis (initial) and 24h storage at 4°C; C. Zeta potential of
nanodroplets after synthesis (NDs) and after 1h incubation with anti-PD-L1 antibody at 4°C and
washing of excess mAb (NDs + IgG); D. Zeta potential distribution of 18% molar DMPG
anionic nanodroplets showing two peaks, at -57 mV and -21.7 mV, respectively; E. Loading
efficiency of antibody vs type of nanodroplets after 1h incubation at 4°C; F. Release of
antibodies after HIFU exposure of droplets.
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3.3.4 In vitro activity of eITD
The release of the antibody from eITDs was estimated in acellular media using fluorescently
labeled mAbs electrostatically bound, as shown before. However, because the interaction
nanodroplet-antibody is non-specific, there is a possibility that these cond itions might
underestimate the amount of antibody that would detach from droplets, with or without
activation, due to the presence of competing sites to bind that have higher affinity constants. For
this reason, the next step in our analysis was to test eITD’s activity in inhibiting the PD-1/PD-L1
pathway. A competitive sandwich ELISA assay was set up, as shown in the schematic in Fig. 3.6
A. The inhibition of the PD-1/PD-L1 interaction was measured in the presence of the anti-PD-L1
antibody used in eITDs to obtain an activity curve (Fig. 3.6B).
In a similar assay employed to estimate the activity of nanodroplets, the luminescence of wells
where the empty droplets were added did not decrease, indicating that droplets alone do not
inhibit the interaction between the two proteins, while eITD had a strong inhibiting effect.
Various dilutions of the droplets’ stock concentration were analyzed to create a response curve
(Fig. 3.6C). The corresponding concentration of antibody in each of the dilutions was computed
using the previously obtained concentration curve. Unfortunately, while the effect of eITDs on
the PD-1/PD-L1 interaction was strong, indicating a good loading of antibody with potential
therapeutic effects, the difference between activating eITDs before adding them to the well or
not activating them was not as drastic as hoped (Fig. 3.6D). The explanation for this was, as
stated before, the non-specific and rather weak electrostatic binding of antibodies on the shell of
droplets that has lower affinity than the very specific PD-L1/a-PD-L1 bond, making some of the
antibodies detach from nanodroplets without requiring external activation. This is concerning for
nanodroplets designed to circulate in vivo, as PD-L1 ligands can be present in normal tissue,
although they are overexpressed by cancer cells.
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Figure 3-6 A. Schematic of the principle behind a sandwich ELISA: PD-L1 protein is coated on
the plate, the test samples (inhibitors) are added to the corresponding plates, followed by the
addition of PD-1 labeled with biotin. The plate is then incubated with streptavidin bound horse
radish peroxidase (HRP), that binds the biotin. A substrate for HRP is added which generates
chemoluminescence. In this context, a drop in the luminescence compared to the positive group
is expected for the inhibitors, as some of the PD-L1 will be occupied by them and unable to bind
to the PD-1; B. Concentration series of mAb alone showing the inhibition with respect to the
positive group; C. Concentration series of eITD activity on the PD-1/PD-L1 inhibition; D. PD1/PD-L1 inhibition results of empty droplets, and eITD non-activated or pre-activated before
adding to the wells.

3.3.5 Cellular activity of eITD on cancer cells overexpressing PD-L1
To further explore this phenomenon in a cellular media, in vitro methods were next explored.
Literature reports that triple negative breast cancer lines, including MDA-MB 231, express the
PD-L1 ligand. To ensure that this is the case for the cell model in our lab, a staining procedure
was followed using the same fluorescently labeled anti-PD-L1 mAb employed in the
nanodroplets encapsulation studies, and a secondary non-specific mAb as negative control. The
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results show clear staining in the case of the PD-L1 mAb, but not the nonspecific antibody,
confirming the assay parameters were in order (Fig. 3.7).

Figure 3-7 A-B. MDA-MB 231 cells stained with 10 μg/mL of AlexaFluor 647-labeled anti-PDL1 mAb in brightfield (A) and Y5 filter image (B); C-D. MDA-MB 231 cells stained with 10
μg/mL of AlexaFluor 647-labeled non-specific mAb in brightfield (C) and Y5 filter (D).
In order to study the release of antibodies from eITDs a competition assay with MDA-MB231
cells was set up. (Fig. 3.8A). The fluorescence images of cells counterstained with a-PD-L1 after
incubation with non-activated eITD or HIFU-activated eITDs did not show significant deviance
from the control group (Fig. 3.8B). However, as can be observed from these images, the droplets
were sticking to the surface of the Petri Dish, making cleaning steps cumbersome and unable to
complete them successfully without cells detaching. Because of the high background, the
fluorescence could not be reliably quantified. Therefore, the decision to move from a plated cell
assay to one where cells are trypsinized, counted and incubated with the fluorescent mAb in a
controlled concentration was taken. This will also account for situations where some of the cell
groups might be more numerous than others and ensure the same ratio of antibody : cell is used
across samples so that they can be compared. This new method worked well for eITD allowing
for several washing steps, and less background noise in the final images (Fig. 3.9A). A one-way
ANOVA analysis indicates that the three groups had a statistically significant difference in mean
cell fluorescence, however the effect was rather modest (p= 0.04). Comparing the three groups
among themselves using t-tests revealed no statistically significant difference in the mean of
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cells and eITD groups (corrected p = 0.11 ), while the activated droplets and cells group differed
more (corrected p = 0.028).
Although there were small differences between the samples, with the activated eITD sample
having a slightly smaller cell fluorescence on average, the differences were not statistically
significant (Fig. 3.9B). This confirms the previous observation that transpired from the inhibition
assay – the release of the antibodies from eITD is not well controlled externally, so more effort
needs to be taken to ensure that the leakage of antibody is kept at a minimum.

Figure 3-8 A. Schematic of competitive binding assay experiments: the cells expressing PD-L1
receptors on the surface are incubated with the agents of interest, in this case droplets containing
a-PD-L1 mAbs, some of which will bind and block the receptors. After washing steps, and some
blocking, a fluorescently-tagged a-PD-L1 antibody is added to the cells, allowed to bind, and
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imaged after washing steps. Since some of the receptors will be occupied with mAb from the
droplets, we expect the fluorescence of those samples to be lower compared to a control; B.
Brightfield and fluorescence images of cells used as control, and cells incubated with nonactivated eITD or HIFU-activated eITD respectively. The imaging parameters were identical
across the samples, and the same scale is used for displaying all images; C. Total fluorescence
intensity of images in panel B.

Figure 3-9 A. Dark field and fluorescence images of cells incubated with different eITD, either
activated or non-activated, and counterstaining with fluorescent a-PD-L1; B. Boxplots of average
cells’ fluorescence intensity of cells from the three groups; * indicates p< 0.05 (p = 0.047) for the
difference of means between the eITD + HIFU and “Cells” groups.

3.3.6 Synthesis and activity of nanodroplets loaded with a-PD-L1 in the core (ITD)
For this purpose, nanodroplets where the antibody was emulsified into the core of the droplets
were obtained (ITD). The encapsulation of antibodies in this case is physical, therefore the
hypothesis was that it would help minimize losses from non-triggered samples. Liposomes were
obtained as described before, and the core emulsion was obtained by adding a buffered antibody
solution in PFP with Krytox™ FSL (Chemours) as an emulsifier. To test whether the
encapsulated antibody maintained its activity through the synthesis process, a PD-1/PD-L1
inhibition assay was used once more (Fig. 3.10A). While the inhibition was still present from
droplets, the extent was much smaller than in the case of the eITD, due to a much lower content
of antibodies that can be physically encapsulated. Further on, the pre-activated group of droplets
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did not seem to generate a much higher inhibition than the non-activated ones. This could be
happening due to issues in the persistence of released antibodies with the microbubbles’ shell in
the pre-activated sample, which form a foam on top of the sample that separat es out partially.
However, when tested in the presence of cells, and activated inside the dish, the difference
between the non-activated ITD and activated ones is clearer in the average cell fluorescence
intensity of the two samples (Fig.. 3.10B, p = 0.023). This seems to corroborate our theory that
one issue with the ELISA kit is the inability to activate the droplets in wells due to the reduced
volume capacity and the incompatibility of size between the HIFU transducer and the 384-well
plate wells’ size.

Figure 3-10 A. PD-1/PD-L1 inhibition by empty droplets, and ITDs non-activated or preactivated before adding to the wells, in two different dilutions: 10x and stock concentration; B.
Boxplots of average cell fluorescence intensity of control cells, and cells subjected to ITDs nonactivated or activated, respectively.

3.3.7 Effect of chemotherapeutics on PD-L1 expression of cancer cells
There have been studies that report PD-L1 function is not only an important component of the
immunosuppressive PD-1/PD-L1 pathway, but also pro-survival functions involved in drug
resistance. [citation]
Several chemotherapeutics have been shown to upregulate the surface expression of PD-L1 in
breast cancer, suggesting an increase in the immunosuppressant state of the tumors 67 . In this
context, the co-administration of agents that could counteract that increasing effect might lead to
synergistic effects. In this study, the PD-L1 expression on the surface of MDA-MB231 cells was
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evaluated by staining with a fluorescently tagged a-PD-L1 antibody, for cells that have been
exposed to Paclitaxel (1 mM), Doxorubicin (1 mM), Paclitaxel (1 mM) + Doxorubicin (1 mM),
and Paclitaxel and Doxorubicin encapsulated in nanodroplets presented in Chapter 2, and added
to cells such that the concentration of both was 1 mM. A one-way ANOVA test revealed a
statistically significant difference between the groups studied here (p < 0.0001). Comparing
control cells where no intervention was made with the cells exposed to the chemotherapeutics for
24h, a decrease in PD-L1 expression was observed in the case of doxorubicin, corroborating
other results in literature that looked at similar conditions, although the effect was rather weak
(corrected p = 0.05) (Fig. 3.11). Meanwhile, exposing the cells to paclitaxel in that dose made
the cells upregulate the PD-L1 expression (corrected p < 0.0001). Combinations of the two drugs
saw an intermediary result, with free drugs and encapsulated drugs showing no significant
difference between each other in terms of PD-L1 expression.

3.3.8 Synthesis and characterization of dual immuno-, chemo- therapeutic nanodroplets
(ICD)
Given the effects of the chemotherapeutics studies on the PD-L1 expression, the decision was
made to synthesize immuno-, chemo- nanodroplets (ICD) containing paclitaxel and a-PD-L1
atezolizumab biosimilar. This is also the current golden standard in advanced TNBC patients that
receive combinations of chemotherapy and immunotherapy. The chemotherapeutic attacks some
of the cancer cell subpopulations, reducing the barrier for immune T-cells to infiltrate, and the
PD-L1 neutralization reinforces that effect by blocking the immunosuppressive PD-1/PD-L1
pathway that stops the T-cell signaling for co-stimulatory factors.
To ensure that the activity of antibodies is maintained through the synthesis, a PD-1/PD-L1 assay
was used to test the inhibitory effect of ICDs, either non-activated or pre-activated with HIFU
prior to adding them to the wells (Fig. 3.12A). Since the experiment with ITDs showed some
issues due to the activation having to take place outside of the wells, this assay included two
additional groups. After activation, a small sample was added to the wells, denoted “ICD +
HIFU”, and the rest of the activated sample was centrifuged and separated carefully into a
“pellet” and “supernatant” groups that were added to their corresponding wells in the assay. The
inhibitory effect of supernatant was the most pronounced from all the groups, accounting for the
antibody that got released from the droplets. Meanwhile, the pellet maintained a reduced effects,
as expected since part of the antibodies were released already and stayed in the supernatant, with
the initial activated sample recording a slightly lower inhibitory effect. This was probably due to
the foaming effect discussed before, effect that went away in the centrifuging process, allowing
for a more reliable measurement of the samples’ activities.
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Figure 3-11 A. Dark field and fluorescence images of cells incubated overnight with different
agents, and counterstaining with fluorescent a-PD-L1; B. Boxplot of average cell fluorescence
intensity of the different groups.
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Figure 3-12 A. PD-1/PD-L1 inhibition of PTX-droplets, ICD (activated or non-activated), and a
sample of the pellet and supernatant separated after activation; B. Cytotoxicity of ICDs
compared to single-agent droplets on MDA-MB231 cells; C. PD-L1 expression, measured as the
average cell fluorescence intensity, of MDA-MB231 cells incubated with PTX-droplets, ICDs,
and ITDs.
The ICD activity was also tested in a cell cytotoxicity assay, in comparison with droplets
containing only paclitaxel, in equivalent concentrations. Surprisingly, the ICDs showed an
enhanced effect on the cells in terms of cytotoxicity. Since the difference in the activated vs
nonactivated sample for this batch was minor, the effect observed here might be due to an
increase in the instability of the droplets containing the antibody. This test will need to be
repeated to ensure that this factor is accounted for and the effects of the combination of the drug
and checkpoint inhibitor understood properly.
Finally, an assay to investigate the PD-L1 expression of cells exposed to either paclitaxel
droplets, ICDs or ITDs, was established (Fig. 3.12C, Fig. 3.13). While the trend of PD -L1
expression increase compared to control for paclitaxel treated cells was maintained when the
paclitaxel was encapsulated in droplets, the addition of the core a-PD-L1 counteracted the
increase. However, it seems like the concentration of antibodies was not large enough to
completely neutralize the effect of paclitaxel, and more studies are needed to establish what the
best working ratio between the two would be. In the case of ITD, the recorded average cell
fluorescence intensity was lower than control, which was the expected result.

93

Figure 3-13 Representative images of a-PD-L1 stained cells after 24h incubation with PTXdroplets, ICD or ITD, compared to control cells.

3.4 Conclusions
This chapter discusses expanding the therapeutic utility of perfluoropentane nanodroplets to the
field of immunotherapy, by employing immune checkpoint inhibitors. Two different modalities
of including a-PD-L1 monoclonal antibodies within the nanodroplets are explored: either by nonspecific electrostatic binding to the nanodroplets’ shell, or physical entrapment within the core of
droplets. An optimization process for the formulation of nanodroplets shell composition was
undertaken to maximize the loading potential of a-PD-L1 antibodies. The nanodroplets were
characterized in terms of size, and zeta potential, as well as loading efficiency and the release by
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high intensity focused ultrasound activation, in acellular media and in the presence of PD -L1
expressing cells.
Given the non-specific nature of the entrapment of antibodies, nanodroplets with antibodies
entrapped in the core were also designed and synthesized. Similar characterization methods were
carried out, and showed promise for the on-demand release of the antibodies in the presence of
MDA-MB231 cells overexpressing PD-L1.
Both these types of droplets can have their applications as vessels for immune checkpoint
inhibitors, the electrostatically bound ones for localized administration – intra-tumoral injection,
and the physically entrapped ones could probably be better suited for iv administration.
Looking forward towards the use of immunotherapy in conjunction with chemotherapy rather
than as a monotherapy, nanodroplets containing paclitaxel in the shell and a-PD-L1 antibodies in
the core were synthesized. Their effects on MDA-MB231 cells, a triple negative breast cancer
model, was studied and showed promising synergistic effects.
One of the limitations this study highlighted was related to the loading capability of large
molecules. The rather large volume of antibodies limits how many molecules can be
encapsulated in each nanodroplet, meaning that a larger concentration of nanodroplets might be
needed to achieve a therapeutic effect. The alternative presented here, the electrostatic
encapsulation, presents its own challenges, as the on-demand aspect is considerably reduced. A
potential avenue worth exploring in this context is a comparison of nanodroplets with the
antibody covalently-bound to the surface with nanodroplets physically entrapping antibodies.
Since functionalization is dependent on the composition, the number of antibody molecules
could be tuned more easily and could prove more efficacious. A different direction all together
would be the use of affibodies, that maintain the functional targeting group, without the same
size constraints as the full antibody. This would, however, add an element of complexity from
the expected safety profile, as the antibodies used in the study are already clinically approved for
the intended application, while no affibody for the same purpose that have cleared FDA regulations exist at the moment.
Overall, this chapter serves as a proof of concept for the expansion of perfluorocarbon
nanodroplets platforms towards image-guided solutions for combination therapies including both
immune- and chemo- treatments in contexts like neoadjuvant regimens.

3.5 References
1.

Mieog, J. S. D., van der Hage, J. A. & van de Velde, C. J. H. Neoadjuvant chemotherapy for
operable breast cancer. British Journal of Surgery 94, 1189–1200 (2007).

95

2.

Kaufmann, M. et al. Recommendations from an International Consensus Conference on the
Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of
Surgical Oncology 19, 1508–1516 (2012).

3.

Kufe, D. W., Holland, J. F., Frei, E. & American Cancer Society. Cancer medicine 6. (BC
Decker, 2003).

4.

Huang, L. et al. Neoadjuvant chemotherapy followed by surgery versus surgery alone for
colorectal cancer: meta-analysis of randomized controlled trials. Medicine 93, e231 (2014).

5.

Jones, R. L. & Smith, I. E. Neoadjuvant treatment for early-stage breast cancer: opportunities to
assess tumour response. The Lancet Oncology 7, 869–874 (2006).

6.

Del Prete, S. et al. Clinical and pathological factors predictive of response to neoadjuvant
chemotherapy in breast cancer: A single center experience. Oncology Letters 18, 3873–3879
(2019).

7.

Asselain, B. et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early
breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet
Oncology 19, 27–39 (2018).

8.

Gianni, L. et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by
cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy:
European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 27, 2474–81 (2009).

9.

Nowak, A., Wilcken, N., Stockler, M., Hamilton, A. & Ghersi, D. Systematic review of taxanecontaining versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of
early breast cancer. The Lancet Oncology 5, 372–380 (2004).

10.

Mrózek, E. et al. Phase II Trial of Neoadjuvant Weekly Nanoparticle Albumin-Bound Paclitaxel,
Carboplatin, and Biweekly Bevacizumab Therapy in Women With Clinical Stage II or III HER2Negative Breast Cancer. Clinical Breast Cancer 14, 228–234 (2014).

11.

Robidoux, A. et al. A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound
Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced
Breast Cancer. Clinical Breast Cancer 10, 81–86 (2010).

12.

Untch, M. et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for
early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial. The Lancet Oncology
17, 345–356 (2016).

13.

Teshome, M. & Hunt, K. K. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol
Clin N Am 23, 505–23 (2014).

14.

Biganzoli, L. et al. Management of elderly patients with breast cancer: updated
recommendations of the International Society of Geriatric Oncology (SIOG) and European
Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13, e148-60 (2012).

96

15.

Lee, B. K., Yun, Y. H. & Park, K. Smart nanoparticles for drug delivery: Boundaries and
opportunities. Chemical Engineering Science 125, 158–164 (2015).

16.

Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what
is the future of nanomedicine? Journal of Controlled Release 244, 108–121 (2016).

17.

Venkatraman, S. Has nanomedicine lived up to its promise? Nanotechnology 25, 372501 (2014).

18.

Chen, H., Zhang, W., Zhu, G., Xie, J. & Chen, X. Rethinking cancer nanotheranostics. Nature
Reviews Materials 2, 17024 (2017).

19.

Merlano, M. C., Abbona, A., Denaro, N. & Garrone, O. Knowing the tumour microenvironment
to optimise immunotherapy. Acta Otorhinolaryngologica Italica 39, 2–8 (2019).

20.

Bailly, C., Thuru, X. & Quesnel, B. Combined cytotoxic chemotherapy and immunotherapy of
cancer: modern times. NAR Cancer 2, (2020).

21.

Marra, A., Viale, G. & Curigliano, G. Recent advances in triple negative breast cancer: the
immunotherapy era. BMC Medicine 17, 90 (2019).

22.

Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y. & Zang, X. Human cancer
immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine
21, 24–33 (2015).

23.

Salmaninejad, A. et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.
Journal of Cellular Physiology 234, 16824–16837 (2019).

24.

Schmidt, E. v. Developing combination strategies using PD-1 checkpoint inhibitors to treat
cancer. Seminars in Immunopathology 41, 21–30 (2019).

25.

Liu, D., Gao, S., Zhai, Y., Yang, X. & Zhai, G. Research progress of tumor targeted drug
delivery based on PD-1/PD-L1. International Journal of Pharmaceutics 616, 121527 (2022).

26.

Zhu, H. et al. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative
breast cancer. Drug Discovery Today 25, 1762–1771 (2020).

27.

Hall, K. H., Liu, Y., Jiang, C. & Harvey, R. D. New and Worsening Long-term Immune-Related
Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer. Pharmacotherapy
40, 133–141 (2020).

28.

Yu, H. & de Geest, B. G. Nanomedicine and cancer immunotherapy. Acta Pharmacologica
Sinica 41, 879–880 (2020).

29.

Yin, W., Li, Y., Gu, Y. & Luo, M. Nanoengineered targeting strategy for cancer immunotherapy.
Acta Pharmacologica Sinica 41, 902–910 (2020).

30.

Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing
potential synergies. Cancer Immunol Res 3, 436–43 (2015).

97

31.

Chen, Q., Sun, T. & Jiang, C. Recent Advancements in Nanomedicine for ‘Cold’ Tumor
Immunotherapy. Nano-Micro Letters 13, 92 (2021).

32.

Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res
2, 361–70 (2014).

33.

Vikas, P., Borcherding, N. & Zhang, W. The clinical promise of immunotherapy in triplenegative breast cancer. Cancer Manag Res 10, 6823–6833 (2018).

34.

Keenan, T. E. & Tolaney, S. M. Role of Immunotherapy in Triple-Negative Breast Cancer.
Journal of the National Comprehensive Cancer Network 18, 479–489 (2020).

35.

Chen, G. & Emens, L. A. Chemoimmunotherapy: reengineering tumor immunity. Cancer
Immunol Immunother 62, 203–16 (2013).

36.

Kyte, J. A., Røssevold, A., Falk, R. S. & Naume, B. ALICE: a randomized placebo-controlled
phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients
with metastatic triple-negative breast cancer. J Transl Med 18, 252 (2020).

37.

Scurr, M. et al. Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which
Associate with Survival in Metastatic Colorectal Cancer. Clin Cancer Res 23, 6771–6780
(2017).

38.

Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to
enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine 25, 920–928 (2019).

39.

Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J
Exp Med 202, 1691–701 (2005).

40.

Schmid, P. et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk,
early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort
KEYNOTE-173 study. Annals of Oncology 31, 569–581 (2020).

41.

Schmid, P. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal
of Medicine 382, 810–821 (2020).

42.

Su, C. et al. Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.
Front Oncol 10, 554313 (2020).

43.

Baxi, S. et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic
review and meta-analysis. BMJ 360, k793 (2018).

44.

Yang, F. et al. Advanced biomaterials for cancer immunotherapy. Acta Pharmacologica Sinica
41, 911–927 (2020).

45.

van der Meel, R. et al. Smart cancer nanomedicine. Nature Nanotechnology 14, 1007–1017
(2019).

46.

Zhong, X. & Sun, X. Nanomedicines based on nanoscale metal-organic frameworks for cancer
immunotherapy. Acta Pharmacologica Sinica 41, 928–935 (2020).
98

47.

Abousaway, O., Rakhshandehroo, T., Van den Abbeele, A. D., Kircher, M. F. & Rashidian, M.
Noninvasive Imaging of Cancer Immunotherapy. Nanotheranostics 5, 90–112 (2021).

48.

Weatherall, P. T., Evans, G. F., Metzger, G. J., Saborrian, M. H. & Leitch, A. M. MRI vs.
histologic measurement of breast cancer following chemotherapy: Comparison with x-ray
mammography and palpation. Journal of Magnetic Resonance Imaging 13, 868–875 (2001).

49.

Heldahl, M. G., Lundgren, S., Jensen, L. R., Gribbestad, I. S. & Bathen, T. F. Monitoring
neoadjuvant chemotherapy in breast cancer patients: Improved MR assessment at 3 T? Journal
of Magnetic Resonance Imaging 34, 547–556 (2011).

50.

Yu, H. J., Chen, J.-H., Mehta, R. S., Nalcioglu, O. & Su, M.-Y. MRI measurements of tumor size
and pharmacokinetic parameters as early predictors of response in breast cancer patients
undergoing neoadjuvant anthracycline chemotherapy. Journal of Magnetic Resonance Imaging
26, 615–623 (2007).

51.

Jahani, N. et al. Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast
Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration.
Scientific Reports 9, 12114 (2019).

52.

Cheung, Y.-C. et al. Monitoring the size and response of locally advanced breast cancers to
neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast
Cancer Res Treat 78, 51–8 (2003).

53.

Cerussi, A. et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse
optical spectroscopy. Proceedings of the National Academy of Sciences 104, 4014–4019 (2007).

54.

Brocato, T. A. et al. Predicting breast cancer response to neoadjuvant chemotherapy based on
tumor vascular features in needle biopsies. JCI Insight 4, (2019).

55.

Peintinger, F. et al. Accuracy of the Combination of Mammography and Sonography in
Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy. Annals
of Surgical Oncology 13, 1443–1449 (2006).

56.

Piotrzkowska-Wróblewska, H. et al. Monitoring breast cancer response to neoadjuvant
chemotherapy with ultrasound signal statistics and integrated backscatter. PLOS ONE 14,
e0213749 (2019).

57.

Rapoport, N., Gao, Z. & Kennedy, A. Multifunctional Nanoparticles for Combining Ultrasonic
Tumor Imaging and Targeted Chemotherapy. JNCI: Journal of the National Cancer Institute 99,
1095–1106 (2007).

58.

Sheeran, P. S., Luois, S., Dayton, P. A. & Matsunaga, T. O. Formulation and Acoustic Studies of
a New Phase-Shift Agent for Diagnostic and Therapeutic Ultrasound. Langmuir 27, 10412–
10420 (2011).

99

59.

Hannah, A., Luke, G., Wilson, K., Homan, K. & Emelianov, S. Indocyanine Green-Loaded
Photoacoustic Nanodroplets: Dual Contrast Nanoconstructs for Enhanced Photoacoustic and
Ultrasound Imaging. ACS Nano 8, 250–259 (2014).

60.

Moghimi, S. M., Hunter, A. C. & Andresen, T. L. Factors Controlling Nanoparticle
Pharmacokinetics: An Integrated Analysis and Perspective. Annual Review of Pharmacology and
Toxicology 52, 481–503 (2012).

61.

Gratton, S. E. A. et al. The effect of particle design on cellular internalization pathways. Proc
Natl Acad Sci U S A 105, 11613–8 (2008).

62.

Goyon, A. et al. Determination of isoelectric points and relative charge variants of 23 therapeutic
monoclonal antibodies. Journal of Chromatography B 1065–1066, 119–128 (2017).

63.

Efimova, A. A., Kostenko, S. N., Orlov, V. N. & Yaroslavov, A. A. Effect of cholesterol on the
phase state and permeability of mixed liposomes composed of anionic diphosphatidylglycerol
and zwitterionic dipalmitoylphosphatidylcholine. Mendeleev Communications 26, 99–100
(2016).

64.

Evjen, T. J. et al. Lipid membrane composition influences drug release from
dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. International
Journal of Pharmaceutics 406, 114–116 (2011).

65.

Semple, S. C., Chonn, A. & Cullis, P. R. Influence of Cholesterol on the Association of Plasma
Proteins with Liposomes. Biochemistry 35, 2521–2525 (1996).

66.

Zhao, Z., Ukidve, A., Krishnan, V. & Mitragotri, S. Effect of physicochemical and surface
properties on in vivo fate of drug nanocarriers. Advanced Drug Delivery Reviews 143, 3–21
(2019).

67.

Gilad, Y. et al. Drug-induced PD-L1 expression and cell stress response in breast cancer cells
can be balanced by drug combination. Scientific Reports 2019 9:1 9, 1–8 (2019).

100

Chapter 4 : Nanodroplets for Enhanced Multimodal
Fluorescence and Ultrasound Imaging
This chapter describes the encapsulation of NIR dyes for the design of a fluorescent nanodroplet
probe that combines ultrasound and fluorescence imaging. The rationale behind the design is
explained, and characteristics such as the loading amounts, or the concentration of droplets are
explored in terms of their capability to provide optically-activatable enhanced fluorescence
signals. Preliminary in vivo data are shown using these droplets, imaging the activation of
droplets after a subcutaneous injection in the hind flank of mice. Several avenues to improve the
fluorescence enhancement from the activation are explored, including changing the location of
the dye in the construct, and leveraging protein-DiR interactions that increase the quantum yield
of the dye.

4.1 Introduction
4.1.1 NIR imaging in cancer
Fluorescence imaging is a nonionizing modality that is ubiquitous in biomedical applications,
with applications ranging from diagnosis to interventional guidance 1 . It can provide information
on the physiological state of tissues, as well as the molecular environment 1 . As a result,
fluorescent imaging is an important tool in cancer diagnosis and treatment. Fluorescence imaging
can be employed intraoperatively, in the form of fluorescent-guided surgery procedures that aim
to improve tumor margins2 , as well as perioperatively for characterizing biopsy samples for
biomarker expression or sentinel lymph node mapping 3,4 .
Due to the strong scattering and absorption of visible light in tissues, however, fluorescence
imaging is generally restricted to superficial applications or ex-vivo measurements5 . To address
this, fluorophores in the near-infrared (NIR) range (700-900 nm), and more recently, in the NIRII window (1000-1700 nm), have been proposed as alternatives1,6–10 . In these wavelength
windows, photon absorption, scattering and autofluorescence are decreased, translating into
higher penetration depths compared to visible light 7 . Unfortunately, even the NIR-II probes
proposed to date are still restricted to sub-centimetric applications in vivo11 , and are unable to
achieve spatial resolution that allows for microscopic information in deep tissues 12 .
To enable imaging with high-resolution at deeper levels in the tissue, the following challenges
need to be addressed: i) confine the fluorescence emission into a small volume for high spatial
resolution; ii) increase fluorescence signal strength and detection sensitivity; iii) increase signalto-background ratio (SBR)13 .
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4.1.2 Switchable NIR probes
In an effort to address these challenges and improve sensitivity to small concentrations of
fluorescent contrast agents, activatable or “turn-on” probes have been developed 6,14 . “Alwayson” probes generally suffer from high background signals, lowering their signal-to-background
ratios. Even for targeted agents (either passive or active), unbound agent in the blood hamper the
imaging, and often require long periods of time to allow for clearance of circulating agents,
which can be on the order of days for probes such as radiolabeled antibodies. Nanoencapsulated
fluorophores benefit from extended circulation times, the possibility to target particular
biomarkers present in the tumor, and enhanced tumor accumulation and retention 15,16 . However,
to maximize their SBR the nanoprobes that are located everywhere but the malignant tumor(s)
have to clear out.
Moreover, a major drawback of using nanoencapsulated fluorophores is the aggregation-caused
quenching phenomenon17 . Fluorophores very often contain aromatic π-conjugated frameworks,
hydrophobic in nature. Due to this character, dispersing fluorophores into aqueous media can
lead to aggregation due to hydrophobic interactions such as π- π stacking, that leads to a reduced
of quenched fluorescence phenomenon. The mechanism behind this quenching goes beyond
simple aggregation and consists of interactions between molecules in both excited and ground
states that lead to the formation of sandwich-shaped excimers and exciplexes. The excited states
of aggregates of this type are often decayed by non-radiative pathways, which accounts for the
reduced fluorescence signal recorded 18 .
In contrast, “turn-on” fluorescent probes are designed in such a way to take advantage of this
phenomenon and enable a switch of the signal to distinguish between on target and off target
probe. This is meant to increase SNR and allow for faster and better-quality imaging. The
mechanism behind switching the fluorescence on and off relies on the propensity of fluorophores
to quench under certain conditions and the capability to design triggers that would unquench said
fluorophores on-demand. Several studies have focused on various fluorescent probes that can be
administered in a quenched or “OFF” state and be activated by a specific environmental stimuli –
such as pH, redox potential, specific amino acids19–23 - to become unquenched. While biological,
intrinsic stimuli are an important tool in the design of such probes, the heterogenicity of the real
tumors can cause a hindrance for their efficiency in vivo. Other groups have dedicated efforts to
creating constructs that can be externally activatable, such that the unquenching is controlled.
Several options for externally-triggered systems have been investigated, including temperaturesensitive nanoparticles, light-activatable probes or ultrasound-sensitive nanoparticles14,24–27 .
Ultrasound is an appealing energy source for external activation of fluorophores because of its
good penetration and minimal scattering in soft tissue. A handful of ultrasound-sensitive agents
have been demonstrated to improve the signal-to-noise ratio of fluorescence images12,28 . Because
of the ability to focus ultrasound into a relatively small volume in tissue, the techniques have an
added benefit of improved imaging resolution29.
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Ultrasound-sensitive fluorescent agents can be synthesized in either microbubble 28,30 or
nanoparticle forms12,25,31,32 . Microbubbles expand and contract in response to incident acoustic
waves. This can lead to increased and decreased spacing between encapsulated fluorescent
molecules. Thus, rapid quenching and unquenching is achieved, yielding a high-frequency
modulated fluorescent signal. However, microbubbles are limited due to their size, and normally
cannot extravasate into tissue, providing information from the vasculature only 33 . Their
micrometer-scale size also makes their circulation times short, usually on the order of minutes,
which limits the window for imaging.
In contrast to microbubbles, nano-encapsulated fluorophores benefit from extended circulation
times and enhanced tumor accumulation and retention 21 . These features make them attractive to
be used as ultrasound-switchable probes. Recently, a group proposed using thermo-sensitive
polymeric particles that respond to temperature increase due to high intensity focused ultrasound
pulses to “turn on”, followed by “turning back off” when the HIFU is stopped 29,34 . This
technique managed to achieve greater On-to-Off ratios as well as more distinction between the
“on” and “off” states, however, the temperature thresholds needed are on the order of 10°C
which might hinder their use due to negative effects on the surrounding tissue.
Phase-changing nanodroplets, containing a perfluorocarbon core that can be vaporized with an
externally applied acoustic or laser pulse, have been used as microbubble precursors in several
applications, including ultrasound and photoacoustic imaging 35,36 , image-guided drug
delivery37,38 or opening the brain-blood barrier33,39 . By relying on a liquid-to-gas phase change,
the drawbacks of temperature responsive agents could be avoided.
The work described in this chapter investigates the feasibility of using such a platform as a
switchable NIR fluorescent probe. This study consists of the design and characterization of a
DIR (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide)-loaded phase-changing
nanodroplet platform that is optically or acoustically activatable. The transition from liquid -core
nanodroplets to gaseous-core microbubbles is leveraged for unquenching the loaded DIR for an
increase in the ratio between signal/background. Several dye loadings are investigated in this
context in an optimization effort to determine the loading with the highest increase in the
signal/background ratio. The concurrent ultrasound contrast obtained after vaporization of
droplets is shown, proving the nanodroplet platform can act as a multimodal imaging contrast
agent, for combined NIR fluorescence and ultrasound. Design considerations for the
optimization of the fluorescence enhancement upon activation are explored and several options
for improvement are studied.
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4.2 Methods
4.2.1 Synthesis of DiR-loaded nanodroplets
Nanodroplets were synthesized with the same method as described in Chapter 2. Lipids were
dissolved in 4 mL chloroform and mixed together in a molar ratio of 2-dipalmitoyl-sn-glycero-3phosphocholine (DPPC, NOF America):1, 2-Distearoyl-sn-glycero-3-phosphoethanolaminePoly(ethylene glycol) (DSPE-PEG2000, NOF America):Cholesterol (Alfa Aesar) =35:15:50.
Epolight 3072 (Epolin), with an activation maximum at 1064 nm was added to impart the
activatable capacity to nanodroplets. The added amounts of each reagent were as follows:
DPCC- 50 µL (25 mg/mL solution), DSPE-PEG 2000 - 215 µL (10 mg/mL solution), Cholesterol75 µL (14 mg/mL solution), Epolight 50 µL (5 mg/mL solution). The DiR dye (Biotium) was
added together with the lipids from a 1 mg/mL concentrated solution in chloroform, and the
mixture was evaporated in a rotary evaporator (Heidolph HEI-Vap) under a 250 mbar vacuum at
39°C until the formation of a thin film. The film was then rehydrated with distilled water,
sonicated in a water bath to form and disperse the liposomes, and transferred to a 15 mL
centrifuge vial. The perfluoropentane was added to the liposomes, followed by sonication with a
QSonica Q700 1/8 inch microtip probe sonicator (20 s total “On time” with 1s on and 3s between
pulses at 1% amplitude, followed by 5 s total “On time”, with 1s on and 10s between pulses at
25% amplitude). At the end of the synthesis, fluorescent nanodroplets were centrifuged and
washed several times to remove unincorporated dyes or lipids, keeping them protected from the
light to prevent photobleaching.

4.2.2 Loading of DIR
Fluorescent nanodroplets were measured with a FluoroMax spectrofluorometer with a 748 nm/
780nm setting for excitation/emission. To evaluate the amount of dye loaded, nanodroplets were
destroyed by dissolving them in ethanol up to a 10x dilution with respect to the stock
concentration and measured with the mentioned settings. The concentration was computed by
interpolating with a calibration curve. The calibration curve was created by preparing DiR
solutions in ethanol, with 0.01 – 0.25 μg/mL concentrations, and measured with the same
parameters mentioned above. The fluorescence intensity against concentration was plotted and
fitted with a linear regression.

4.2.3 In vitro studies of laser-triggered DiR unquenching
Polyacrylamide tissue-mimicking phantoms were obtained by a procedure described before 40 .
Briefly, a 10% polyacrylamide gel was prepared from a solution of acrylamide:bisacrylamide
(29:1, Sigma Aldrich) adding up to 4.0% v/v nanodroplets suspension, and N,N,N′,N′tetramethylethylendiamine (TEMED, Thermofisher) and ammonium peroxodisulfate (APS,
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Sigma Aldrich) as initiator system. To assess whether the concentration of droplets in phantoms
plays a role in the unquenching effect, a range of concentrations were studied for each of the dye
loadings. These concentrations ranged from 2% v/v with respect to the total phantom volume to
4% v/v with respect to the total phantom volume. This interval has been found to allow
visualization of all samples with good contrast, including ones with lower dye loadings. Imaging
was done using a Li-Cor Pearl Impulse imager, using an excitation of 785 nm and measuring the
emission at 820 nm. A plastic stencil with 3 circular holes of 15 mm diameter was used for the
activation of spots on phantoms. Phantoms were imaged, and for processing, the signal intensity
inside the activation ROI was measured with ImageJ, as was signal from the non-activated or
“background” region. The ratio between the intensity of signal in the activated spots and that of
the background is denoted “ON/OFF” ratio and computed using an average intensity across the 3
activated spots on each phantom to account for any heterogeneity from activation. For each dye
concentration, 4 phantoms with different nanodroplets volumetric concentration were obtained
(2%, 2.5%, 3%, 4% volume concentrations with respect to the stock of nanodroplets), and the
reported “ON/OFF”ratio is the average of the 4 different phantoms.

4.2.4 Ultrasound contrast
A polyacrylamide gel phantom was obtained as described above, with a 2% concentration of
nanodroplets with respect to the total phantom volume. To gauge the ultrasound contrast
capabilities of activated nanodroplets, a stencil was used to activate a region of the phantom
similar to the procedure described for the concentration study above. The main difference was
that the stencil in this experiment spelled “FMI” with the total height of letter of 10 mm and
width of 25 mm. The phantom was imaged with a L22-8v Verasonics linear array ultrasound
transducer connected to a Verasonics Vantage 256 imaging system. B-mode ultrasound was
collected by scanning the phantom beneath the transducer in the Y dimension (TravelMax, Thor
Labs). Each B-mode created a XZ plane with the x dimension spanning the width of the 256 US
transducer elements (35 mm) and the depth of the phantom (20 mm). In the Y -dimension, 27
images were taken at increments of 0.5 mm. For the 2D image reconstruction, the image stack
was first passed through a 5 x 5 x 5 3D median filter. The mean US signal was then averaged in
the z-dimension, normalized to the maximum intensity and displayed as a single XY plane.

4.2.5 In vivo imaging of DiR-loaded nanodroplets
Nu/Nu nude mice (Charles River) were used as an in vivo model. Mice were sedated with 2.5%
isofluorane (VetOne) volume concentration in oxygen, with a flow rate of 1.5 L/h for the
duration of the procedure.
Each mouse received two injections in the hind flanks, of 50 µL DiR-loaded nanodroplets/flank.
The nanodroplets had a DiR concentration of 4.5 µM in the stock, and were used in a 5x dilution
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for the injections. Fluorescence images were acquired prior to injection, immediately after
injection, after pulsed-laser activation of the droplets. One of the injection sites was activated
(1064 nm Opotek pulsed-laser, 15 mJ/cm2 , 10 s total activation time at 10 Hz frequency of pulse
repetition; the laser was kept at approximately 5 mm from the injection bolus for the duration of
activation), while the other one was used as internal control to compare the changes in dye
intensity over time. Images were acquired with the Li-Cor Pearl Impulse imaging system using
the same settings as in the case of phantoms.
To study the lymph drainage of DIR-loaded nanodroplets, healthy Nu/Nu nude mice were
injected submucosally with ~30 μL dispersion of nanodroplets diluted 5x. The mice were imaged
with Li-Cor Pearl Impulse imaging system with the settings described above. Images were taken
before the injection, after injection, and every hour up to 6h totals, as well as 24h post injection.
The fluorescence intensity in the lymph nodes was measured with ImageJ by selecting a region
of interest for each of the nodes.

4.2.6 Dual emulsion synthesis of perfluorocarbon nanodroplets with DiR in the core
Perfluoropentane nanodroplets with DiR in the core were synthesized by a double emulsion
method similar to the one detailed in Chapter 2. The lipids (DPPC, DSPE-PEG, Cholesterol)
were added to chloroform and the solvent vaporized by means of a rotary evaporator (250 mbar,
39 °C, Heidolph HEI-Vap). The lipids were rehydrated with a mixture of distilled
water/Dulbecco’s phosphate buffer saline (Hyclone) in a 3:2 v/v ratio. The core emulsion was
obtained by adding 60 µL of the emulsifier Krytox™ FSL (Chemours) to 1.5 mL
perfluoropentane (Fluoromed), together with a volume of 160 µL of aqueous phase and a volume
of DiR according to the desired dye content, and sonicated with the probe sonicator for 15 s
continuously at 35% amplitude (QSonica Q700 1/8 inch microtip). The two phases- rehydrated
lipids and core emulsion- were mixed by adding a volume of the core emulsion corresponding to
a 5% perfluorocarbon volume content in the suspension, 200 µL. For the aqueous solution in the
core emulsion, several options were investigated: distilled water, human serum albumin (HSA,
Sigma Aldrich) solution (20 mg/mL concentration in water) or bovine serum albumin (BSA,
Sigma Aldrich) (20 mg/mL concentration in water). The droplets obtained in this manner were
centrifuged (Eppendorf MiniSpin) at 43 rcf for 60s, and the supernatant was kept, while the
pellet was discarded. The supernatant was further centrifuged at 2100 rcf, each time replacing the
media with fresh distilled water to remove unreacted or encapsulated components. Their
fluorescence was evaluated with a FluoroMax spectrofluorometer, as well as Pearl Impulse
Imager before and after vaporization of droplets.
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4.2.7 Protein-shell perfluorocarbon nanodroplets
The nanodroplets were obtained in a similar manner to one described before 41 , and the dye
encapsulated by adding it directly to the synthesis mixture prior to sonication. Briefly, a 2
mg/mL BSA solution was used as a basis for the synthesis. The BSA solution and a DiR solution
in methanol (Fischer Scientific), 1 mg/mL, were added together to a 20 mL glass vial. The
concentration of DiR was controlled by changing the volume of DiR solution added to the
synthesis, with volumes between 5 – 120 µL being used. PFP (0.5 mL or 14 % volumetric
concentration) was then added to the mixture, and sonicated with the probe sonicator (QSonica
Q700 1/8 inch microtip, 20 s total “On time” with 1s on and 3s between pulses at 1% amplitude,
followed by 10 s total “On time”, with 1s on and 10s between pulses at 35% amplitude). After
nanodroplet formation, the sample was centrifuged (Eppendorf MiniSpin) – first at 43 rcf when
the supernatant was kept, then at 2100 rcf three times, keeping the pellet and resuspending it in
distilled water each time.
The obtained fluorescent nanodroplets were characterized in the same manner to the lipid-shelled
one, as detailed in Sections 4.2.2 and 4.2.3.

4.3 Results
4.3.1 Synthesis of Nanodroplets and DiR-Loading
Nanodroplets loaded with DiR were obtained by the synthesis method described (Fig 4.1), and
the measurement of the amount of loaded dye was done by means of a calibration curve. All
nanodroplets samples showed a clear emission peak when dissolved in ethanol (Fig 4.2). To gain
insight into the extent of the quenching, the nanodroplets were measured as dispersed in water –
to get the fluorescence of quenched dye- and measured destroyed in ethanol- to get the
fluorescence of (theoretically) unquenched dye. The ratio between the two intensities should give
a good indication of the degree of quenching experienced in the various nanodroplets samples
(Fig 4.3 A). However, even for the lowest concentration of dye used in this study, the ratio was
around 0.15 or 15%, rather than the ideal 100% that should be expected for non-quenched
samples. The explanation for this lies in the difference in quantum yield of DiR in the two
different solvents: water and ethanol. To confirm this, 5 different concentrations of dye either in
water or in ethanol were obtained and measured under the same conditions to record the
fluorescence intensity (Fig 4.3 B-C). The results clearly show a striking difference between the
two media of around 2 orders magnitude. With this in mind, the ratio between the quenched dye
fluorescence and unquenched dye fluorescence from the nanodroplets is still a useful
measurement in relative terms, and it shows a steady decrease for the range of loaded dye
concentrations studied within this work.
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Figure 4-1 A. Thin-layer evaporation method to obtain DIR-loaded liposome; B. Mixing
preformed liposomes with perfluoropentane to get DiR-loaded PFP nanodroplets; C. Schematic
of the switchable fluorescent nanodroplets going from the nanodroplet state to the microbubble
state due to vaporization of the core. The transition causes quenched DiR encapsulated into the
nanodroplets to partially unquench, resulting in an increase in fluorescence intensity.
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Figure 4-2 Total loaded DiR in nanodroplets measured in completely destroyed nanodroplets in
ethanol

.
Figure 4-3 A. Ratio of fluorescence of nanodroplet-encapsulated dye in water and fluorescence
of total DiR measured from destroyed droplets in EtOH; B. Emission of different concentrations
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of DiR dye dissolved in water; C. Emission of different concentration of DiR dye dissolved in
ethanol.
4.3.2 Laser Activation and NIR Fluorescence Increase
In order to capture the fluorescence enhancement from the quenched nanodroplets’ activation, a
dispersion of nanodroplets was added to the ends of a plastic tube such that the two liquid
sections did not touch (Fig 4.4 A). Images were captured with Li-Cor Pearl Impulse of the tube
before activation, and after activating one of the ends with a single laser pulse (Fig 4.4 B).
Further, a similar experiment was performed using a blood phantom – obtained by dispersing 6
μM DiR nanodroplets in heparin bovine whole blood. Two different nanodroplets dilutions were
used, 20x and 200x, together with a blank of only blood with no droplets. Two equivalent
columns were obtained, with each sample in triplicate, and images were captured with Li-Cor
Pearl Impulse initially and after activating the second column by laser while shielding the first
column from the exposure (Fig 4.5 A-B). For both concentrations, the non-activated wells show
a decrease in the signal in the second image compared to the initial one– of 9.72% and 4.11% for
the 20x and 200x dilution, respectively (Fig 4.5 C-D). On the other hand, the activated droplets
register a drastic increase in the signal for both dilutions, of 167.3% f or the more concentrated
sample and 155.4% for the more diluted one. This increase is likely higher than the one recorded
in water dispersion due to the larger quantum yield of the released dye in the blood media
compared to water. Previous studies have shown that DiR interacts non-covalently with bovine
serum albumin experiencing a ~50-60 fold increase in recorded fluorescence intensity, which
might explain the very drastic increase observed during this experiment 42 . Our own experiments
(not shown here) saw an increase in the signal originally recorded from nanodroplets incubated
in the presence of BSA compared to water or even ethanol, that diminished after several washing
steps, especially if the washing steps are performed with a BSA solution. The presence of
unencapsulated DiR could explain the high intensity of nanodroplets recorded prior to activation.

Figure 4-4 A. 20x dilutions nanodroplets ( 5.87 μM) dispersed on either end of a plastic tube
without contact between the parts; B. Image of the same tube immediately after applying a laser
pulse on the left end of the tube.
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Figure 4-5 A. Blood phantom with DiR-loaded droplets (6 uM) in two different dilutions: 20x
(first 3 rows) and 200x (next 3 rows); B. Same phantom imaged after activation of the wells in
the second column and no activation of wells in the first column showing an increase in
fluorescence for both concentrations; C. Quantification of fluorescence intensity change before
and after laser exposure for both non-activated wells and activated ones containing nanodroplets
in the 20x dilution; D. Quantification of fluorescence intensity change before and after laser
exposure for both non-activated wells and activated ones containing nanodroplets in the 200x
dilution.

4.3.4 Fluorescence Enhancement in Phantom Studies
In order to confirm the fluorescence enhancement for non-moving nanodroplets, in an
environment where it would be easier to distinguish between activated and non-activated
regions, tissue-mimicking phantoms were used.
A series of nanodroplets-laden phantoms was obtained using nanodroplets loaded with different
dye concentrations, in the range of 0.24-15 μM. Each phantom was activated using a stencil with
three circular spots to allow for a good delimitation of activated (or “ON”) vs. non-activated
(“OFF”) areas. To gauge the degree of quenching of loaded DiR, the ratio of fluorescence
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intensity in the activated area was normalized by the fluorescence intensity of the background.
(Fig 4.6).

Figure 4-6 A. Ratio of fluorescence intensity of activated regions of phantoms and background
regions against total loaded DiR concentration; B-D. PAA phantoms containing nanodroplets ( 3
% v/v) with DIR loaded in different concentrations: 0.49 μM (B); 5.66 μM (C); 8.29 μM (D). All
phantoms contained the same volumetric concentration of nanodroplets. The top row are NIR
fluorescence images, while the bottom row contains the white images of the same phantoms.
Figure 4.6 panels B-D show examples of activated phantoms, representing nanodroplets loaded
with a total of 0.49 μM, 5.66 μM, and 8.29 μM DiR respectively. The molar concentration of the
dye is reported to the total volume of nanodroplets obtained after synthesis. All the images have
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the same intensity-map to allow for direct comparison. Our hypothesis for the used range of DiRloaded nanodroplets was that we can find a “lower” limit, where the loaded DiR would be in an
unquenched state, where the activation would not make a large difference on the ON/OFF ratio.
Increasing the DiR encapsulated in nanodroplets was expected to see an increase in the ratio, as
the dye becomes more and more quenched as molecules are closer to one another in the
nanodroplets. This was confirmed in our experiments (Fig 4.6A), and moreover, we observed a
sort of threshold above which the ON/OFF ratio started to decrease again. One explanation for
this the dye concentration is so high that even when the dye molecules get further apart in the
formed microbubbles, they are so numerous that they are still in an aggregation-induced
quenched state.
To determine whether inter-particle quenching effects occur when nanodroplets are in dispersion,
an experiment was setup to image the NIR fluorescence of a batch of a 1.85 μM DiR-loaded
nanodroplets in various dilutions, with no activation (Fig 4.7). In the studied concentration range,
the fluorescence increased linearly with the increase in droplet concentrations. If interparticle
effects would be observed, we would expect the linearity to break as a higher concentration of
nanoparticles would increase the likelihood of interactions and result in a quenched state of DiR
with lower fluorescence. This was not the case either initially after synthesis or after 1.5h of time
in dispersion for the droplets.

Figure 4-7 A. Well-plate showing the fluorescence of 1.85 μM DiR-nanodroplets in various
dilutions :100% with respect to the stock solution down to 5% with respect to the stock solution
after synthesis (“Initial”) and after 1.5h of being incubated in the plate, protected from light
(“1.5h mixed”) ; B. Quantification of fluorescence signal linearity in the studied range of
concentrations of nanodroplets, for samples immediately after synthesis and 1.5h after synthesis.
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Figure 4-8 Activated PAA phantoms containing DIR-loaded nanodroplets (4.46 μM) with
various volumetric concentrations of nanodroplets: : A. 2.0%; B. 2.5% ; C. 3.0%; D. 4.0%; E.
Graph showing the ratio between activated regions and background for phantoms shown in
panels A-D.
To confirm this holds in phantoms, several concentrations of the same droplets were used to
obtain polyacrylamide phantoms as described before. Nanodroplets with a dye loading of 4.66
μM were chosen as they had shown a relatively high signal/background ratio indicating the dye
getting unquenched by nanodroplet vaporization. After activation, phantoms containing 2%,
2.5%, 3.0% and 4.0% nanodroplets in the total phantom volume, were measured using the same
settings as the previous experiments. The results showed that the ratio was similar regardless of
volumetric concentration of nanodroplets in the phantoms (Fig 4.8), with no statistically
significant differences being recorded between the four phantoms. This indicates that the role of
any inter-particle phenomenon is negligible in this case, and only intra-particle dynamics come
into play in the quenching and unquenching of nanodroplet-encapsulated DiR.

4.3.5 Ultrasound imaging
In order to showcase the ultrasound contrast capabilities of DiR-nanodroplets following
activation, a nanodroplets-laden polyacrylamide phantom was activated using a pulsed -laser
through a stencil spelling “FMI”, a nod to our lab’s name- Functional and Molecular Imaging
(Fig 4.9A). After the activation of the nanodroplets within the letters, the fluorescence of the
phantom was imaged (Fig 4.9B), indicating a fluorescence enhancement in the area of activated
nanodroplets when compared to the background of inactivated ones in the same phantom. To
confirm the nanodroplet vaporization resulted in microbubbles, which are highly echogenic and
thus visible with ultrasound, a similar nanodroplets-laden phantom was obtained. A reduced
concentration of nanodroplets was used with respect to the total phantom volume compared to
the fluorescent imaging. The ultrasound images were acquired, and a 2D reconstruction was
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obtained that clearly shows the “FMI” activated area of the phantom (Fig 4.9C). This indicates
the vaporization of nanodroplets with pulsed-laser generates microbubbles that are visible in
ultrasound, as well as provide an enhanced fluorescence signal, demonstrating the use of this
platform for multimodal imaging.

Figure 4-9 A. Schematic of laser activation of a nanodroplets-laden phantom through a stencil
with the letters “FMI”; B. Fluorescence imaging of the activated phantom after ultrasound
imaging. Note that some of the nanodroplets were activated by the ultrasound transducer itself;
C. 2D reconstruction of the ultrasound signal in the FMI activated region of the phantom.

4.3.6 In vivo studies
In order to confirm the DiR-nanodroplets can be used to increase the signal/background ratio of
DIR upon droplet activation in vivo, a subcutaneous injection model was employed. Nude mice
were injected into the hind legs with a volume of 2 x 50 μL of a 5x dilution of DiR-loaded
nanodroplets. Immediately after the injection, images were acquired and used to measure the
fluorescence intensity in the two injection spots in the “OFF” state. Following the imaging, a
NIR pulsed laser was applied onto only one of the spots, and an image recorded at the end of
activation, denoted as the “ON” state. The non-activated spot was used as internal control to
account for changes independent of activation, such as any non-specific interactions between
unencapsulated dye and proteins present at the injection spot. The ratio between the ON/OFF
states was computed for each of the mice and plotted for both the non-activated spot as well as
the activated one. The results showed a significant increase in the signal intensity of activated
spots compared to non-activated one (Fig 4.10 A-D), characterized by a ON/OFF ratio of 1.3 ±
0.12 and 1.07 ± 0.01 respectively (p=0.025). When looking at each individual mouse, results
indicated that the change of signal in the non-activated spot was very similar between the
samples, while the signal change in the case of the activated spot varied by a larger degree. This
might be explained by the difference in size of the injection for each of the mice- for situations
where the bolus spread right after the injection, the activated area ended up constituting a smaller
fraction of the total area. This was in contrast with situations where the bolus remained more
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spatially concentrated, and the laser exposure covered most of the spot during activation. For
non-activated spots this did not play a role, so the change was more uniform.
Due to the rather modest improvement in the signal upon activation, the decision was taken to
improve the performance of nanodroplets in vitro more before further testing in vivo.

Figure 4-10 A-B. Example image of a mouse in the subcutaneous study of the DiR-loaded
nanodroplets before (A) and immediately after (B) pulsed-laser activation. The yellow dashed
line indicates the left spot on the mouse, which gets activated, while the right one serves as
internal control; C. Mouse from panel A with an overlay of ON/OFF ratios for pixels in both the
left and the right spots; D. Average ON/OFF ratio for nanodroplets in both the non-activated
spots, as well as activated ones. The “OFF” here indicates the signal intensity in nodes in the
“Before activation“ images and the “ON” is the signal intensity of the nodes in the “After
activation”. Error bars indicate the standard deviation from 4 mice.

4.3.7 Lipid-protein shelled nanodroplets
As observed in the previous experiments where nanodroplets dispersed in bovine blood had a
considerable increase in their fluorescence (Fig 4.5A). This is due to the interaction of BSA and
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the DiR in the droplets, a non-specific hydrophobic interaction that increases the quantum yield
of the dye. Our experiments showed that this increase is dependent on the amount of protein
present in the sample (Fig 4.11 A). Comparing the same concentration of dye in either BSA (40
ug/mL) or ethanol, the quantum yield in ethanol was larger (Fig 4.11 B-C). Interestingly, this
interaction between BSA and DiR seems to be encouraged by the presence of a strong
hydrophobic agent, like PFP (Fig 4.11 D-E). The obtained DiR-BSA micelles, denoted here
“BSA-DIR no PFP”, were compared to the same batch of micelles getting the PFP liquid added
to them and extra sonication. Although the amount of DiR inside the droplets, measured by
dissolving them in ethanol, showed a decrease from the one in the micelles, as was expected due
to the droplets undergoing additional washing steps. However, in water dispersion, the
nanodroplets well-exceeded the fluorescence intensity of the micelles. These observations were
hopeful for the improvement of the probes fluorescence, for optimizing the amount of
fluorophore needed to get a similar resolution.
Because the difference in the enhancement of the signal of DiR as “loose” dye compared to
encapsulated dye was so large, a hypothesis that the BSA gets inside the lipid shell of
nanodroplets loaded with DiR during washing steps was formed. The alternative, that the
increase in the signal of nanodroplets dispersed in BSA (fig 4.12 A) is due to the interaction of
unencapsulated DiR and BSA outside the droplets seemed highly unlikely given what was seen
when looking at the interactions described above.

Figure 4-11 A. Fluorescence measurements of 3 uM free DiR dispersed in BSA solutions of
three different concentration: 1 mg/mL, 2 mg/mL, 10 mg/mL.; B. Fluorescence of 0.4 ug/mL
117

DiR solution in BSA 40 ug/mL; C. Fluorescence of 0.4 ug/mL DiR solution in ethanol; D.
Comparison of fluorescence of BSA-shelled DiR nanodroplets and BSA-shell liposomes (‘no
PFP”) dispersed in water; E. Comparison of fluorescence of BSA-shelled DiR nanodroplets and
BSA-shell liposomes (‘no PFP”) dissolved in ethanol.
To test out this hypothesis, lipid-nanodroplets containing DiR were synthesized and divided into
three groups, their fluorescence measured by the Pearl: unwashed nanodroplets, nanodroplets
that were washed with DI water 3 times, and nanodroplets that were washed with a BSA
solution, 20 mg/mL, 3 times. Following washing, the resulting nanodroplets in each group were
resuspended and measured in water, and in BSA. The supernatants after each washing step were
also measured. The results indicate that both unwashed and water washed droplets record an
increase in their fluorescence when dispersed in BSA compared to water (Fig 4.12 C-D). By
comparison, nanodroplets that were washed with BSA, where the protein was given time to
attach or infiltrate the lipid shell, show very little difference between the signal in the two
dispersion media. Zeta potential measurements also support the same conclusion, with the charge
of nanodroplets dropping slightly after BSA incubation and washing steps, in line with the
negatively charged BSA incorporating into the shell (Fig 4.12 D).
The droplets containing a hybrid lipid-BSA shell also showed good fluorescence enhancement
properties upon activation (high-intensity focused ultrasound was used here). The ON/OFF ratio
for nanodroplets that were incubated in two different amounts of BSA was investigated (Fig 4.12
F) and compared to their water-incubated lipid-shelled counterparts. The BSA recorded
somewhat of an increase for the ratio for the specific DiR concentration studied, which seemed
to be inversely correlated to the Ethanol/Water ratio as measured with the spectrofluorometer.
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Figure 4-12 A. Fluorescence intensity of DiR-loaded lipid-shelled droplets dispersed in water,
BSA solution (20 mg/mL), PAA solution (30%), ad ethanol; B. Fluorescence intensity of lipid shelled DiR-loaded nanodroplets that were unwashed, washed with DI water, or BSA 20 mg/mL
solution, respectively. The measurements show each sample’s fluorescence intensity measured
for the sample dispersed in water or BSA 20 mg/mL solution; C. Fluorescence of supernatant
from each washing step of the two washed samples, in water or BSA; D. Zeta potential graph
showing the nanodroplets prior and after washing with BSA; E. Fluorescence intensity
measurements in the spectrofluorometer of DiR-loaded lipid-shelled nanodroplets dispersed in
various media: water, HSA, BSA, before and after activation with HIFU; F. ON/OFF ratios and
Ethanol/Water ratios for droplets with BSA-lipid hybrid shells, with various amounts of BSA,
measured in dispersion with the help of Pearl.
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4.3.8 Nanodroplets with DiR inside the core
In an attempt to increase the degree of quenching of nanodroplets for a more pronounced
ON/OFF ratio following activation the option of dispersing DiR inside the core of nanodroplets
was made. The synthesis procedure used the same steps as the process for obtaining doxorubicinloaded nanodroplets. DiR, dissolved in chloroform was added to the aqueous solution with
Krytox™ FSL (Chemours), and left to evaporate the solvent at room temperature. The PFP was
added, and all the mixture sonicated. Although the initial samples used distilled water as the
media for the core, the emulsion was very unstable, and seemed to yield rather small loadings
(Fig 4.13 B). Therefore, a decision to switch to a protein solution instead, was made. The BSA
solution has a two-fold effect: it improves the quantum yield of DiR, as shown before, which
makes the probes brighter, and, due to its amphiphilic nature, provid es extra stability for the core
emulsion. However, as shown before, the intensity of the fluorescence in the non-activated
samples is considerably larger for droplets where BSA was added alongside DiR in the core. A
different protein solution, human serum albumin (HSA), was used in similar samples as a
comparison. The HSA droplets were expected to benefit from a more modest increase in the
quantum yield of the dye, therefore allowing the differentiation of the fluorescence enhancement
from activation better than the BSA counterparts.

Figure 4-13 A. Ratio ON/OFF as measured in nanodroplets suspension after activation for
nanodroplets with different amounts of DiR and BSA or water in their core, respectively; B. The
loading efficiency of DiR in nanodroplets obtained by means of a core emulsion containing a
BSA solution or DI water, respectively.
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The response of droplets with BSA and DiR in the core was shown to depend on the amount of
BSA that gets added to the core emulsion. The best values for the ON/OFF ratio were obtained
for samples where the core had ~3.5 mg BSA added. The water counterparts followed a similar
trend (Fig 4.13 A), indicating than rather than the amount of protein added in itself, the ratio of
the volumes of aqueous phase and DiR was the determining factor. For consistency, in the next
samples, the volume of the aqueous phase was kept constant, and the DiR volume varied to
obtain a range of dye concentrations.

Figure 4-14 A. Ethanol/water ratios for batches of nanodroplets with DiR-protein cores with
BSA, and HSA respectively; B. ON/OFF ratio graph against loaded DiR concentration for
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nanodroplets with BSA or HSA in their core; C. Non-activated spots’ fluorescence intensity in
the tubes with BSA, or HSA and DiR in the core in increasing concentrations; D. Activated
spots’ fluorescence intensity for droplets with either BSA or HSA and DiR in their core; E.
Examples of tubes containing nanodroplets with a core with a BSA and DiR emulsion, activated
(left) vs non-activated (right); F. Examples of tubes containing nanodroplets with a core of HSA
and DiR emulsion, activated (left) vs non-activated (right). All fluorescent images are plotted
with the same intensity scale.
The use of both HSA and BSA as core aqueous phase resulted in a range of DiR-loaded
nanodroplets. However, interestingly, the two proteins seem to be more beneficial at different
dye loadings (Fig 4,14 A-B). HSA containing nanodroplets showed both an increase in their
ethanol/water ratio and well as the ON/OFF ratio at lower concentrations than the BSA
containing ones. The former seemed to benefit from higher dye loadings in both the
measurement methods used. The highest values for the fluorescence enhancement in suspension
of droplets was around 3.5-4 ON/OFF ratio, which is an improvement from the lipid -shell only
nanodroplets. However, the domain for the optimum ratio observed was rather narrow, and
batch-to-batch variability was an issue in obtaining a repeatable and reliable range of
formulations for optimum performance, especially for HSA-containing nanodroplets. One
explanation might be in the fact that in the case of HSA, given its slightly different physicochemical properties from BSA, a different ratio of protein solution: dye solution might have been
the optimum one. However, because this was meant to serve only as a comparison item, the ratio
used for BSA containing nanodroplets was maintained, in an attempt to keep the two samples as
level as possible.
Since quenching is a molecular phenomenon, that depends on the closeness of dye molecules in
the nanodroplets, a short study was designed to evaluate whether there are significant differences
between batches obtained with HSA and BSA, in terms of nanodroplet concentration and/or
particle size. Two different dye volumes were used (80 μL and 120 μL, respectively), while the
protein solution volume was kept constant and contained 20 mg/mL HSA or BSA.
DLS results showed similar mean sizes of nanodroplets for the samples (Fig 4.15A). An
approximate concentration of nanodroplets/μL was computed with the concentration tool in the
Zetasizer software. The concentration of particles/μL varied between samples with HSA and
BSA, with the difference being more pronounced at the lowest concentration of DiR used (Fig
4.15 B). The relations between the ON/OFF ratio and the concentration of nanodroplets was, as
expected, inversely proportional. As the number of particles obtained in the batch increased, the
molecules of DiR are spread across multiple particles, meaning less degree of quenching (Fig
4.15C-D). This might explain some of the irregularities obtained in the previous graph, over a
range of concentrations – using only the DiR concentration in the batch as an indicator ignores
the differences that might be present in the sample nanodroplets’ concentration. Therefore,
correcting the concentration of dye by the concentration of nanodroplets, possibly obtaining a
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dye/particle concentration would be a good future direction to aid in the interpretation of the
results and optimization of activatable constructs.

Figure 4-15 A. Results of DLS measurements of nanodroplets with DiR and either BSA or HSA
in the core; the numbers in the legend correspond to the loading, in μg/mL of DiR as measured
by fluorospectrometry; B. Nanodroplets concentration, approximated by DLS results and
expressed in number of particles/μl; C. Activated spots and non-activated spots in samples with
HSA and BSA counterparts; D. Computed ON/OFF ratios for samples in suspension, activated
by HIFU.

4.3.9 BSA-shelled nanodroplets
In order to study the possibility of improving the nanodroplets’ properties by completely
switching the shell from lipid to protein, BSA-shelled nanodroplets were obtained. These
droplets are designed to take advantage of the strong increase in the quantum yield of DiR in the
presence of BSA, especially since previous results seemed to indicate the presence of the
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perfluoropentane enables that interaction. Secondly, since albumin is transported from tissues via
the lymphatics43 , an albumin-shelled nanodroplet system might be able to take advantage of that
property to localize in the lymph nodes.
The fluorescence of droplets, measured as dispersed in water or dissolved in ethanol, showed an
obvious quenching of the DiR past a particular concentration (Fig 4.16 A-B), as we can see the
ethanol signal increases steadily with the amount of added DiR increasing, while as the signal in
water starts to drop. The studied range of dye concentration was not fine enough to determine a
set threshold for this phenomenon, but according to the results the range of 2.5 -4 μM is where
we expect the quenching effect to take place. Similarly, tube results with BSA-shelled
nanodroplets dispersed in water and activated via HIFU showed fluorescence enhancement upon
activation, but did not seem to align with the Ethanol/Water ratios of samples in the range of dye
concentrations where unquenching can be observed upon activation. The difference between the
thresholds of quenching registered by fluorospectroscopy and wide-field fluorescence
measurement may be related to the angle of measurement of the sample. This was shown before,
in the case of indocyanine green and methylene blue, where the concentration-dependent
quenching behavior of the dyes was different for measurements taken at 90° angle geometry
compare to ones in a 0° angle geometry44 .
Compared to lipid nanodroplets, the BSA-shelled nanodroplets showed ratios of up to values
equal to 6, in suspension (Fig 4.16 E). The localized activation with HIFU, rather than NIR laser,
allows to select the activated nanodroplets giving more accurate measurements (Fig 4.16 C).
These are encouraging results for the performance in vivo of these constructs, especially since
they require lower DiR loadings than their lipid counterparts, which can further help in
decreasing the background from leaching dye from nanodroplets in circulation.

Figure 4-16 A. BSA-shelled nanodroplets batches with various amounts of DiR dye loaded,
measured in suspension in water; B. BSA-shelled nanodroplets dissolved in ethanol and
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measured for DiR signal; C. Example of two batches of BSA-shelled nanodroplets with different
DiR concentrations (measured in the stock solution) activated, or non-activated respectively; D.
Ratio of ethanol/water fluorescence intensity in BSA-shelled droplets; E. Ratio ON/OFF of
BSA-shelled nanodroplets activated in suspension; F. Fluorescence intensity of activated, and
non-activated BSA-shelled nanodroplets with various DiR dye loadings.

4.4 Conclusions
In this study we used a phase-changing perfluoropentane nanodroplet to act as a laser-switchable
NIR fluorescent probe. Loading a sufficient amount of DiR, a lipophilic dye, makes the
nanodroplets encapsulate dye in a quenched state, which decreases their fluorescence. However,
after optically vaporizing the nanodroplets with NIR laser stimuli, microbubbles are formed, with
a size up to 5x larger, which gives the DiR molecules more space and has them partially
unquenched. This leads to an increase in the fluorescence intensity, which we capture here by
NIR fluorescence imaging. The release of the dye from the nanodroplets causes further
unquenching, contributing to the increase of signal overtime. Within this study, we tested the
validity of using this platform to increase the signal/background signal upon activation by
analyzing a range of DiR concentrations and establishing its functionality in a subcutaneous
injection model. Several methods of improving the NIR image at depth were investigated by
leveraging the interaction of DiR and proteins such as BSA and HSA, that increase the dye’s
quantum yield, increasing their fluorescence intensity. We found that switching from a lipid to a
BSA shell reduces the amount of dye needed, while maintaining the sensitivity of the detection,
and the enhancement obtained from activating the nanodroplets can be tuned and reach up to a 6 fold increase in fluorescence intensity.

4.5 References
1.

Kosaka, N., Ogawa, M., Choyke, P. L. & Kobayashi, H. Clinical implications of near-infrared
fluorescence imaging in cancer. Future Oncol 5, 1501–11 (2009).

2.

Lauwerends, L. J. et al. Real-time fluorescence imaging in intraoperative decision making for
cancer surgery. Lancet Oncol 22, e186–e195 (2021).

3.

NAKAMURA, T., KOGASHIWA, Y., NAGAFUJI, H., YAMAUCHI, K. & KOHNO, N.
Validity of Sentinel Lymph Node Biopsy by ICG Fluorescence for Early Head and Neck Cancer.
Anticancer Research 35, (2015).

4.

Frumovitz, M. et al. Near-infrared fluorescence for detection of sentinel lymph nodes in women
with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority
trial. Lancet Oncol 19, 1394–1403 (2018).

125

5.

Pirovano, G., Roberts, S., Kossatz, S. & Reiner, T. Optical Imaging Modalities: Principles and
Applications in Preclinical Research and Clinical Settings. Journal of Nuclear Medicine 61,
1419–1427 (2020).

6.

Chen, C., Tian, R., Zeng, Y., Chu, C. & Liu, G. Activatable Fluorescence Probes for “Turn-On”
and Ratiometric Biosensing and Bioimaging: From NIR-I to NIR-II. Bioconjugate Chemistry 31,
276–292 (2020).

7.

Li, C., Chen, G., Zhang, Y., Wu, F. & Wang, Q. Advanced Fluorescence Imaging Technology in
the Near-Infrared-II Window for Biomedical Applications. J Am Chem Soc 142, 14789–14804
(2020).

8.

Kosaka, N., Ogawa, M., Choyke, P. L. & Kobayashi, H. Clinical implications of near-infrared
fluorescence imaging in cancer. http://dx.doi.org/10.2217/fon.09.109 5, 1501–1511 (2009).

9.

Miao, Y. et al. Recent Progress in Fluorescence Imaging of the Near-Infrared II Window.
ChemBioChem 19, 2522–2541 (2018).

10.

Deng, G. et al. Near-infrared fluorescence imaging in the largely unexplored window of 9001,000 nm. Theranostics 8, 4116–4128 (2018).

11.

Chen, C., Tian, R., Zeng, Y., Chu, C. & Liu, G. Activatable Fluorescence Probes for “Turn-On”
and Ratiometric Biosensing and Bioimaging: From NIR-I to NIR-II. Bioconjugate Chemistry 31,
276–292 (2020).

12.

Yu, S. et al. New generation ICG-based contrast agents for ultrasound-switchable fluorescence
imaging. Scientific Reports 2016 6:1 6, 1–10 (2016).

13.

Cheng, B. et al. High-Resolution Ultrasound-Switchable Fluorescence Imaging in CentimeterDeep Tissue Phantoms with High Signal-To-Noise Ratio and High Sensitivity via Novel
Contrast Agents. PLOS ONE 11, e0165963 (2016).

14.

Yu, S., Wang, Z., Yao, T. & Yuan, B. Near-infrared temperature-switchable fluorescence
nanoparticles. Quantitative Imaging in Medicine and Surgery 11, 1010–1022 (2021).

15.

He, X., Wang, K. & Cheng, Z. In vivo near-infrared fluorescence imaging of cancer with
nanoparticle-based probes. Wiley Interdisciplinary Reviews: Nanomedicine and
Nanobiotechnology 2, 349–366 (2010).

16.

Altınoğlu, E. İ. & Adair, J. H. Near infrared imaging with nanoparticles. WIREs Nanomedicine
and Nanobiotechnology 2, 461–477 (2010).

17.

Reisch, A. & Klymchenko, A. S. Fluorescent Polymer Nanoparticles Based on Dyes: Seeking
Brighter Tools for Bioimaging. Small 12, 1968–92 (2016).

18.

Qi, J. et al. Towards more accurate bioimaging of drug nanocarriers: turning aggregation-caused
quenching into a useful tool. Advanced Drug Delivery Reviews 143, 206–225 (2019).

126

19.

Mizusawa, K. et al. Disassembly-Driven Turn-On Fluorescent Nanoprobes for Selective Protein
Detection. J Am Chem Soc 132, 7291–7293 (2010).

20.

Cheng, B. et al. The Mechanisms and Biomedical Applications of an NIR BODIPY-Based
Switchable Fluorescent Probe. International Journal of Molecular Sciences 18, 384 (2017).

21.

Park, H. S., Cho, M. Y., Noh, Y.-W., Hong, K. S. & Lim, Y. T. Contrast agents based on
switchable near-infrared fluorescent nanoprobes for highly sensitive optical imaging. Dyes and
Pigments 136, 583–589 (2017).

22.

Liu, J. et al. pH-Switchable Fluorescent Probe for Spatially-Confined Visualization of
Intracellular Hydrogen Peroxide. Analytical Chemistry 88, 5865–5870 (2016).

23.

Xu, Y. et al. Switchable and selective detection of Zn 2+ or Cd 2+ in living cells based on 3′-Osubstituted arrangement of benzoxazole-derived fluorescent probes. Chem. Commun. 50, 7514–
7516 (2014).

24.

Furukawa, H., Misu, M., Ando, K. & Kawaguchi, H. Light-Controlled On-Off Switch of a
Fluorescent Nanoparticle. Macromolecular Rapid Communications 29, 547–551 (2008).

25.

Cheng, B. et al. Development of ultrasound-switchable fluorescence imaging contrast agents
based on thermosensitive polymers and nanoparticles. IEEE Journal on Selected Topics in
Quantum Electronics 20, (2014).

26.

Cheng, B. et al. The Mechanisms and Biomedical Applications of an NIR BODIPY-Based
Switchable Fluorescent Probe. International Journal of Molecular Sciences 2017, Vol. 18, Page
384 18, 384 (2017).

27.

Li, C. & Liu, S. Polymeric assemblies and nanoparticles with stimuli-responsive fluorescence
emission characteristics. Chemical Communications 48, 3262–3278 (2012).

28.

Benchimol, M. J. et al. Phospholipid/carbocyanine dye-shelled microbubbles as ultrasoundmodulated fluorescent contrast agents. Soft Matter 9, 2384 (2013).

29.

Pei, Y. et al. High resolution imaging beyond the acoustic diffraction limit in deep tissue via
ultrasound-switchable NIR fluorescence. Sci Rep 4, 4690 (2014).

30.

Liu, Y., Feshitan, J. A., Wei, M.-Y., Borden, M. A. & Yuan, B. Ultrasound-modulated
fluorescence based on fluorescent microbubbles. J Biomed Opt 19, 085005 (2014).

31.

Zhang, Q., Morgan, S. P. & Mather, M. L. Nanoscale Ultrasound -Switchable FRET-Based
Liposomes for Near-Infrared Fluorescence Imaging in Optically Turbid Media. Small 13,
1602895 (2017).

32.

Liu, R. et al. Temperature-sensitive polymeric nanogels encapsulating with β-cyclodextrin and
ICG complex for high-resolution deep-tissue ultrasound-switchable fluorescence imaging. Nano
Research 2020 13:4 13, 1100–1110 (2020).

127

33.

Kooiman, K. et al. Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery.
Ultrasound in Medicine & Biology 46, 1296–1325 (2020).

34.

Yuan, B., Uchiyama, S., Liu, Y., Nguyen, K. T. & Alexandrakis, G. High-resolution imaging in
a deep turbid medium based on an ultrasound-switchable fluorescence technique. Appl Phys Lett
101, 33703 (2012).

35.

Hannah, A. S., Luke, G. P. & Emelianov, S. Y. Blinking Phase-Change Nanocapsules Enable
Background-Free Ultrasound Imaging. Theranostics 6, 1866–76 (2016).

36.

Sheeran, P. S., Luois, S., Dayton, P. A. & Matsunaga, T. O. Formulation and Acoustic Studies of
a New Phase-Shift Agent for Diagnostic and Therapeutic Ultrasound. Langmuir 27, 10412–
10420 (2011).

37.

Lea-Banks, H., O’Reilly, M. A. & Hynynen, K. Ultrasound-responsive droplets for therapy: A
review. J Control Release 293, 144–154 (2019).

38.

Zhang, Z. et al. Light-Activatable Theranostic Agents for Image-Monitored Controlled Drug
Delivery. ACS Applied Materials & Interfaces 10, 1534–1543 (2018).

39.

Hallam, K. A. & Emelianov, S. Y. Toward optimization of blood brain barrier opening induced
by laser-activated perfluorocarbon nanodroplets. Biomedical Optics Express 10, 3139 (2019).

40.

Zell, K., Sperl, J. I., Vogel, M. W., Niessner, R. & Haisch, C. Acoustical properties of selected
tissue phantom materials for ultrasound imaging. Physics in Medicine & Biology 52, N475
(2007).

41.

Chang, N. et al. Efficient and controllable thermal ablation induced by short-pulsed HIFU
sequence assisted with perfluorohexane nanodroplets. Ultrasonics Sonochemistry 45, 57–64
(2018).

42.

Xu, L. et al. Folic acid-modified fluorescent dye-protein nanoparticles for the targeted tumor cell
imaging. Talanta 194, 643–648 (2019).

43.

Abdallah, M. et al. Lymphatic targeting by albumin-hitchhiking: Applications and optimisation.
J Control Release 327, 117–128 (2020).

44.

Gioux, S., Choi, H. S. & Frangioni, J. v. Image-Guided Surgery Using Invisible Near-Infrared
Light: Fundamentals of Clinical Translation: http://dx.doi.org/10.2310/7290.2010.00034 9, 237–
255 (2010).

128

Chapter 5 : Nanodroplets formulations for longerterm storage
This chapter discusses the options for additives to allow the frozen storage of loaded
nanodroplets. Different formulations are investigated, as well as two freezing methods, to
investigate the feasibility of storing nanodroplets long-term.

5.1 Introduction
Longer term stability of nanodroplets is an important metric to judge the feasibility of translating
the technology into the clinic. Since nanodroplets are still an emergent type of nanoparticle, not a
lot of literature exists exploring the stability and methods to enable the properties of nanodroplets
are maintained, especially for drug-loaded constructs. Our own stability studies, showcased in
Chapter 2 for nanodroplets kept at 4 °C showed that some size effects take place, and the
emulsion starts to show phases of destabilization as early as a couple hours past synthesis.
However, in order to be able to use them clinically, nanodroplets have to be formulated such that
long-term storage can ensure maintaining of their properties and safe of use.
The closest benchmark for nanoparticles and pharmacological formulations for storage are
liposomes, which are employed in the clinic in a few instances, but still suffer from physical or
chemical instabilities1 . Factors such as hydrolysis or oxidation of phospholipid molecules
resulting in leakage of payload and changes in size have been described 2,3 , which might be
applicable for our lipid-shell nanodroplets as well for long-term stability. A common approach
with liposomes is to produce a dry liposomal product by freeze-drying. However, this might not
be a workable method for nanodroplets, since the drying would imply the loss of the
perflurocarbon core, and the need to readd it after rehydration would probably impact the
structure of the nanodroplets. Moreover, the method suffers from issues even for liposomes, due
to the loss of encapsulated drug in the process, and the potential for physico-chemical changes of
the lipid membranes during the process4,5 .
A secondary method of storage for such nanoparticles, to try and avoid the aforementioned
problems, and that could apply to our system is freezing. However, this method can also impact
the function of nanoparticles: mechanical stress from ice crystal formation during freezing can
damage the lipid membrane1 , the possibility of osmotic stress from increased solute
concentrations in the remaining unfrozen matrix surrounding the droplets 6 . Moreover, during
freezing, the lipid layer might become transiently leaky, due to the co-existence of gel and liquid
crystal phases for some of the component lipids, as they have different transition temperatures 7,8 .
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A way to avoid or delay the degradation of nanodroplets during freezing and storage is the use of
cryoprotectants, additives that are noneutectic, hence they do not crystalize when cooling 6 . The
mechanisms of function of these agents are not completely understood, but it is believed that
they contribute to protecting lipid-layered nanoparticles by interacting with the headgroups of
phospholipids to counteract fusion or membrane disruptions or by increasing the viscosity of the
solution which reduces the crystallization rate 2,6 . Some cryoprotective agents, called
“permeating agents”, can move across the membrane of liposomes and provide protection to the
core of liposomes/nanoparticles. They are also thought to act in a variety of ways including
stabilizing biomolecules, minimizing osmotic stress and limiting the damage from ice formation
by forming a glassy state in which the material is embedded 9 . Cryoprotectants that were studied
for liposome stability while freezing include dimethyl sulfoxide, glycerol, quaternary amines and
carbohydrates like sucrose, trehalose or lactose1,5 .
In this chapter, several excipients for nanodroplets are studied to determine a formulation
optimization for storage of loaded nanodroplets, by using particles with fluorophores as model
drugs, and following the size and dye leakage of nanodroplets frozen in the presence of several
cryoprotectants: mannitol, glycerol or D-glucose.

5.2 Methods
5.2.1 Synthesis nanodroplets
The dye loaded nanodroplets were synthesized by a double emulsion method. The first
emulsion was synthesized by a thin-layer hydration-sonication method. Typically, a mixture of
dipalmitoylphosphatidylcholine (DPPC, NOF America), 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP, NOF America) and cholesterol (Alfa Aesar) was added to 3 mL chloroform
and evaporated under vacuum (250 mbar) with a rotary evaporator (Heidolph HEI -Vap) at 38.5
°C. After the mixture evaporated and formed a thin film, 3 mL of 2:3 v/v water: Dulbecco’s
phosphate-buffered saline (Corning) were used for rehydration, and the mixture was subjected to
a sonicating bath for 5 minutes at room temperature. Next, the mixture was dispersed with a
sonication probe (QSonica, Q700, 1/8 inch microtip) for 30 s, continuous sonication at 27 W/cm2
in an ice-bath to prevent the sample from over-heating. For varying the charge of these droplets,
the ratio between the component lipids was varied, whilst keeping all the other parameters of the
synthesis identical. The recipes for the tested formulations are shown in table 5.1.
The second emulsion was constituted by aqueous Rhodamine B solution (Advanced
ChemBlocks) in perfluoropentane (PFP, Fluoromed). The Rhodamine solution (0.15 mL, 7.0
mg/mL) was added to a mixture of PFP (1.5 mL) and emulsifier (Krytox™ FSL, Chemours 30
µL), and sonicated with the ultrasonic probe under the same conditions described before.
Different formulations were tested before settling for these specific ratios between the drug
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solution, PFP and emulsifier. A volume of 200 µL of this emulsion was added to the lipid
mixture and sonicated for an additional 30 s with the same settings.
The nanodroplet mixture was centrifuged (Eppendorf MiniSpin) at 43 rcf for 45s, to remove
large aggregates and unencapsulated components, such as Epolight, that settle out of the
dispersion due to poor solubility in water. This was followed by collecting of the supernatant and
two more steps of centrifugation at 2100 rcf for 60s each. For each of these steps, the supernatant
was discarded and replaced with distilled water, to remove micelles or unincorporated
components.
For nanodroplets with
the payload
in the shell, 1,1′-dioctadecyl-3,3,3′,3′tetramethylindotricarbocyanine iodide (DiR, Biotium) dye was used. DiR-loaded nanodroplets
were synthesized by a similar method, slightly modified. Due to its hydrophobic nature, 40 µL of
a 1 mg/mL solution of DiR in chloroform was added to the lipid mixture. The core did not have
any emulsion, rather consisting only of perfluorocarbon (200 µL, Fluoromed). The rest of the
synthesis details were identical between the two samples.

5.2.2 Nanodroplets samples for stability study
In order to evaluate the stability over time of nanodroplets stored in cold conditions DiR-loaded
nanodroplets and Rhodamine B-loaded nanodroplets were used as a model for loading of
compounds in the shell or core, respectively. Various cryoprotectants were used and their
performance compared: glycerol (Sigma Aldrich), mannitol (Fisher Scientific), D-glucose
(Sigma Aldrich). The nanodroplets were stored at -20 °C in a 10x dilution, aliquoting samples
for each of the cryoprotectants for 3 different timepoints. All the samples used in the studies
presented in this chapter are described in Table 5.1
Table 5-1 Sample formulations loaded nanodroplets kept stored.

Sample name

Droplets loading

Molar
ratio
cryoprotectant

No cryoprotectant

DiR

-

Day 0, 1, 5, 15

Glycerol

DiR

2.5 % v/v

Day 0, 5, 11

Mannitol

DiR

1:6

Day 0, 5, 11

D-Glucose

DiR

1:20

Day 0, 5, 11

No cryoprotectant

Rhodamine

-

Day 0, 5, 11
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lipids: Timepoints for
measurements

Glycerol

Rhodamine

2.5 % v/v

Day 0, 1, 5, 15

Mannitol

Rhodamine

1:6

Day 0, 1, 5, 15

D-Glucose

Rhodamine

1:20

Day 0, 1, 5, 15

No cryoprotectant

Rhodamine

-

Day 0, 11

D-glucose

Rhodamine

1:10

Day 0, 11

1:0 D-Glucose

Rhodamine

-

Day 0, 5,11,18

1:1 D-Glucose

Rhodamine

1:1

Day 0, 5,11,18

1:4 D-Glucose

Rhodamine

1:4

Day 0, 5,11,18

1:6 D-Glucose

Rhodamine

1:6

Day 0, 5,11,18

1:10 D-Glucose

Rhodamine

1:10

Day 0, 5,11,18

1:20 D-Glucose

Rhodamine

1:20

Day 0, 5,11,18

5.2.3 Size and derived count rate
Average nanodroplet diameter and size distribution were determined by a Malvern Zetasizer
Dynamic Light Scattering (DLS) instrument after 100x dilution to ensure the concentration was
low enough for single-scattering events. All samples were subjected to 3 measurements each,
with an automatic number of runs per measurement, as determined by the instrument. Size is
reported as the d-average, together with the standard deviation of the 3 measurements. The
derived count rate, which is the corrected count rate DLS provides for each sample was used as a
measure of sample concentration, ensuring that all samples were prepared with the same
dilutions throughout the studies in order to be able to compare them. The derived count rate is
reported as the average of three measurements together with the standard deviation.

5.2.4 Encapsulated and non-encapsulated compounds measurement
For fluorescence measurements, a Horiba FluoroMax spectrofluorometer was used, with an
excitation wavelength of 748 nm and emission at 780 nm (DiR), and excitation wavelength of
550 nm with 575nm emission (Rhodamine B), respectively. To determine the concentration of
dye in the samples, the measurements were compared against calibration curves for the
respective dyes.
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The percentage of unencapsulated Rhodamine, and DiR, respectively was computed by
centrifuging the nanodroplets’ samples at 2000 rcf for 60s, and separating the supernatant and
the pellet. Both were measured in the same solvent – a mixture of water-ethanol- to allow any
droplets to dissolve, and the unencapsulated % of dye was computed by:
% 𝑢𝑛𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑦𝑒 =

𝑚 𝑑𝑦𝑒𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎 𝑛𝑡
𝑚 𝑑𝑦𝑒𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡 +𝑚 𝑑𝑦𝑒𝑝𝑒𝑙𝑙𝑒𝑡

(3)

5.2.5 Freezing method and thawing
The sample freezing was achieved by either placing the samples in a -20 °C freezer or by dipping
the samples in liquid nitrogen for 20 s, followed by placing them in the freezer at -20 °C for
storage. All samples were placed in 15 mL polypropylene centrifuge vials with caps, at a volume
of 3 mL for each sample.
This latter method is referred to in this chapter as “flash freezing”. The effects of the freezing
method on the droplets’ stability in storage is explored.

5.2.6 Ultrasound measurement
To study the activation of nanodroplets after storage, Nanodroplet-laden polyacrylamide gel
phantoms were obtained with a similar method as described before 10 , with some slight
modifications. Briefly, two mixtures of acrylamide:bisacrylamide (29:1, Sigma Aldrich) and
~1% v/v nanodroplets suspension were obtained from each of the droplets types. N,N,N′,N′ tetramethylethylendiamine (TEMED, Thermofisher) and ammonium peroxydisulfate (APS,
Sigma Aldrich) were used as initiation system for the polymerization of both gels. Images were
acquired with a single-element high-frequency (40 MHz) ultrasound transducer (Visualsonics
Vevo 770) right after activation with a single-element high-intensity ultrasound (HIFU, 1.1
MHz, 5 pulses of 10 cycles each, at 5.7 MPa peak focal pressure) transducer, coupled with a
polyacrylamide cone.

5.3 Results
5.3.1 DiR-loaded nanodroplets
The work herein set out to study the stability of nanodroplets, frozen, in the presence of several
cryoprotectants: glycerol (2.5% v/v), mannitol (1:6 molar ratio of lipids: carbohydrate), dglucose (1:20 molar ratio of lipids: carbohydrate) and compared to nanodroplets with no
cryoprotectants. For all samples, the nanodroplets’ size as shown in the main peak (Fig 5.1 A-D)
seemed to decrease slightly as storage time went on. This is probably due to the destruction of
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some of the nanodroplets, process that might select for smaller nanodroplets as the larger ones,
or ones that have fused with one another, will have a thinner membrane and be easier to
spontaneously vaporize during thawing. The reduction in the derived count rate of the samples is
in line with this explanation, with the numbers decreasing, indicating a loss of nanodroplets,
especially in the sample with no cryoprotection, but also for the mannitol sample (Fig 5.1 E).
The leakage of the drug, which in this case was DiR dye encased in the shell of nanodroplets,
was also measured and supported the observations from the DLS measurements: glycerol and d glucose samples had the lowest amount of dye leakage, while the mannitol and no cryoprotectant
samples failed to contain most of the loaded DiR inside the nanodroplets.

Figure 5-1 A. DLS measurement results of DiR-containing nanodroplets frozen and kept at 20°C with no cryoprotectant for 15 days total; B. DLS measurement results of DiR-containing
nanodroplets frozen and kept at -20°C with 2.5% v/v glycerol for 15 days total; C. DLS
measurement results of DiR-containing nanodroplets frozen and kept at -20°C with mannitol for
15 days total; D. DLS measurement results of DiR-containing nanodroplets frozen and kept at 20°C with d-glucose for 15 days total; E. Derived count rate of DiR-nanodroplets stored in the
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presence of various cryoprotectant agents; F. Fluorescence intensity of released DiR from
samples of DiR-containing nanodroplets stored at -20°C with various cryoprotectants.

5.3.2 Rhodamine-loaded nanodroplets
In order to get insight into the stability of nanodroplets with a payload in the core, rhodamine
B was used as a stand in for the payload due to ease of measurement. The same cryoprotectants
were used as for DiR-loaded nanodroplets. DLS results for these nanodroplets were similar to the
ones observed in the case of DiR-nanodroplets (Fig 5.2 A), with the mean size of nanodroplets
slightly decreasing for all samples, probably due to phenomena like fusing or breaking apart
during freezing and thawing. Looking at the derived count rate of the samples and their
evolution, the cryoprotectants that performed best were glycerol and d -glucose in this case as
well (Fig 5.2 B), however, a small drop in the derived count rate of the samples was recorded
between day 5 and day 11 measurements. The percentage of rhodamine that was released from
nanodroplets from loss of structure was in line with the DLS results, as well as the other
nanodroplets samples, with the glycerol and d -glucose formulated samples showing the lowest
percentage of excess rhodamine released after storage.

Figure 5-2 A. DLS results from Rhodamine B-loaded nanodroplets samples frozen and stored
at -20°C in the presence of various cryoprotectants for 11 days; B. Derived count rate of
nanodroplets samples frozen and stored at -20°C in the presence of various cryoprotectants for
11 days; C. Percentage of Rhodamine B released from the nanodroplets’ samples that were
stored at -20°C in the presence of various cryoprotectants.

5.3.3 Flash-freezing method
All previous samples were frozen by placing them into the freezer at -20°C. However, this
relatively slow rate of cooling allows for water to crystallize, which might lead to damage of the
lipid shell of nanodroplets. Therefore, a small study investigating whether flash-freezing, by
liquid nitrogen dipping, would be feasible for these samples was conducted. The DLS results for
flash-frozen samples were in line with the ones normally frozen in terms of size of nanodroplets
(Fig 5.3 A), however where the freezing method seemed to play the biggest part was in the
derived count rate measurement, with flash-frozen samples outperforming the ones that were
allowed to freeze slowly (Fig 5.9 B). This was also reflected in the amount of Rhodamine that
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was measured outside of the nanodroplets, after thawing, indicating that even without the use of
a cryoprotectant, the freezing procedure made a distinct difference on the longer-term stability of
nanodroplets.

Figure 5-3 A. DLS results of nanodroplets samples frozen either by placing them in the -20°C
freezer, or flash-frozen by dipping into liquid nitrogen, either with no cryoprotectant or d glucose, after 11 days of storage at -20°C; B. Derived count rates comparison of the two samples
frozen by placing them in the freezer at -20°C or liquid nitrogen dipping; C. The percentage of
Rhodamine B released out of the samples stored at -20°C from the two different freezing
methods.

5.3.4 D-glucose concentration series
Therefore, the next experiments were conducted using the flash freezing technique, and due to its
performance in the studies highlighted above, d -glucose was chosen as a cryoprotectant, and a
series of concentrations was studied to determine whether there is an optimum molar ratio
between the cryoprotectant and the lipids in the nanodroplets. Size measurements of the samples
were similar among the samples studied here, with no distinct trend observed when increasing
the amount of d-glucose used (Fig 5.4 A). All nanodroplets’ samples showed higher
polydispersity than the sample measured after synthesis, indicating destabilization of the samples
to an extent. The same effect can be observed in the measurement of derived count rates of the
nanodroplets’ samples (Fig 5.4 B), where the sample with a 1:6 ratio seemed to outperform the
other ratios at all three timepoints. Rhodamine release experiments show percentages up to
almost 25% of the rhodamine released in the supernatant of the samples, with the both the 1:1
and 1:6 ratios, being the samples that showed the lowest percentage of unencapsulated
rhodamine along the duration of the study.
The ultrasound contrast of nanodroplets of the 1:10 sample was also investigated straight after
synthesis and after flash-freezing the droplets and storing them at -20°C for 5 days and thawing
them at room temperature in the same manner as samples described above. These experiments
revealed that nanodroplets have excellent contrast after HIFU activation in tissue-mimicking
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phantoms , either on their own or in the presence of d -glucose (Fig 5.4 D-E). The same was true
after the freezing and storage of nanodroplets for 5 days, and nanodroplets either with no
additive or in the presence of d-glucose in a 1:10 molar ratio were easily activatable and
provided ultrasound contrast. The slight increase in the background ultrasound magnitude (Fig
5.4 F-G) is an indication of a fraction of nanodroplets that were destabilized, and was similar
between the two samples studied here.

Figure 5-4 A. Average size evolution of nanodroplets’ samples frozen and stored at -20°C in
the presence of d-glucose in various lipid:d-glucose ratios; B. Derived count rates of
nanodroplets’ samples frozen and stored at -20°C in the presence of d-glucose in various lipid:dglucose ratios; C. Percentage of unencapsulated rhodamine in samples of nanodroplets’ stored
with d-glucose in various amounts; D. B-mode frame of HIFU-activated spot in a phantom laden
with nanodroplets and no additive after synthesis; E. B-mode frame of HIFU-activated spot in a
phantom laden with nanodroplets dispersed in a d-glucose solution (1:10 lipid to d-glucose molar
ratio) after synthesis F. B-mode frame of HIFU-activated spot in a phantom laden with
nanodroplets and no additive after being frozen and stored at -20°C for 5 days; G. B-mode
frame of HIFU-activated spot in a phantom laden with nanodroplets dispersed in a d -glucose
solution (1:10 ratio) after being frozen and stored at -20°C for 5 days.

5.4 Conclusions
This is the first study to investigate the longer-term stability of loaded nanodroplets. Taking
inspiration from liposome counterparts, several excipients were studied for their capabilities of
maintaining droplets structure intact upon freezing and thawing. The most difference was found
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to be made by flash-freezing the nanodroplets. However, the study did not look at controlling the
thawing rate of samples, which might also impact the maintaining of functionality. This could be
an interesting avenue to explore.
The best excipient was found to be d-glucose, in a molar ratio of 1:6 to 1:10 with respect to the
total lipids in the sample, coupled with a flash-freezing technique. Future steps could include the
study of the nanodroplets stability in vitro and in vivo after thawing, and whether the drugloaded nanodroplets maintain their biologically activity, especially in terms of particle-cell
interactions.
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Chapter 6 : Conclusions and Future Directions
This chapter briefly presents the motivation of the thesis, and its main conclusions and
contributions. Some limitations are also highlighted, together with future directions for the work
that would be needed towards the translation of the technologies presented in this thesis.

6.1 Motivation
Nanotheranostic particles, that can achieve simultaneous enhanced drug distribution at the tumor
site, as well as imaging of the treatment response monitoring, are well sought after in the field of
personalized cancer therapy. However, at present, a considerable proportion of nanotheranostics
are limited to imaging the drug distribution, or provide one-timepoint information, without the
ability for real-time monitoring of the drug being released 1,2 . Methods for controlling the release
of drugs and contrast agent, under one of several types of stimuli are needed to achieve more
precise treatment options. Additionally, single-agent therapies, either chemotherapy or immune
checkpoint inhibitors, suffer from the development of drug-resistance, dose-limiting toxicity and
heterogeneity in the tumor that can lead to genetic drifts contributing to tumor initiation and
resistance to therapy3 . Therefore, nanotheranostic systems that allow the use of two or more
therapeutic agents need to be developed to reflect the reality of treatments used in the clinic.
The overarching goal of this thesis was to design, synthesize and characterize a perflurocarbon
nanodroplet platform that can serve as an on-demand image-guided nanotheranostic solution for
combination therapies. Ultrasound was the imaging method of choice due to its good resolution,
spatial and temporal, as well as the possibility of safe continuous imaging. The capabilities of
simultaneously delivering small molecular compounds with different physico-chemical
properties, and large molecules, while providing ultrasound contrast upon activation of the
platform were investigated. The work contained herein included bench-top design, extensive in
vitro characterization as well as in vivo testing, and formulation studies looking towards enabling
the translatability of the platform into a clinically useful design.
Specifically, Chapter 2 discussed the design components and choices for perfluropentane
nanodroplets synthesized by a double-emulsion method to contain both hydrophilic and
hydrophobic chemotherapeutics, and tested their applicability to a triple negative breast cancer
mouse model. Chapter 3 explored the expansion of this platform to enable the inclusion of
immune checkpoint inhibitors- namely an anti-PD-L1 (atezolizumab biosimilar) antibody was
used- and the possibility of co-delivery of chemotherapeutics like paclitaxel and monoclonal
antibodies for synergistic combination therapies. Chapter 4 focused on expanding the imaging
capabilities of the platform beyond ultrasound, showcasing the applicability of perfluorocarbon
nanodroplets at switchable fluorescent probes to improve the signal-to-noise ratio in cancer
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applications. Finally, Chapter 5 investigated an array of formulations to allow for storage of
droplets which is crucial for their translational potential.
Overall, the nanodroplets platform presented here has shown a good potential for applications in
image-guided therapeutics of solid tumors, whether that entails single or combination therapies,
as well as multimodal imaging capabilities with applications in non-invasive diagnosis and tumor
treatment and progression monitoring.

6.2 Summary and contributions to the field
6.2.1 Dual-drug nanodroplets synthesis and characterization
DDDs were synthesized by a double emulsion method, assembling a water-in-oil core emulsion
with perfluoropentane as continuous phase and doxorubicin aqueous solution as dispersed phase,
with pre-formed liposomes containing paclitaxel and NIR absorbers for activation. This method
is versatile and allows a wide range of therapeutics to be encapsulated in nanodroplets,
regardless of their hydrophilicity or hydrophobicity. This is the first-time lipid-shelled,
perfluoropentane nanodroplets simultaneously loaded with multiple chemotherapeutics were
described and characterized.
The droplets obtained were able to be sized by methods commonly employed for liposomes,
which is encouraging for their ease of fabrication and processing at scale of narrowly distributed
nanodroplets. The activation with NIR pulses laser was reliable, and shown with various
commercially available optical absorbers, including ICG, an FDA-approved agent.
6.2.2 Ultrasound contrast enhancement
DDDs and their contrast enhancement capabilities upon activation with pulsed NIR laser or highintensity ultrasound were studied in tissue mimicking phantoms. After activation, nanodroplets’
showed excellent contrast in ultrasound, accounting for a 10x increase in the signal magnitude in
the ultrasound frames. A processing method reliant on a differential signal mapping w as
developed and used to identify a range of concentrations for DDDs where the magnitude of said
differential signal was linearly dependent on the concentration of droplets. This is an initial step
towards being able to use ultrasound quantitatively to determine the amount of drugs being
released upon activation.
In vivo, a modified version of the method was used to map the differential signal in the HIFU activated tumors, although the lower resolution of the method showed some difficulty in
positively identifying the tumor during the setup of the imaging. Further optimization of the
imaging setup may yield results that are more quantitative and could allow for a better
understanding of the events after iv injection.
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6.2.3 In vitro and in vivo effects of DDDs
The activity of DDDs on cell viability was studied in vitro, on various cancer cell lines (FaDu,
MCF7, MDA-MB231), showing an enhancement of toxicity due to intracellular activation. This
work also introduced a study for the timing of activation and investigated the mechanism of the
nanodroplets-cell interactions, which was underdefined in literature so far. Moreover, a study
concluding the lack of an impact of mechanical effects from single-pulse optical droplets
vaporization on cell permeation was performed. Previously, only acoustic droplets vaporization
followed by ultrasound-induced cavitation was investigated in this context, while the
contribution of the activation itself remained unclear.
Compared to previous examples in literature, DDDs were able to encapsulate two drugs at the
same time, both in therapeutic amounts, which was reflected in both in vitro and in vivo studies.
In vivo, a preliminary mouse study evaluated the tumor accumulation, comparing differences
between activated and non-activated tumors. The percentage of nanodroplets getting to the
tumors was found to be rather modest (~6% cumulative between the two tumors). The effects of
DDDs on the tumor growth rate were studied in a single-dose regimen, where one of the tumors
on each mouse was activated, whereas the other one was kept as internal control. To assess the
effects that the activation itself might have on the tumor growth rate (from HIFU activation and
any mechanical effects of ADV), a group of mice receiving non-loaded nanodroplets was used as
a control in the study. A new bespoke imaging setup was created, integrating a 2D matrix array
imaging transducer, co-axially aligned with an annular HIFU transducer, for simultaneous
activation and acquisition of ultrasound frames.
While tumors kept growing for the duration of the study for the mice in both groups, the mice
receiving DDDs showed a delay in the growth in the case of activated tumors compared to nonactivated counterparts. No such effect was observed in the case of the empty nanodroplets group.
In order to increase the effect that DDDs can have beyond the delay, future efforts to improve the
nanodroplets’ extravasation have to be undertaken, with some examples of how that could look
like being described in Section 6.3.
While images acquired during activation show some differences in the ultrasound signal before
and after HIFU pulses, the reduced resolution did not allow for confident identification of the
tumor area in order to allow us to quantify the differential signal. Better processing techniques,
or modifications of the current setup, could aid in increasing the usefulness of this type of
acquired data.
6.2.4 Nanodroplets for combination immunotherapy and chemotherapy
PFP nanodroplets encapsulating anti-PD-L1 antibodies were synthesized by two different
methods: tuning the composition of nanodroplets’ shell to allow for electrostatic binding of the
large molecules (obtaining nanodroplets denoted eITDs), or physically entrapping the antibodies
in the core of a double emulsion (obtaining nanodroplets denoted ITDs). Compared to other
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constructs that contain different antibodies, these nanodroplets did not use the antibodies as
targeting agents, but rather as therapeutics, and did not aim to conjugate them to the surface, but
physically entrap them to allow for on-demand delivery. The nanodroplets obtained in these
manners were characterized in terms of size and activity in binding PD-L1, either expressed on
the surface of cells, or in a PD-1/PD-L1 interaction assay. Both types of droplets were found to
be capable of inhibiting the PD-1/PD-L1 pathway, with a tradeoff seemingly emerging: eITDs
had a higher amount of mAbs, hence a stronger activity, but ITDs were more stable, and the
release of mAbs could be better controlled by activation of nanodroplets.
Finally, nanodroplets containing paclitaxel in the shell and anti-PD-L1 antibodies in the core
were synthesized and their effects in vitro evaluated. Although encapsulation of a-PD-L1
antibodies and various active pharmaceutical ingredients (APIs) has been shown in preclinical
studies with liposomes, to our knowledge, this is the first perfluorocarbon-core nanodroplet
construct to co-encapsulate a chemotherapeutic (paclitaxel) and an antibody.

6.2.5 Switchable NIR probes
Several designs were shown for DiR-loaded nanodroplets to be employed as switchable NIR
probes, based on quenching of the dye in the nanodroplets and unquenching by activation of
nanodroplets. Different avenues were employed to obtain probes where the ON/OFF ratio, or the
ratio between the activated nanodroplets to non-activated counterparts, was maximized. Signals
in the activated state were up to 6 times higher than non-activated ones. Overall, these studies
showed the feasibility of using nanodroplets as activatable NIR and ultrasound contrast agents.
Given the versatility of the platform, as well as the myriad of fluorophores that can be employed,
we believe this could be a useful tool in preclinical studies, as well as have clinical
translatability.

6.2.6 Storage of nanodroplets
Recognizing the challenges of long-term storage of lipid-shelled nanodroplets in aqueous
dispersion, several excipients were investigated for their cryoprotective properties. The size,
concentration and model-drug leakage from nanodroplets were used to follow the stability of
samples frozen and stored at -20°C for several days in the presence of excipients such as
glycerol, mannitol or d-glucose. No similar study has been performed to date to investigate
formulations and storage techniques of loaded nanodroplets. Future studies extended over longer
periods of times could be beneficial for the translatability of the platform.
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6.3 Future Directions
6.3.1 Nanoparticle-driven delivery to the tumors
As described in Chapter 2, the accumulation of nanodroplets (DDDs) in the tumors was rather
small, and the particles were found to have cleared through the liver and spleen in two hours in
85% proportion. Several approaches might be beneficial to explore to increase the rate at which
the nanodroplets localize into the tumor: i) targeting the nanodroplets by functionalizing their
surface with targeting moieties for factors overexpressed in certain tumors; ii) priming the tumor
by administering vasculature-enhancing drugs to aid in the (more) uniform development of
vasculature through the tumor; iii) using methods such as ultrasound -driven sonoporation to
temporarily widen the endothelial gaps at the tumor site; iv) creating a selection criteria, possibly
based on vascularity of the tumor, for stratification of expected responders and non-responders.
Since the nanodroplets are designed to work as an iv formulation, understanding the vasculature
and the barriers they encounter within, are essential to improving their performance. We
employed HIFU for activating the nanodroplets, and expect the effect on the tumor growth rate
observed in the case of activated tumors is partially due to the effects of ADV on the endothelial
junctions. However, our work used a stationary HIFU transducer with a relatively small focal
volume, and without pre-mapping of the vasculature, the activation spot might have not been the
optimum one. Therefore, a setup that allows for motorized moving of the HIFU transducer for
better coverage might be beneficial.
Several strategies have been investigated for enhancing tumor permeability and extravasation of
nanodroplets into tumors4 : irradiation5 , photodynamic therapy6 , chemical strategies7 ,
hyperthermia8 and ultrasonication9 . In this context, a preliminary study was conducted looking at
using a co-delivery of two different nanodroplets: one that could be activated by an external
stimulus like NIR pulsed laser to disrupt the endothelial lining, and a second one that is loaded
with the therapeutic payload. We hypothesize that this would enable the loaded nanodroplets to
enter the tumor in a larger number, and being able to be activated after extravasation, would have
a larger efficacy of the treatment. Moreover, the strategy to employ “decoy nanoparticles” to
saturate Kupfer cells that play an important role in sequestering and clearing out nanoparticles
has shown promise in previous studies4,10 . In this way, the nanodroplets that are meant to open
the endothelium could have a twofold role in improving the accumulation of drug-loaded
nanodroplets inside the tumor.
To prove this is possible, a multiplex formulation of droplets was designed, using two different
optical absorbers: Epolight 3072, with an activation maximum at 1064nm, and Epolight 699,
with an activation maximum of 700 nm. Nanodroplets containing the two absorbers were
denoted “ND 1064 ”, and “ND 700 ” respectively. Insert phantoms were obtained with the two types
of nanodroplets and after activation with 1064nm laser, for 10s at 10 Hz, in a spot spanning both
the ND 1064 and ND 700 laden gels, the US signal difference was evident in the inner part of the
phantom, denoting the activation of ND 1064 (Fig. 6.1 A). The second activation, with 700nm NIR
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light, showed activation in the outer region, corresponding to ND 700,, as expected. Since the
images shown are difference between the frames, the signal in the inset is much lower, and only
shows any signal increase in that area from microbubbles increasing in size, phenomenon that we
observed in other experiments as well.
To confirm that the independent activation of multiplex nanodroplets can be used to
independently release encapsulated drugs, we used ND 700 and doxorubicin loaded nanodroplets
ND 1064 (denoted “Dox-ND 1064 ”). A mixture of 1:1 volume ratio was obtained from the two
nanodroplet types, and divided into three equal parts to be incubated at 37°C for 1h. After each
of the samples was subjected to their corresponding treatment- no activation, activation with
1064nm laser, and activation with 700nm laser respectively- the doxorubicin was measured. The
results revealed that the sample activated with 1064nm had the highest amount of doxorubicin
released (Fig. 6.1B), with the other two samples having similar averages. Both the no-activation
and 700 activation groups showed statistically significant differences compared to the sample
where Dox-ND 1064 were activated (pno-activation =0.004% and p700 activation =0.007%), while no
statistically significant difference was recorded within the two. This confirmed the possibility to
use multiplex nanodroplets to independently release the payload of one nanodroplet
subpopulation.

Figure 6-1 A. Schematic (a) and US differential frames of insert phantoms containing
neighboring regions encapsulating nanodroplets with different NIR dyes (b-c). Activating
consecutively by the two corresponding wavelengths shows localized activation of nanodroplets;
B. ND 700 empty nanodroplets and ND 1064 dox-loaded nanodroplets in a mixture 1:1, kept at 37C
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for 1h and subjected to no activation, 1064 nm pulsed laser or 700 nm pulsed laser. * Indicates a
p< 0.01 between the 1064nm Activation group and the respective group; C. 2D cryoslice slice of
mouse with two hind leg tumors after iv injection of a 1:1 cocktail of ND 1064 labeled with FITC,
and Rhodamine B-loaded nanodroplets containing no optical absorber.

Additionally, a preliminary in vivo study was conducted, where mice received an iv injection
containing a 1:1 cocktail of FITC-labeled ND 1064 nanodroplets and Rhodamine B-loaded
nanodroplets with no optical absorber. The mice had two hind leg tumors, one of which was
activated by a 1064 nm pulsed laser, and another that served as control. Immediately after
activation, mice were sacrificed and snap-frozen. Images obtained by cryoslicing, after spectral
unmixing processing steps, revealed that the activated tumor had a larger FITC and rhodamine
signals compared to non-activated counterparts (Fig. 6.1 C). This was encouraging in supporting
our hypothesis, and could open avenues for tumor permeation to increase nanomedicine efficacy.
This, together with vasculature mapping techniques would maximize the benefits of using
perflurocarbon nanodroplets for drug-delivery.
Moreover, a comprehensive pharmacokinetic characterization of nanodroplets in mice would be
needed to understand the dose and timing of doses that is required for maximizing the benefits of
the on-demand delivery. Further, a comparison between the nanodroplets-encapsulated
compounds and the free drugs, to mirror the tests in vitro, should be performed to better
understand whether this method would improve on existing standard of care regimens.
Finally, the nanodroplets’ functionality might be extended to other types of cancer, or diseases.
Given their propensity to accumulate in the liver, hepatocarcinoma could an interesting target,
either as primary tumors or metastases derived from a different cancer type.

6.3.2 Immunotherapy combinations
The nanodroplets containing an immune checkpoint inhibitor and a chemotherapeutic showed
promise in the in vitro testing, and the two components are expected to work synergistically.
More work on the optimization of the nanodroplets’ formulation would be beneficial as to
determine whether there are particular ratios of chemo/immuno-therapeutics that yield the best
outcome. Further, an animal model using an immunocompetent mouse like BALB/c 11 , must be
setup and used to observe the effects in vivo, focusing especially on the comparison of
formulations with both components co-encapsulated with ones where the two agents are
administered successively/ with some delay. The chemotherapeutic is supposed to help some of
the extraneous tumor cells become apoptotic and clear out, allowing more space for infiltrating
T-cells to act. Then, the a-PD-L1 can block the PD-1/PD-L1 interaction, “waking” the exhausted
T-cells and enabling them to attack the cancer cells. Due to the difference in the timescales of
these mechanisms, a study investigating the optimal timing of co-administration is needed.

146

6.3.3 Sentinel lymph node involvement in cancer progression
Lymph node metastasis is a well-known clinical predictor in the case of many solid cancers12 .
Regional lymph node involvement was shown to reduce the five-year survival rate in squamous
cell cancer of head and neck by 50%13 . Therefore, detecting and assessing the sentinel lymph
node (SLN), the first node that cancer cells drain to from the primary tumor, is extremely
important. Several imaging techniques are being used for identification of SLN, such as
lymphoscintigraphy (LS) with radiocolloid injection, magnetic resonance imagining (MRI) and
positron emission tomography (PET). However, these techniques each have their drawbacks,
such as low imaging resolution (lymphoscintigraphy), cost and difficulty in acquiring images
during surgery or biopsy (MRI), and lower specificity and sensitivity (PET) 12 . Another imaging
option is ultrasound, that has been used in the past to guide SLN biopsies in real-time, as a
method with good temporal and spatial resolution and much more cost-effective14 . However, the
contrast between lymph nodes and the surrounding background is rather limited, which calls for
ultrasound contrast agents, like microbubbles, to be used. Nevertheless, their size in the range of
microns limits their flow into the lymphatics, and their short circulation time allows for a brief
window of imaging. A different option for SLN identification being investigated is fluorescence
imaging. The dye being used is indocyanine green (ICG), a tracer used in the clinic across a great
range of imaging. Some studies have shown the use of ICG and fluorescence imaging in the case
of breast cancer15–17 , either perioperative or during surgery 18 , while other types of cancer were
also considered for fluorescence detection of SLN 19 , including head and neck cancer20 .
Often, in practice, techniques combining two or more of these methods are used for the
identification of SLN, the localization and guiding of the biopsy or complete excision.
Fluorescence imaging is particularly useful during the biopsy/excision steps, as a lot of the tissue
is removed out of the way, removing potential interference that usually represent a drawback for
fluorescence imaging at depth. An example of this is the multispectral optoacoustic tomography
method that combines US/PA imaging in a system commercially available for human use which
demonstrated success in identifying metastatic SLNs in melanoma patients 21 , as well as other
preclinical and clinical applications22,23 . While this method benefits from being non-invasive, the
high number of false positive results indicates further improvement is needed for this to become
a de facto tool in the clinic. A similar imaging method, employing ultrasound contrast agents and
ICG as a co-injection, but this time looking at the NIR fluorescence of ICG rather than its
photoacoustic signal, was also investigated in vivo in a head and neck cancer model. Kogashiwa
et al. showed that sentinel nodes could be identified transcutaneously by ultrasound and
fluorescence used to guided the resection of nodes24 , reducing the time needed for the operation.
Combining these two approaches, Kang et al. developed a trimodal imaging systems to aid
during sentinel lymph node biopsy, made up of US, PA and FL imaging and showed its efficacy
for SLN localization and biopsy in vivo in a rabbit model25 . However, using a mixture of
different agents with such different properties (i.e., microbubbles for ultrasound contrast and

147

small molecular dyes for fluorescence) can cause mismatch in the information being measured
due to very distinct pharmacokinetics of the two agents. Although fluorescent microbubbles have
been proposed for these applications before, they have limitations related to their size 26,27 ,
hindering their biodistribution and the window for imaging.
Chapter 4 highlighted the feasibility of using perfluorocarbon nanodroplets as simultaneous
“turn-on” fluorescent and ultrasound probes. Due to their size, they are expected to address some
of the limitations associated with microbubbles. The chapter describes in detail the design
considerations and in vitro testing of perfluoropentane nanodroplets containing DiR and
recording improvements in signal upon activation of up to 6 times.
Preliminary lymph node drainage studies were conducted using one of the initial DiR-loaded
nanodroplets prototype – the lipids shelled nanodroplets with DiR in the shell- to assess whether
sub-mucosal injected nanodroplets drain to the lymphatics. Our study confirmed that was indeed
the case, and after 1 h post-injection the signal in the lymph nodes was apparent for all the
studied mice. The drainage was followed hourly for 6h, with an additional image taken at 24 h.
The intensity in the nodes was measured over time and normalized with the background to
account for any autofluorescence. Data from the 5 measured mice is plotted against time in Fig.
6.1. Future directions in this work include getting similar data for BSA-shelled nanodroplets, as
those have shown the best ON/OFF ratios and performing activation of one of the nodes during
drainage to observe and characterize the change in signal in this particular system. These will
allow for a more complete characterization of the fluorescent nanodroplets, and could confirm
their use as multimodal imaging agents, combining ultrasound and fluorescence.
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Figure 6-2 A. Example of images captured during DiR-nanodroplets drainage through the lymph
nodes at various timepoints during the experiment; B. Average node/background ratio over time
for the studied mice. The error bars correspond to the standard deviation from 5 measurements;
C. Example of mouse where the lower node was activated after the 1h drainage time point.

6.5 Conclusion
The present thesis set to design, synthesize, characterize, and optimize a perfluorocarbon
nanodroplets platform that can provide simultaneous image-guided delivery of multiple
therapeutics. Towards this goal, a double emulsion synthesis method was developed and
optimized to enable encapsulation of small molecules (Chapter 2), or large molecules (Chapter 3)
both in the shell and core of nanodroplets. Two different methods of encapsulating large
molecular compounds were described (Chapter 3). Imaging and processing algorithms were
adapted to acquire ultrasound images during nanodroplets activation in phantoms and in mice
(Chapter 2). Various formulations for storage of nanodroplets were developed and optimized
(Chapter 5). A secondary goal of the thesis was the expansion of nanodroplets to incorporate
multi-modal imaging, combining NIR fluorescence and ultrasound. This goal was achieved by
developing nanodroplets encapsulating DiR in the shell or the core or leveraging protein-DiR
interactions (Chapter 4).
Dual-loaded nanodroplets are a promising solution to limitations posed by single-agent
constructs, and the versatility of the platform, partially shown within this thesis, makes them
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appropriate for an array of applications. While extensive characterization of in vivo properties is
needed towards making nanodroplets a clinical reality, the work described herein represents a
step forward in the development of nanotheranostic agents that can provide on-demand delivery
of active pharmaceutical ingredients with real-time ultrasound monitoring.
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